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ABSTRACT 
 
Dysregulation of adipose tissue metabolism is associated with multiple metabolic 
disorders. One such disease, known as Dunnigan-type familial partial lipodystrophy 
(FPLD2) is characterised by defective fat metabolism and storage. FPLD2 is caused 
by a specific subset of mutations in the LMNA gene. The mechanisms by which 
LMNA mutations lead to the adipose specific FPLD2 phenotype have yet to be 
determined in detail. Previous work employed RNA-Seq analysis to assess the effects 
of wild-type (WT) and mutant (R482W) LMNA on the expression profile of 
differentiating 3T3-L1 mouse preadipocytes and identified over 200 transcripts whose 
expression was altered. Four of these genes namely ITM2A, IGFBP5, PTPRQ and 
WNT6 were selected for detailed investigation using the 3T3-L1 model for 
adipogenesis. Extensive methodological work was carried out aimed at developing a 
system that facilitated robust analysis of transfected gene activity in the adipocyte 
differentiation 3T3-L1 cell model. 
  
Preliminary investigations were carried out on IGFBP5, PTPRQ and WNT6 and while 
some progress was made in exploring these genes in adipogenesis, significant 
obstacles were encountered. A complex endogenous IGFBP5 expression profile is 
shown in 3T3-L1 differentiation, with IGFBP5 over-expression and shRNA mediated 
knockdown leading to inhibited and enhanced differentiation, respectively. 
Investigation into the effects of LMNA over-expression on IGFBP5 yielded 
conflicting results and further analysis is required to elucidate the mechanisms 
regulating IGFBP5 expression in adipogenesis. PTPRQ and WNT6 are lowly 
expressed in pre-adipocytes and further down-regulated during 3T3-L1 
differentiation. PTPRQ over-expression is reported to inhibit the adipogenic 
programme, and in this thesis shRNA mediated knockdown of PTPRQ is shown to 
inhibit differentiation as well. WNT6 knockdown is reported to enhance adipogenesis, 
however technical difficulties in the accurate detection of WNT6 mRNA render this 
gene challenging to study in the context of adipogenesis. 
  
Detailed investigations were carried out on ITM2A. In this thesis ITM2A is identified 
as a novel modulator of adipogenesis and results show that endogenous ITM2A 
expression is transiently down-regulated during induction of 3T3-L1 differentiation. 
 10 
ITM2A over-expression was seen to moderately inhibit differentiation of 3T3-L1 
preadipocytes while shRNA mediated knockdown of ITM2A significantly enhanced 
3T3-L1 differentiation. Investigation of PPARγ levels indicate that this enhanced 
adipogenesis is mediated through the stabilization of the PPARγ protein at specific 
time points during differentiation. The results demonstrate that ITM2A knockdown is 
sufficient to rescue the inhibitory effects of LMNA WT and R482W mutant over-
expression on 3T3-L1 differentiation and indicate a novel therapeutic approach for 
FPLD2. 
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CHAPTER 1: INTRODUCTION 
 
Nuclear Lamins 
Nuclear lamins are type V intermediate filament proteins that polymerise to form 
components of the nuclear lamina; a fibrous meshwork associated with the inner 
nuclear membrane 1.The localisation of lamin filaments within the nuclear lamina in 
relation to the nuclear envelope is illustrated in figure 1.1 along with the main 
components of the nuclear envelope environment. The inner and outer nuclear 
membranes depicted below contain nuclear pore complexes, which function to 
regulate active transport of molecules between the nuclear and cytoplasmic 
compartments 2. Several of the many known integral inner membrane proteins, such 
as emerin and lamin-associated polypeptide 1/2β, are shown to interact with lamins 
and mediate the tight association between the nuclear lamina and inner membrane of 
the nuclear envelope 3,4.  
 
 
Figure 1.1: The nuclear lamina is shown in red at the nucleoplasmic side of the inner 
nuclear membrane. Taken from Worman et al., (2009) (4). 
The mammalian genome contains three lamin genes; LMNA, LMNB1 and LMNB2 
that encode lamin A/C, lamin B1 and lamin B2 respectively. The LMNA gene is 
alternatively spliced to produce two main isoforms, lamin A and lamin C, the 
expression of which is developmentally regulated 6. Unlike B type lamins, which are 
ubiquitously expressed during development, A type lamins are not detected in 
undifferentiated cells but are expressed in most differentiated somatic cells 7. A type 
lamins are found both at the nuclear periphery and within the nucleoplasm 8. 
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Lamins have a tripartite structure, characteristic of intermediate filament proteins, 
consisting of a conserved central α-helical coiled-coil rod domain flanked by variable 
tail and head domains 4,9. The carboxy (C)-terminal tail domain of Lamin A is globular 
in nature, it contains a conserved immunoglobulin-like fold, a nuclear localization 
signal and a C-terminal CaaX (cysteine - aliphatic amino acid - aliphatic amino acid - 
any amino acid) motif 3,9. The CaaX motif directs a series of sequential enzymatic 
reactions, which function to process the lamin A precursor (prelamin A) into mature 
Lamin A. This post-translational modification involves the farnesylation of the CaaX 
motif, followed by C terminal cleavage by the protease ZMPSTE24. This in turn is 
followed by the methylation of the now exposed farnesylcysteine. Finally, Prelamin 
A is cleaved again by ZMPSTE24, and the removal of the terminal 15 amino acids 
results in the generation of mature lamin A 4. This process is thought to be essential 
for the future assembly and integration of lamin A filaments into the nuclear lamina 
and is illustrated in figure 1.2 10. 
 
 
Figure 1.2: Post-translational processing of prelamin A. Enzymes responsible for 
farnesylation (FTase), C-terminal cleavage (ZMPSTE24), methylation (ICMT) and 
upstream cleavage (ZMPSTE24) are shown on the right of the schematic in green. 
Adapted from Worman et al., 2009 5. Abbreviation; FTase – farnesyltransferase, 
ICMT – isoprenylcysteine carboxyl methyltransferase. 
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Lamins are important structural components of the nucleus and are essential for 
nuclear integrity (1). The lamina contributes to the mechanical stability of the nucleus 
and plays a role in complex interactions between the nuclear envelope and various 
cytoskeletal components 4,12. In addition to providing structural support lamins play a 
role in regulating many nuclear processes. These include DNA replication and repair 
where alterations in lamin organization can block DNA repair and generate genomic 
instability 13,14. Disruption of nuclear lamins can influence gene transcription by 
inhibition RNA-Polymerase II activity 15 and modulate cell proliferation by regulating 
retinoblastoma protein function 16,17. In addition, lamins have been shown to play a 
role in the differentiation of various tissue types, through their ability to cause diverse 
disease phenotypes such as Emery-Dreifuss muscular dystrophy 18, Hutchinson-
Gilford progeria syndrome 19 and Familial Partial Lipodystrophy 20.Lamins interact 
directly with chromatin as well as indirectly, through lamin binding proteins 21–25. 
They have been shown to modulate chromatin organization in a number of different 
contexts and determine chromosome positioning within the nucleus in conjunction 
with their associated internal membrane proteins 8,26. Transcriptionally silent 
heterochromatin is ‘anchored’ at the nuclear periphery through interactions with the 
lamina although lamin-chromatin interactions are not exclusively associated with a 
transcriptionally repressive state 8,27,28. The diverse nature of lamin A function is 
evident upon examination of the LMNA null mouse phenotype. Distinct changes 
appear in nuclear morphology where LMNA deficient cells display irregular and 
elongated nuclei, loss of heterochromatin association at the nuclear periphery and 
dramatic alterations in emerin localization in a tissue specific manner 29,30. 
Homozygous LMNA null mice display severe skeletal and cardiac muscular 
dystrophy along with complete loss of white adipose tissue 29,30. 
 
 
 
 
 
 
 
 
 21 
Laminopathies  
Mutations in the LMNA gene are responsible for a wide spectrum of inherited 
disorders. Collectively known as primary ‘laminopathies’, these disorders can affect 
various tissues in either a systemic or specific manner 31. Affected tissues include 
striated muscle (Emery-Dreifuss muscular dystrophy, dilated cardiomyopathy and 
limb-girdle muscular dystrophy 1B), adipose tissue (Dunnigan-type familial partial 
lipodystrophy), skeletal tissue (mandibular dysplasia) and peripheral nerve tissues 
(Charcot-Marie-Tooth disorder type 2B), while premature ageing syndromes 
(Hutchinson-Gilford progeria syndrome and atypical Werner’s syndrome) are multi-
systemic 31,32. Secondary laminopathies derive from mutations in the ZMPSTE24 gene 
that encodes the enzyme responsible for post-translational processing of prelamin A 
33, and have been reported to affect skeletal, muscle and adipose tissues 34–36, and cause 
restrictive dermopathy (RD) 37,38. 
 
 
 
Figure 1.3: LMNA mutations and associated laminopathies. LMNA gene exons 
and their corresponding lamin A protein domains are shown in the same colour. The 
LMNA splice site is shown in red on the LMNA gene schematic and HGPS mutations 
that lead to the generation of alternative splice sites are shown in black (c.1824C>T, 
c.1968+1G>A and c.1821G>A). Mutations causing various laminopathies and their 
locations are shown along the lamin A protein. The colour legend on the right indicates 
which mutations lead to which diseases. Lamin A protein regions and their associated 
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interacting proteins are shown in black. Abbreviations; A-EDMD – Autosomal 
Emery-Dreifuss muscular dystrophy, DCM - dilated cardiomyopathy, LGMD1B - 
limb-girdle muscular dystrophy 1B, L-CMD - LMNA-related congenital muscular 
dystrophy, FPLD2 – Dunnigan-type familial partial lipodystrophy 2, CMT2B - 
Charcot-Marie-Tooth disorder type 2B. †; same amino acid substitution generates 
different laminopathies. Adapted from Scharner et al., 2010 and Burk and Stewart 
2002 33,39. 
 
Figure 1.3 illustrates a subset (<20%) of the many mutations that lead to the 
development of various laminopathies. The locations of these mutations within the 
different lamin A protein domains are shown, along with the known lamin A 
interacting proteins 40. Laminopathies are most commonly produced by missense or 
frame shift mutations in the LMNA gene 39. One of the better-studied laminopathies, 
HGPS, is caused by mutations in exon 11 that generate alternative splice sites resulting 
in a truncated lamin A protein. This protein product is known as ‘progerin’ and bears 
a 50 amino acids internal deletion within the carboxy (C)-terminal tail domain 9,37,41. 
In addition, the most common HGPS mutation (G608G) leads to loss of the second 
ZMPSTE24 cleavage site resulting in a permanently farnesylated form of the progerin 
protein 42. Accumulation of progerin in the cell is thought to drive the HGPS multi-
systemic premature ageing phenotype through distortion of normal nuclear 
morphology and function 43.  
 
Dunnigan-type familial partial lipodystrophy   
Dunnigan-type familial partial lipodystrophy (FPLD2) is caused almost exclusively 
by heterozygous missense mutations in the 8th and 11th exons of the LMNA gene 4. 
Mutations that result in lipodystrophies are mainly found in the immunoglobulin-like 
fold of the lamin A protein. They do not alter the three-dimensional structure of the 
protein, however the majority of these mutations generate amino acid substitutions 
that lead to a decrease in the surface positive charge of the immunoglobulin-like 
domain, which may affect protein-protein interactions 9,31. Common mutations leading 
to FPLD2 occur at amino acid 482, in which the positively charged arginine if often 
substituted with a neutral amino acid such as tryptophan (R482W) or glutamine 
(R482Q) 44,45.  
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FPLD2 is an autosomal dominant laminopathy characterized by defective fat 
metabolism and storage 46. Symptoms of this disorder manifest at puberty and include 
the loss of peripheral, subcutaneous adipose tissue from the extremities (limbs, truncal 
and gluteal regions) with a build-up of visceral and nuchal adipose tissue. This is 
accompanied by a myriad of metabolic symptoms such as hepatic steatosis, 
atherosclerosis and insulin resistance, which leads to type II diabetes mellitus 44. 
Defective energy storage is thought to be the primary pathogenic factor in such 
lipodystrophies, leading to the development of the characteristic metabolic disease 
state 47. The biochemical and clinical study of FPLD2 patients has identified a sex 
dependent aspect of the disease phenotype, where symptoms appear significantly more 
severe in female patients 48,49. In addition, the first case of homozygous LMNA R482Q 
mutations has recently been reported, and these individuals appear to have a 
combination of EDMD and generalized lipodystrophy 49. 
 
FPLD2 mouse models 
A number of mouse knock-in models exist for different laminopathies, including AD-
EDMD (L530P, H222P), DCM (N195K) and progeria (LMNA HG/+, LMNA HG/HG), 
however currently there is no data published on an FPLD2 mutation knock-in mouse 
model 50–54. Interestingly a few of these laminopathy models do exhibit a complete or 
partial loss of adipose tissue (AD-EDMD L530P Knock-in, LMNA HG/+, LMNA HG/HG, 
Zmpste24-/-), along with the distinct symptoms associated with each respective 
laminopathy mutation. A transgenic mouse model of FPLD2 has previously been 
generated where human LMNA R482Q mutant was expressed from the aP2 adipose 
tissue specific promoter 55. These mice expressed endogenous levels of wild type 
LMNA as well as additional aP2 driven R482Q mutant LMNA in their adipose tissue, 
as transgene expression was not detected in most other tissues. FPLD2 transgenic mice 
accumulated significantly less white and brown adipose tissue than wild type 
littermates and acquired FPLD2 metabolic symptoms including decreased insulin 
sensitivity and hepatic steatosis. Wojtanik et al., (2009) determined that their FPLD2 
transgenic mice exhibited reduced adipocyte differentiation by comparing the in vitro 
differentiation potential of epididymal fat-pad stromovascular fractions from FPLD2 
versus wild-type mice. They propose that defective adipocyte differentiation rather 
than impaired lipid droplet accumulation or fat loss leads to the lipodystrophic 
phenotype in FPLD2.   
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Adipose tissue  
Adipose tissue is a complex organ that plays an important role in the regulation of 
whole body metabolism. As well as providing energy storage, it functions to modulate 
energy homeostasis and has key endocrine/paracrine functions 56.  
 
There are two types of adipose tissue in mammals, white adipose tissue (WAT) and 
brown adipose tissue (BAT), which differ in cell composition, morphology and 
function. White adipocytes contain a single large lipid droplet and relatively few small 
elongated mitochondrial around the periphery of the cell whereas brown adipocytes 
contain many smaller lipid droplets and are rich in large mitochondria  The adipose 
organ comprises a number of distinct anatomical depots including WAT subcutaneous 
(femoral, truncal and gluteal) and intra-abdominal (visceral and omental) fat depots 
which differ in biological function as well associated disease risk 57,58. These depots 
are composed of mature white adipocytes and stromal vascular cells (SVC) which 
include fibroblasts, adipocyte progenitors (ASC), preadipocytes, endothelial cells, 
pericytes and immune cells 57,59. BAT depots are most commonly observed in new-
borns and are found mainly around the neck and upper chest regions 58. They are 
highly vascularized, containing brown adipocytes, adipocyte progenitors and a dense 
network of capillaries 60,61. BAT functions primarily to generate heat in a process 
called non-shivering thermogenesis, and plays an important role in maintaining body 
temperatures in a cold environment 61. Recently, numerous studies have reported BAT 
function in adults 62,63, and a role for BAT has been described in protection against 
obesity 58. The microenvironment of fat depots is influenced by various factors 
including cellular composition, extracellular matrix (ECM) composition, metabolic 
characteristics and secretory products. These differences in microenvironment are 
responsible for the distinct endocrine and metabolic functions of the different adipose 
depots within the body 57. The notion of adipose tissue functioning as a secretory 
endocrine organ was first suggested after the discovery of circulating factor leptin 64 
and adipose tissue derived tumour necrosis factor-  (TNF)65. Since then, numerous 
adipocyte derived secreted proteins or adipokines have been identified, such as resistin 
and adiponectin, establishing adipose tissue as a dynamic endocrine organ, that plays 
an integral role in the regulation of metabolism 66. 
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The differences in adipose tissue depot development and control are of interest as fat 
distribution plays an important role in metabolic disease pathogenesis, with the 
accumulation of fat in visceral or intra-abdominal depots being strongly associated 
with obesity related metabolic syndrome 67.  Numerous factors are known to affect 
adipose tissue distribution, including age, sex, energy balance, endocrine signalling 
and genetic factors 68. Metabolic syndrome is characterised as group of related 
physiological and metabolic factors that lead to increased risk of type II diabetes 
mellitus (T2DM) and atherosclerotic cardiovascular disease (ACVD). These factors 
include hypertension, insulin resistance, glucose intolerance and dyslipidaemia, which 
are usually associated with an excess in body weight 69.  
 
Lipodystrophies  
Lipodystrophy refers to a disease state in which adipose tissue is deficient or defective. 
Impaired adipose tissue function leads to the development of metabolic syndrome 
symptoms, surprisingly similar to those observed in obesity 70. These include insulin 
resistance, type 2 diabetes mellitus, hepatic steatosis and the ectopic accumulation of 
lipids in non-adipose tissues such as the liver and muscle 71. Genetic lipodystrophies 
include familial partial lipodystrophy and congenital generalized lipodystrophy 
(CGL), the latter of which is caused by mutations in AGPAT2, BSC12 or CAV1 71,72. 
Acquired lipodystrophies are not associated with any genetic mutations but rather are 
thought to develop as a result of immune-mediated fat loss 71. Currently the most 
common acquired form of the disease is HIV-associated lipodystrophy, driven by HIV 
treatment with highly active antiretroviral therapy (HAART). The mechanism by 
which fat redistribution occurs in these patients is currently unknown 73,74. 
Partial lipodystrophies are more common than general lipodystrophies and exhibit a 
milder phenotype, characterised specifically by the re-distribution of adipose tissue as 
well as total fat loss. FPLD1, also known as Köbberling-type lipodystrophy, is 
considered to be familial although a specific genetic mutation has yet to be linked to 
this disease 75. FPLD2 arises from mutations in the LMNA gene (as previously 
described) and FPLD3 is caused by loss-of-function mutations in peroxisome 
proliferator-activated receptor-γ (PPARγ), a key adipogenic factor, essential for the 
development of mature adipocytes 76. Although FPLD2 and FPLD3 are genetically 
distinct they exhibit similar clinical features, most notably the specific pattern of fat 
loss from the gluteal and limb regions, insulin resistance, hepatic steatosis and type II 
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diabetes mellitus 77,78. Considering these similarities, it could be suggested that FPLD2 
LMNA mutations might lead to reduced or impaired PPAR function during 
adipogenesis. Several additional genes have been implicated in the development of 
partial lipodystrophies. Mutations in ZMPSTE24, AKT2 and CIDEC have been 
reported to cause the lipodystrophic phenotype (34,36,80,81). ZMPSTE24 plays a key 
role in LMNA processing as previously described and its mutation most likely leads 
to a lipodystrophy through similar mechanisms as LMNA mutation 78. AKT is 
involved in downstream insulin signalling and its mutation has been reported to result 
in the autosomal dominant inheritance of a lipodystrophic state with severe insulin 
resistance and type 2 diabetes 80. Finally, mutation of the cell death-inducing Dffa-
like effector C (CIDEC) gene that is involved in the formation of lipid droplets in 
adipose tissue, has recently been reported to produce a new subtype of familial partial 
lipodystrophy identified by the characteristic loss of subcutaneous fat from the limbs 
and insulin-resistance driven diabetes 81.  
 
The mechanisms by which these distinct mutations lead to either partial or generalised 
lipodystrophy are not all clear, but can be divided into various functional categories. 
AGPAT2 and BSCL2 are involved in triacylglycerol (TAG) synthesis, CAV1 effects 
fatty acid uptake by adipocytes and CIDEC is involved in the process of lipid droplet 
formation. In contrast, LMNA, PPARG, ZMPSTE24 and AKT2 mutations are 
considered to drive the lipodystrophic phenotype by affecting the expression of genes 
involved in adipogenic differentiation 78.  
 
Lipodystrophy mouse models  
A number of knock-out mouse models have been produced in order to study adipose 
tissue development and related diseases. AGPAT2 and CAV1 null mice appear to 
mimic the CGL disease state in humans with varying degrees of metabolic syndrome 
82,83 while PPAR and CEBP knockout (KO) mice fail to develop WAT 71,84,85. An 
unexpected lipodystrophy mouse model was generated when over-expression of a 
dominant-positive form of sterol regulatory element-binding protein 1 (nSREBP1c) 
was directed from the adipose specific aP2 promoter in transgenic mice. SREBP1 is a 
key transcription factor in the regulation of lipogenesis and nSREBP1c is the active 
form of this transcription factor 86. Shimomura et al., (1998) reported reduced and 
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defective WAT development with the expansion of a large intrascapular fat pad 
consisting of pale adipose tissue where BAT is normally found. These mice exhibited 
severe hepatic steatosis, insulin resistance and diabetes mellitus 87. The over-
expression of nSREBP1c in these mice was seen to perturb development of both white 
and brown adipose tissue. An incomplete block in WAT differentiation was observed 
as transgenic mouse fat pads contained immature white adipocytes with interspersed 
islands of normal mature adipocytes.  Brown adipocyte depots were dramatically 
enlarged and cells within these depots contained more fat in comparison to those of 
wild type littermates 87. SREBP1 regulates many lipogenic genes and is up-regulated 
during the early stages of adipogenic differentiation 88. It has been shown to promote 
adipogenesis in an in vitro differentiation context 89. It is therefore surprising that 
increased SREBP1c in mouse adipose tissue leads to lipodystrophy. Interestingly, 
transgenic mice overexpressing nSREBP1a (a more potent transcriptional activator 
isoform of SREBP1c) in their adipose tissue exhibit a completely different phenotype, 
exhibiting normal plasma insulin and glucose levels, white and brown adipocyte 
hypertrophy and hepatic steatosis 90. These contrasting phenotypes suggest distinct 
roles for SREBP1a and SREBP1c in mouse adipocyte metabolism.  
 
Adipogenesis  
The development of adipose tissue and the regulation of fat metabolism are not fully 
understood. Mesenchymal stem cells (MCS) have the potential to differentiate into 
numerous cell types including chondrocytes, osteocytes, myocytes and adipocytes. In 
an in-vivo setting these cells respond to various signals to undergo determination 
towards one of the above cell lineages 91. The process of adipogenesis involves 
commitment of pluripotent MSC to the adipocyte lineage, followed by terminal 
differentiation of pre-adipocytes into mature adipocytes 88. In an undifferentiated state, 
MSCs express low levels of respective lineage specific factors which repress each 
other and function to maintain the pluripotent state 92. Although the exact mechanism 
of adipogenic commitment is unclear, various factors are known to be involved. In 
vivo, prolonged excessive intake of energy leads to a metabolic state that produces 
various signals that stimulate MSC commitment to the adipogenic cell lineage 88. In 
vitro studies have identified bone morphogenetic protein (BMP) 4 93, BMP2 94 and 
Wnt 95,96 as activators of adipogenic commitment while Hedgehog is reported to 
inhibit this process 97. Finally, mechanical cues have been shown to affect MSC 
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lineage commitment, where cell shape, density and cytoskeleton tension influence cell 
fate 98. 
Primary pre-adipocytes, harvested from the vascular stroma of in-vivo adipose tissue, 
have a limited capacity to proliferate and a finite potential to differentiate in vitro 99. 
As a result, the signalling transduction pathways and molecular mechanisms that 
regulate adipogenesis have largely been studied in pluripotent (C3H10T1/2) or 
preadipocyte cell lines (3T3-L1).  
 
Terminal Differentiation  
Adipocyte terminal differentiation involves a transcriptional cascade in which the 
expression of pro-adipogenic factors is temporally induced alongside the down-
regulation of various anti-adipogenic factors 92.Preadipocyte cell lines have been used 
to characterise key events of the adipogenic differentiation programme, and terminal 
differentiation of mouse pre-adipocytes has been studied extensively using the 3T3-
L1 cell model. In this well-established system, the pre-adipocytes are grown to 
confluency and undergo growth arrest, after which point an adipogenic cocktail is 
applied to activate insulin growth factor (Insulin/IGF-1), cAMP (IBMX/Forskolin) 
and glucocorticoid (dexamethasone) signalling pathways. Figure 1.4 illustrates the 
temporal cascade of differentiation events that occur post-induction.  
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Figure 1.4 : The in-vitro adipogenic differentiation programme, taken from Tang and 
Lane (2012) 88. 
  
Directly after addition of the induction cocktail, cyclic AMP response element-binding 
protein (CREB) phosphorylation induced expression of the CCAAT- enhancer-
binding protein  (C/EBP) transcription factor 100. However, at this stage C/EBP is 
unable to bind DNA 101. At approximately 16 to 20 h post induction, 3T3-L1 cells re-
enter the cell cycle to undergo a few rounds of mitotic clonal expansion (MCE), at 
which point C/EBP acquires the ability to bind DNA, and initiates the adipogenic 
transcriptional cascade 102. Sequential phosphorylation of C/EBP by MAP kinase and 
GSK-3β are important post-translation modifications that confer DNA-binding 
activity 103. Once able to bind DNA, C/EBP activates C/EBP and PPAR expression 
through C/EBP elements in their respective promoters 103.Subsequently, C/EBP and 
PPAR cross-regulate each other, in a positive-feedback loop that plays an important 
role in maintaining the differentiated state 104,105. C/EBP stimulates both PPAR 
expression 103,106 and its own expression through auto-regulation 107. PPAR and 
C/EBP are considered the master regulators of adipogenesis and are transcriptionally 
activated approximately 18-24hrs post induction 88. These transcription factors then 
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function to activate the expression of various adipogenic genes through regulatory 
elements in their promoters 108,109.  
 
CCAAT- enhancer-binding proteins  
The importance of these factors in adipogenesis has been highlighted in various in-
vitro and in-vivo studies. Constitutively active CREB has been shown to promote 3T3-
L1 differentiation through C/EBP activation (100). Both C/EBP KO MEFs and 
3T3-L1 cells over-expressing a dominant negative C/EBP with no DNA-binding 
capacity, are unable to undergo MCE, which is essential for MEF and 3T3-L1 
adipogenic differentiation (102,103,100). A certain amount of redundancy has been 
demonstrated between the CCAAT- enhancer-binding proteins in adipogenesis. 
C/EBP KO and C/EBP KO mice show relatively normal WAT accumulation while 
C/EBP and C/EBP double KO mice show significantly reduced WAT volume, due 
to a reduced number of adipocytes 111. C/EBP over-expression is sufficient to 
stimulate 3T3-L1 differentiation 112, while C/EBP silencing has been shown to 
suppress adipogenesis in these cells 113. C/EBP KO mice die shortly after birth due 
to hypoglycaemia and their adipocytes are unable to accumulate lipid droplets 114. 
Although clearly important in the process of adipogenesis, ectopic expression of 
C/EBP is unable to rescue adipogenesis in PPAR KO fibroblasts (105). In addition, 
Zuo et al., (2006) demonstrated that C/EBP is unable to induce C/EBP in the 
absence of PPAR during 3T3-L1 cell differentiation. In this context PPAR is 
required to dislodge the repressive histone deacetylase-1 (HDAC1) from the C/EBP 
proximal promoter 116. C/EBP is however essential for efficient insulin-sensitive 
glucose transport, as demonstrated by PPAR over-expression in C/EBP KO 
fibroblasts that are able to differentiate but lack insulin-sensitivity 117.  
 
Peroxisome proliferator-activated receptor  (PPAR) 
PPAR is a member of the nuclear hormone receptor superfamily that controls the 
expression of adipogenic and lipogenic genes through binding to PPAR-response 
regulatory elements as heterodimers with the retinoid X receptor (RXR)  118–120. 
PPAR action is essential in adipogenesis as the numerous signalling pathways and 
pro/anti-adipogenic factors that influence this process converge on the regulation of 
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PPAR activity and expression 92. Figure 1.5 illustrates the transcriptional regulation 
of adipocyte differentiation and depicts the role of pro- and anti- adipogenic factors in 
modulating PPAR expression and activity during this process 121. 
 
Through the use of distinct promoters and alternative splicing, the PPAR gene 
encodes a number of splice variants and two principle protein isoforms, PPAR2 and 
PPAR1 122. These proteins have differential abilities to promote adipogenesis. 
PPAR2 has an additional 28 N terminal amino acids and is exclusively expressed in 
adipose tissue, where it functions as a master regulator of adipogenesis (118,124,125). 
PPAR1 is expressed in various tissues and cell types, including fat, liver, muscle and 
macrophages 126–128.  
 
 
Figure 1.5: Transcriptional regulation of adipogenesis. Early (green), late (blue) 
and anti- (orange) adipogenic factors are shown. Solid lines represent modulation of 
gene expression and dashed lines represent modulation of activity.  Abbreviations: 
COUP-TFII - chicken ovalbumin upstream promoter transcription factor II, FOXO1- 
forkhead box O1, LXR- liver X receptor, TR- thyroid hormone receptor, CHOP10- 
C/EBP homologous protein, RAR - retinoic acid receptor, RORa - RAR-related 
orphan receptor a. Taken from Siersback et al., (2011) (121).  
 
PPAR is a ligand-inducible transcription factor, where ligand binding results in a 
conformational change that leads to interactions with various co-activating proteins to 
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modify PPAR activity 130. To date, no endogenous high-affinity PPAR ligands have 
been identified, however potent synthetic PPAR agonists known as 
Thiazolidinediones (TZDs) have been used as insulin-sensitizers in the treatment of 
type II diabetes for some time 131. 
 
Various studies have shown that PPAR2 is both necessary and sufficient to induce 
adipogenesis, and is also required for the maintenance of a differentiated adipogenic 
state 92. Ectopic expression of PPAR2 in non-adipogenic fibroblasts was shown to 
stimulate the adipogenic differentiation of these cells 132, and since then numerous in-
vitro and in-vivo studies have characterised the role of PPAR2 in adipogenesis and 
lipid metabolism. PPAR KO in mice leads to embryonic lethality due to impaired 
placental development, however a chimeric WT/KO model produced a lipodystrophic 
phenotype in which any adipose tissue present was derived from PPAR WT cells 
(117). Several PPAR mouse models have been generated in which adipocyte specific 
PPAR KO or PPAR2 isoform specific KO in adipose tissue lead to insulin resistance 
and varying degrees of lipodystrophy (127,135–137). Dominant negative PPAR 
knock-in models exhibit abnormal fat distribution 138 and features of metabolic 
syndrome 139. These models have played an important part in dissecting the complex 
physiological functions of PPAR in vivo, and highlight its role in regulation of energy 
metabolism and metabolic disease development 130,140. Figure 1.6 summarises PPAR 
regulation of adipogenic and lipogenic pathways, as well as its modulation of glucose 
homeostasis and adipose secreted factors, all of which combine to influence insulin 
sensitivity 118.  
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Figure 1.6: PPAR mediated control of adipose tissue development and 
metabolism. (1) High fat diet (HFD), ligand and TZD activation of PPAR-RXR 
heterodimerization and (2) binding to PPAR-response regulatory elements of genes 
involved in adipocyte differentiation and maintenance of metabolic homeostasis, (3) 
as well as genes responsible for adipose secreted proteins. Abbreviations: 
STAT1/STAT5A/STAT5B - signal transducer and activator of transcription 1, 5A and 
5B, ACBP - acyl-CoA–binding protein, LPL- lipoprotein lipase, aP2 - fatty acid 
binding protein 2, CD36 - cluster of differentiation 36, ACS - acyl-CoA synthetase, 
PEPCK - phosphoenolpyruvate carboxykinase, PI3K - phosphoinositide 3 kinase, 
IRS-1/IRS-2 - insulin receptor substrate 1 and 2, GyK- glycerol kinase and Glut4 - 
glucose transporter 4. Taken from Ahmadian et al., (2013).  
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FPLD2 biology  
The physiological characteristics of FPLD2 support the hypothesis that LMNA 
mutation leads to altered or impaired lamin A function, which in turn influences the 
dynamic process of adipogenesis. Although the exact molecular mechanisms leading 
to the disease phenotype remain unclear, a number of factors have been implicated.  
 
Nuclear organization and transcription 
Recently the relationship between A type lamins and chromatin state has been 
described in human adipocyte stem cells (ASC) both pre, and post terminal 
differentiation. In this context A type lamins are reported to interact with thousands of 
promoters within the genome, and to modulate chromatin modifications at these sites. 
In addition, lamin A-promoter interactions are shown to be remodelled during the 
adipogenic programme, with variable impact on the transcriptional outcome of the 
genes involved (28). Characterisation of the immunoglobulin like fold in the lamin A 
carboxyl-terminal tail has identified reduced DNA binding affinity of this peptide in 
response to FPLD2 R482W and R482Q mutation 142. It is therefore possible that 
reduced or altered lamin-DNA interaction influences the remodelling of lamin A-
promoter interactions during adipogenesis, and play a role in FPLD2 disease 
pathophysiology.  
 
Prelamin A 
Abnormal accumulation of progerin or farnesylated prelamin A is reported to 
contribute to nuclear distortion in HGPS 43,143. Previously, a number of studies have 
described mutant prelamin A accumulation in FPLD2 patient fibroblasts 144,145. The 
accumulation of this unprocessed form of the lamin A protein was suggested to 
generate the lipodystrophic disease phenotype by sequestering the SREBP1 
transcription factor at the nuclear membrane and preventing its action in adipocyte 
differentiation 145. In contrast, a recent study has reported no prelamin A accumulation 
in fibroblasts carrying a number of FPLD2 LMNA mutations 146. As the mutations 
that cause FPLD2 are distant from the sequences required for LMNA farnesylation 
and cleavage, it is unlikely that prelamin A processing plays a role in the mechanism 
of FPLD2 pathophysiology.  
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Altered SREBP1 activity 
The SREBP transcription factors play important roles in lipid metabolism, and 
SREBP1 is known to promote adipocyte differentiation through activation of PPAR 
89,147. The SREBP1 gene produces SREBP1a and SREBP1c through the use of distinct 
promoters and alternative splicing 148,149. SREBP1 is a basic-helix-loop-helix-leucine 
zipper (bHLH-LZ) transcription factor, and is synthesized as an endoplasmic 
reticulum membrane bound precursor protein that undergoes a two-step proteolytic 
cleavage to release an active nuclear SREBP1. Once translocated into the nucleus 
SREBP1 binds to sterol regulatory elements (SRE) and activates the transcription of 
target genes involved in lipid biosynthesis 150.  
Numerous studies have suggested FPLD2 mutant mediated dysregulation of SREBP1 
transcription factors as the primary mechanism driving the lipodystrophic phenotype. 
Lloyd et al (2002) first identified SREBP1 and 2 as binding partners of lamin A, and 
reported that FPLD2 mutation (R482W) resulted in reduced lamin A binding to 
SREBP1 151. They proposed that lamin A might play a role in the import of the SREBP 
transcription factors into the nucleus and that lamin A mutations could lead to 
lipodystrophy through the dysregulation of the SREBP activity. Since then several 
studies have reported lamin A-SREBP interactions 144,152,153, the most recent of which 
reported that the LMNA Ig fold is important in LMNA-SREBP interactions and that 
LMNA R482W mutation reduced LMNA-SREBP interaction leading to the up-
regulation of SREBP1 target genes in FPLD2 patient fibroblasts 154.  
 
Finally, a recent publication reported reduced binding of FPLD2 mutant LMNA to the 
fragile X-related protein 1 (FXR1P), leading to elevated FXR1P expression in FPLD2 
patient fibroblasts. Ectopic expression of FXR1P was shown to stimulate a myogenic 
differentiation programme in human adipocyte progenitors and a model was proposed 
in which FPLD2 LMNA mutation leads to a remodelling of the adipogenic programme 
towards a myogenic lineage, through FXR1P up-regulation 155.  
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Treatment 
Currently, limited therapy options are available to FPLD2 patients. Lipodystrophy 
treatments vary depending on the type of lipodystrophy and the severity of symptoms 
observed in individual patients. Current treatments include lifestyle modifications 
(Nutrition and exercise)  as well as a number of therapeutic drugs or hormones such 
as TZDs, lipid-lowering drugs, metformin and metreleptin or insulin administration 
156,157.  Numerous reports have described improvements in glucose metabolism, 
reduced serum triglyceride concentrations and improvements in insulin sensitivity 
through treatment with the PPAR agonist rosiglitazone (TZD) 158–160. TZD treatment 
leads to increased body fat which is credited with the improved metabolic control, 
however there are adverse side effects associated with this therapy, including a risk of 
hepatoxicity 161. In addition TZD treatment is seen  to produce inconsistent results 
across different studies and patients 156. In recent years, the development of 
recombinant methionyl human leptin replacement therapy (r-metHuLeptin-
replacement therapy / metreleptin), has led to trials in patients with varying 
lipodystrophic syndromes. Severe lipodystrophy in characterised by a complete loss 
of adipose tissue. It follows that individuals suffering from severe forms of 
lipodystrophic syndrome would be deficient in adipose secreted compounds 162. 
However only moderate effects have been observed with this treatment in FPLD2 163. 
In recent years, there has been increased interest in the development of partial 
lipodystrophy therapies as numerous patients with HIV/AIDS that are receiving highly 
active antiretroviral therapy (HAART) develop HAART-associated lipodystrophy 
syndrome (HALS). HALS is associated with a redistribution of adipose tissue similar 
to that observed in FPLD2, as well as numerous metabolic symptoms, and while the 
antiretroviral treatment is implicated in the pathophysiology of the disease, the 
mechanisms involved are not understood 156.  
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THESIS AIMS 
The aim of this research is to investigate the effects of LMNA overexpression on the 
transcriptional profile of 3T3-L1 cell differentiation. The terminal differentiation of 
mouse preadipocytes has been studied extensively using the 3T3-L1 cell model, and 
the over-expression of both wild-type and R482W mutant LMNA are reported to have 
a similar inhibitory effects on 3T3-L1 differentiation. During the adipogenic 
programme, PPARγ expression is up-regulated approximately 24 to 48hrs post 
induction 88. Boguslavsky et al., (2006) 20 observed a decrease in PPARγ expression 
and a significant reduction in lipid droplet accumulation in LMNA transfected cells 
when compared to an empty vector control. In addition, numerous PPARγ loss of 
function mutations are seen to generate a disease phenotype similar to that of FPLD2, 
referred to as FPLD3 (78,77) . Due to these similarities observed in FPLD phenotype 
and the previously described LMNA effect on PPARγ expression 20, it follows that 
FPLD2 LMNA mutations may lead to reduced or impaired PPARγ function during 
adipogenesis. Previously in the McCarthy lab, RNA-Seq analysis was performed at 
36hrs post induction of 3T3-L1 pre-adipocytes in order to investigate the effects of 
wild-type and R482W mutant LMNA on gene expression profiles at this initial phase 
of terminal differentiation, around the time of PPARγ induction.  3T3-L1 
preadipocytes were stably transfected with human LMNA overexpression constructs 
(pCDNA3-LMNA-WT and pCDNA3-LMNA-R482W) or empty vector control 
(pCDNA3) and induced to differentiate. Total RNA was isolated 36 h post application 
of the induction cocktail and RNA-Seq analysis was performed.  
 
Significant changes in the expression of 212 and 232 transcripts were identified when 
comparing the empty vector control transfected cells to cells over-expressing LMNA 
WT and LMNA R482W, respectively. Analysis of these data sets identified 76 
common transcripts, affected by both LMNA WT and R482W mutant in comparison 
to the control. Table 1 and 2 list the transcripts up-regulated and down-regulated by 
LMNA overexpression.  
 
The ultimate aim of this research is to identify novel therapeutic approaches for 
reversal of the FPLD2 phenotype through exploring genes altered by LMNA 
overexpression in adipogenesis. Based on the literature and transcripts identified in 
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the previously described RNA-Seq analysis, a number of genes were investigated in 
this context. Genes highlighted in red in tables 1 and 2 are considered in this thesis.  
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Table 1.1: Transcripts up-regulated in response to LMNA WT and R482W 
mutant overexpression. Fold down-regulation in comparison to empty vector 
control. 
 Fold Increase 
Gene ID LMNA WT LMNA R482W 
Alcam 1.53 1.34 
Apod 3.92 2.52 
Atp6v0c-ps2 2.98 3.56 
Cacna1c 1.38 1.46 
Ces2g 3.14 2.40 
Cpm 2.02 2.55 
Fgf10 1.37 1.46 
Gas2l3 1.31 1.43 
Gm14440 19.30 7.89 
Gm5886 2.38 2.13 
H2-M1 2.89 3.15 
Heph 1.67 1.81 
Hr 1.81 1.73 
Igfbp3 1.53 2.21 
Il1rn 6.23 2.24 
Itga11 2.43 2.13 
Itm2a 16.27 8.28 
Kcnj15 1.61 1.72 
Kif21a 1.23 1.24 
Lgals3 1.26 1.29 
Lmo7 1.47 1.49 
Malat1 1.72 1.66 
Nfat5 1.26 1.27 
Nptxr 7.92 4.37 
Nqo1 1.42 1.44 
Nrp2 1.15 2.77 
Pcdh19 1.25 1.26 
Pi15 2.60 1.48 
Ptprq 4.15 10.65 
Rap1gap2 1.64 1.53 
Rassf5 1.61 1.57 
S100a8 2.08 2.37 
Saa3 1.79 1.84 
Sertad4 1.45 1.38 
Slc29a1 1.31 1.24 
Slc38a1 1.89 1.47 
Srgap3 1.36 1.47 
Syne1 1.63 2.27 
Sytl2 1.42 1.42 
Tgfbi 1.36 1.38 
Timeless 1.27 1.27 
Wnt6 5.98 7.49 
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Table 1.2: Transcripts down-regulated in response to LMNA WT and R482W 
mutant overexpression. Fold down-regulation in comparison to empty vector 
control. 
 Fold Decrease 
Gene ID LMNA WT LMNA R482W 
Adamts15 4.57 3.61 
Angptl7 5.28 5.04 
Cacna2d1 1.19 1.19 
Cd36 1.95 2.06 
Clec14a 1.36 2.59 
Col23a1 2.77 5.63 
Ddx51 1.48 1.45 
Dkk3 1.90 1.67 
Dlk1 1.14 1.25 
Dpt 1.87 2.70 
Elfn1 1.78 1.83 
Epha4 1.62 1.86 
Hs6st2 1.25 1.33 
Igfbp5 50.15 5.21 
Il1r2 2.59 3.80 
Il1rl1 1.57 1.59 
Lars2 3.34 3.62 
Ndrg1 1.94 1.56 
Nlrp4e 3.36 5.05 
Nod1 1.27 1.36 
Pcdh17 2.49 0.40 
Pvrl2 1.30 1.47 
Retnla 3.86 4.07 
Rmrp 3.16 42.58 
Sema3a 1.30 1.62 
Stc1 1.43 1.66 
3110007F17Rik 1.57 1.96 
5730469M10Rik 1.56 1.75 
9630013A20Rik 2.60 3.13 
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CHAPTER 2: MATERIALS AND METHODS 
 
MATERIALS 
 
Cell Lines 
3T3-L1 cell lines were purchased from ZenBio (SP-L1-F), 3T3-L1 cells originally 
from ATCC (ATCC CL-173) were a kind gift from Professor Rosemary O’Connor 
(UCC, Cork, Ireland), and a third 3T3-L1 cell line indicated as 3T3-L1 M.S. was a 
kind gift from Professor Michael Schupp (Charite, CCR, Berlin, Germany). 3T3-NIH 
cells were a kind gift from Professor Tom Moore (UCC, Cork, Ireland).  LMNA WT 
and KO MEF cells were kindly provided by Professor Colin Stewart (Institute of 
Medical Biology, Singapore). 
 
Bacterial strains  
The E. coli DH5α strain from McCarthy lab was used for all cloning transformations 
and plasmid preparations. The bacterial cells were grown in Luria-Bertani (LB) broth 
and agar.  
 
Chemicals, consumables and reagents 
Table 2.1: Chemicals, consumables and reagents used in the experiments outlined in 
this thesis. 
Product Brand/Company  
Tissue Culture  
Dublecco’s Modified Eagle Medium (DMEM) Sigma-Aldrich D6429 
L-Glutamine solution Sigma-Aldrich G7513 
Penicillin-Streptomycin  Sigma-Aldrich P4333 
Trypsin-EDTA Sigma-Aldrich T4049 
G418 disulfate salt  Sigma-Aldrich A1720 
Puromycin dihydrochloride Sigma-Aldrich P8833 
Dublecco’s Phosphate buffered Saline (PBS) Sigma-Aldrich D8537 
Gibco Fetal Bovine Serum, South American  Bio Sciences 10270-106 
Fetal Bovine Serum Sigma-Aldrich F7524 
3-Isobutyl-1-methylxanthine Sigma-Aldrich I7018 
Insulin solution human  Sigma-Aldrich I9278 
Dexamethasone Sigma-Aldrich D4902 
Formaldehyde solution 36.5-38% in H2O Sigma-Aldrich F8775 
Oil Red O solution  Sigma-Aldrich O1391 
Lipofectamine 2000 reagent  Invitrogen, Bio-Sciences 11668-027 
TurboFect in vitro Transfection reagent  Fermentas, Fisher Scientific R0531  
Testosterone  Applichem A0671,0010 
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5α-Androstan-17β-ol-3-one (DHT) Sigma-Aldrich A8380 
Cell culture dishes/flasks Sarstedt 
Cell scrapers Sarstedt 83.183 
Dimethylsulfoxide (DMSO) - MTT Sigma-Aldrich D8418 
Dimethylsulfoxide (DMSO) sterile  Sigma-Aldrich D2438 
100% Ethanol  Central stock  
MycoAlertTM mycoplasma detection kit Lonza 
Trypan Blue  Sigma-Aldrich  
  
Quantitative RT-PCR   
Fluka, BioUltra, Phenol, 99.5% Sigma-Aldrich 77608 
Guanidine thiocyanate  Promega V2791 
Ammonium thiocyanate Sigma-Aldrich A7149 
Sodium acetate  Sigma-Aldrich S7545 
Glycerol Sigma-Aldrich G5516 
Tetro cDNA Synthesis Kit  Bioline BIO-65043 
PrimeTime qPCR Assays Integrated DNA Technologies (IDT) 
5X HOT FIREPol Probe pPCR mix plus (ROX) Solis BioDyne 08-14-00001 
96 well Multiply PCR plate Sarstedt 72.1980.232 
Lighcycler 480 sealing foil  Roche 4729757001 
Rnase Zap  Bio-Sciences AM9780 
Isopropanol  Sigma-Aldrich 19516 
  
Molecular biology   
dNTP New England Biolabs N0446S 
Q5 –High-Fidelity DNA Polymerase  New England Biolabs M0491S  
Phusion High-Fidelity DNA Polymerase New England Biolabs M0530S 
Taq DNA Ligase New England Biolabs M0208S 
T5 Exonuclease  New England Biolabs M0363S 
β-Nicotinamide adenine dinucleotide (NAD+) New England Biolabs B9007S 
Instant Sticky-end Ligase Master Mix  New England Biolabs M0370S 
T4 DNA Ligase New England Biolabs M0202S 
100-bp DNA ladder New England Biolabs N3231S 
1kb DNA Ladder New England Biolabs N3232S 
Agarose Molecular Biology Reagent  Sigma-Aldrich A9539 
SafeView Nucleic acid stain  NBS Biologicals NBS-SV5 
QIAquick PCR purification Kit Qiagen 28104 
QIAprep Spin Miniprep Kit  Qiagen 27106 
LB Broth  Sigma-Aldrich L3022 
Agar  MERCK Millipore 111925 
Ampicillin sodium salt Sigma-Aldrich A9518 
Kanamycin sulfate  Sigma-Aldrich K4000 
Chloramphenicol  Boehringer Mannheim 634 433 
Restriction Endonucleases  New England Biolabs  
PureYield Plasmid Midiprep system  Promega A2492 
Primers Sigma-Aldrich and IDT 
Taq DNA polymerase New England Biolabs M0267S 
Polyethylene glycol 8000 Sigma-Aldrich P2139 
Lithium hydroxide monohydrate Sigma-Aldrich L4533 
Boric Acid Sigma-Aldrich 
  
Luciferase assay  
Solid assay microplate 96 well solid white  Fisher Scientific 10167481 
Coelenterazine native  Nanolight technologies 303-01 
LAR II buffer Recoding Lab  
Passive Lysis Buffer (PLB) Promega  
  
Western Blotting   
Trizma HCL Sigma-Aldrich T5941 
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Trizma Base  Sigma-Aldrich 
Glycine  Sigma-Aldrich 
Sodium Chloride (NaCL) Sigma-Aldrich 
Potassium Chloride (KCL) Sigma-Aldrich 
Monopotassium phosphate (KH2PO4) Sigma-Aldrich 
Disodium phosphate (Na2HPO4) Sigma-Aldrich 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich L4390 
Bromophenol Blue  BDH Chemicals ltd.  
Dithiothreitol (DTT) Sigma-Aldrich D9779 
30% Acrylamide  Sigma-Aldrich A3574 
Ammonium persulfate  Sigma-Aldrich A3678 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich T9281 
Protein Ladder EZ-run  Fisher Scientific, Fermentas, BPE3603  
Whatman Protran nitrocellulose membranes Sigma-Aldrich Z613657 
Chromatography paper  GE healthcare and life sciences 3030672 
Methanol  Sigma-Aldrich 34860-2 
Ponceaux S Sigma-Aldrich P3504 
Marvel dried skimmed milk  Centra Ireland  
Tween 20  Sigma-Aldrich P2287 
Bovine serum albumin (BSA) Sigma-Aldrich A7906 
CL-XPosureTM Films  Fisher Scientific 34090 
Parafilm   
RestoreTM stripping buffer  Thermo Scientific 21059 
SuperSignalTM West Pico and Femto substrates Thermo Scientific, 34087 and 34094 
Trichloroacetic acid  Sigma-Aldrich 
Acetone Sigma-Aldrich 270725 
 
Antibodies 
Table 2.2: Antibodies used in the Western blotting experiments described in this 
thesis. 
Antibody  Clone Company  
THETM DYKDDDDK Tag antibody   GenScript  
Anti-Flag  M2 Sigma-Aldrich 
Anti-Β-actin AC-15 Sigma-Aldrich 
Anti-α-tubulin  B-5-1-2 Sigma-Aldrich 
Anti-MYC 9E10 Santa Cruz Biotechnology  
Anti-PPARγ 81B8 Cell Signalling Technology  
Anti-Lamin A/C (2032)  Cell Signalling Technology 
Anti-ITM2A (14407)  Proteintech 
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PrimeTime® qPCR Assays 
Table 2.3: All PrimeTime qPCR probe-based assays utilised in quantitative RT-PCR 
experiments. All assays were purchased from IDT.  
Gene  Assay ID  Primer 1  Primer 2 
NoNo Mm.PT.58.16299938 5'CATCATCAGCATCACCACCA3' 5'TCTTCAGGTCAATAGTCAAGCC3' 
LMNA Hs.PT.58.39267032 5’GGTCACCCTCCTTCTTGGTAT3’ 5’AGACCCTTGACTCAGTAGCC3’ 
ITM2A Mm.PT.58.11424567 5'CTGTCCGAGCTCAAATCCTG3' 5'ACAATCAGTCCTGCC AAGATG3' 
ITM2A Mm.PT.58.6163978.gs 5’TCACTCCTGACAGATCTTGGT3’ 5’AAATCCTTCCGCCTTAGACG3’ 
C/EBPα Mm.PT.58.30061639.g 5’TCATTGTCACTGGTCAACTCC3’ 5’ACAAGAACAGCAACGAGTACC3’ 
PPARγ Mm.PT.56a.31161924 5'CTGCTCCACACTATGAAGACAT3' 5'TGCAGGTTCTACTTT GATCGC3' 
IGFBP5 Mm.PT.56a.11593699 5’GTACCTGCCCAACTGTGAC 3’ 5'GCTTCATTCCGTACTTGTCCA3' 
PTPRQ Mm.PT.58.30283019 5’GTGAAGTTACACTGCCTGACA3’ 5’AACAAGCCAGTGACAGTCTT3’ 
WNT6 Mm.PT.58.5344953 5'AGTCAAGACTCTTTATGGATGCG3' 5'CATGGCACTTACACTCGG T3' 
WNT6 
CP* 
 5'GCTCTCCAGATGCTAGCG 3' 5'CACCGAGTGTAAGTGCCAT3' 
*CP denotes Custom Primer. These primers were designed and ordered as a probe-
based assay from IDT. All other assays were pre-designed by IDT.  
 
Plasmids 
Table 2.4: Plasmids used in the experiments outlined in this thesis.  
Plasmid Source 
pCDNA3-FLAG-LMNA WT Worman lab 
pCDNA3-FLAG-LMNA R482W Worman lab 
pCMV6.ITM2A Origene MR203468  
pCMV6.IGFBP5 Origene MR203605 
pIRES-EGFP Clontech - O’Connor Lab 
pCMV(PB) PB terminal repeats from pCyL50 amplified and cloned into 
pIRES-EGFP 
pCMV(PB)- FLAG-LMNA WT LMNA amplified from pCDNA3-FLAG-LMNA WT 
pCMV(PB)-FLAG-LMNA R482W LMNA amplified from pCDNA3-FLAG-LMNA R482W 
pCMV(PB)ITM2A ITM2A amplified from pCMV6.ITM2A 
  
pMSCVpuro Clontech - Schupp lab  
pMSCV(PB) PB terminal repeats from pCyL50 amplified and cloned into 
pMSCVpuro 
pMSCV(PB)- FLAG-LMNA WT LMNA amplified from pCDNA3-FLAG-LMNA WT 
pMSCV(PB)-FLAG-LMNA R482W LMNA amplified from pCDNA3-FLAG-LMNA R482W 
pMSCV(PB)ITM2A ITM2A amplified from pCMV6.ITM2A 
pMSCV(PB)IGFBP5 IGFBP5 amplified from pCMV6.IGFBP5 
pRFP-C-RS Origene 
pRFP-C-RS.shITM2A.1 Origene - TF501127C / FI540152 
pRFP-C-RS.shITM2A.2 Origene - TF501127A / FI348274 
pRFP-C-RS.shITM2A.3 Origene - TF501127D / FI540153 
pRFP-C-RS.shITM2A.4 Origene - TF501127B / FI540151 
pRFP-C-RS.shControl Origene - TR30015  
pRFP(PB) PB terminal repeats from pCyL50 amplified and cloned into 
pRFP-C-RS 
pRFP(PB).shITM2A.1 PB terminal repeats from pCyL50 amplified and cloned into 
pRFP-C-RS.shITM2A.1 
pRFP(PB).shITM2A.2 PB terminal repeats from pCyL50 amplified and cloned into 
pRFP-C- RS.shITM2A.2 
pRFP(PB).shControl PB terminal repeats from pCyL50 amplified and cloned into 
pRFP-C-RS.shControl  
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pRFP(PB).shIGFBP5 IGFBP5 shRNA amplified and cloned into pRFP(PB) 
pRFP(PB).shPTPRQ.1 PTPRQ shRNA.1 amplified and cloned into pRFP(PB) 
pRFP(PB).shPTPRQ.2 PTPRQ shRNA.2 amplified and cloned into pRFP(PB) 
pRFP(PB).shPTPRQ.3 PTPRQ shRNA.3 amplified and cloned into pRFP(PB) 
pRFP(PB).WNT6 WNT6 shRNA amplified and cloned into pRFP(PB) 
pCMV(PB)-Flag-LMNA-WT.shITM2A  shITM2A amplified and cloned into pMSCV(PB)- FLAG-
LMNA WT 
pCMV(PB)-Flag-LMNA-WT.shControl  shControl amplified and cloned into pMSCV(PB)- FLAG-
LMNA WT 
pCMV(PB)-Flag-LMNA-R482W.shITM2A shITM2A amplified and cloned into pMSCV(PB)- FLAG-
LMNA-R482W 
pCMV(PB)-Flag-LMNA-R482W.shControl  shControl amplified and cloned into pMSCV(PB)- FLAG-
LMNA-R482W 
pCMV(PB).shITM2A shITM2A amplified and cloned into pMSCV(PB) 
pCMV(PB).shControl  shControl amplified and cloned into pMSCV(PB) 
pGlucBasic New England Biolabs 
pGluc(PB)Basic PB terminal repeats from pCyL50 amplified and cloned into 
pGlucBasic  
pGluc(PB)ITM2A/2kb  ITM2A promoter amplified from genomic DNA and cloned 
into pGluc(PB)Basic 
pGluc(PB)ITM2A/1.5kb ITM2A promoter amplified from genomic DNA and cloned 
into pGluc(PB)Basic 
pGluc(PB)ITM2A/1kb ITM2A promoter amplified from genomic DNA and cloned 
into pGluc(PB)Basic 
pGluc(PB)ITM2A/0.5kb ITM2A promoter amplified from genomic DNA and cloned 
into pGluc(PB)Basic 
pGluc(PB)ITM2A/0.35kb gBlock purchased from IDT and cloned into pGluc(PB)Basic 
pGluc(PB)ITM2A/GATA.mt gBlock purchased from IDT and cloned into pGluc(PB)Basic 
pGluc(PB)IGFBP5/1.2kb IGFBP5 promoter amplified from genomic DNA and cloned 
into pGluc(PB)Basic 
pGluc(PB)IGFBP5/2.4kb IGFBP5 promoter amplified from genomic DNA and cloned 
into pGluc(PB)Basic 
pCyL50 Wellcome Trust Sanger Institute, Ref (165) 
mPB Wellcome Trust Sanger Institute, Ref. 165 
 
 
METHODS 
 
Tissue culture  
3T3-L1 and mouse embryonic fibroblasts (MEFs) were maintained in standard growth 
medium; Dulbecco's modified Eagle's medium with 10% fetal bovine serum (Gibco – 
South American origin), 2 mM L-glutamine and 100U/ml penicillin, 100μg/ml 
streptomycin, at 37°C in a 5% CO2 incubator. 3T3-NIH cells were maintained in 
standard growth medium with alternatively sourced 10% fetal bovine serum (Sigma-
Aldrich). 3T3-L1 and MEF cell lines were sub-cultured in fresh medium every 2 days 
at a 1:4 ratio. 3T3-NIH cells were sub-cultured in fresh medium every 2-3 days at a 
1:10 ratio. To sub-culture, cells were washed once in PBS and Trypsin-EDTA was 
used to detach the cells from the growth surface. To cryopreserve, cells were washed 
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with PBS, tripsinised and spun at 1500 rpm for 5 minutes, at room temperature. Cell 
pellets were re-suspended in a mixture of 70% standard growth medium, 20% FBS 
and 10% sterile DMSO. Cell suspensions were initially stored at -80C and then in 
liquid nitrogen for long term storage. Cryopreserved cells were thawed at 37C and 
transferred to culture flask containing pre-warmed standard growth medium and 
cultured at 37C overnight. Fresh medium was applied the next day.  
 
3T3-L1 differentiation  
For differentiation, 3T3-L1 cells were grown to confluence in standard growth 
medium (day -2). Two days post confluence (day 0) cells were induced in fresh 
medium containing 0.5mM 3-Isobutyl-1-methylxanthine (IBMX), 1μM 
dexamethasone (D) and 10 μg/ml insulin (I). This induction cocktail is referred to as 
MDI. For submaximal induction fresh medium was applied containing 10 μg/ml 
insulin and 1μM dexamethasone (DI) or just 1μM dexamethasone (D) alone. Two days 
later (day 2) fresh medium containing 10 μg/ml insulin was applied. Fresh standard 
medium was applied every two days after that until day 8 when cells were fixed and 
stained with Oil Red O.  
 
Oil Red O staining 
3T3-L1 cells were washed with phosphate buffer saline (PBS) and fixed with 10% 
formaldehyde solution (Sigma-Aldrich) in PBS for 15-30 minutes at 37°C. Fixed cells 
were washed with water (x 2) and a working Oil Red O solution (0.5% in isopropanol 
– diluted 3:2 with ddH20) applied overnight with gentle rocking. Oil Red O 
quantification was performed using ImageJ as previously described 166 and expressed 
as Oil Red O absorbance units (ORO a.u.).  
 
3T3-L1 stable transfection  
For all stable transfections, 3T3-L1 cells were co-transfected with piggyBac 
transposable vectors and the mPB transposase using Lipofectamine 2000 transfection 
reagent (Invitrogen). Cells were seeded the day before in 60mm dishes, so that cells 
were at 50-70% confluency. Plasmid DNA and Lipofectamine were diluted in serum 
free DMEM separately and allowed to incubate at room temperature for 5 minutes. 
Diluted DNA was added to diluted Lipofectamine and incubated at room temperature 
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for 20 minutes. To transfect cells at 50-60% confluency in a 60mm dish, a total of 8g 
DNA and 20l of Lipofectamine were diluted in 0.5mls of serum free media 
respectively. For co-transfections, equal amounts of DNA were used i.e. 4g of 
transposase and 4g of overexpression/knockdown (KD)/luciferase construct. Prior to 
transfection fresh standard medium was applied to the cells and the 
DNA/Lipofectamine mix was added drop-wise. Cells were incubated with the 
transfection mix for 4-6hrs at 37°C in a 5% CO2 incubator, after which fresh standard 
medium was applied. Between 24 and 48hrs post transfection, depending on cell 
morphology and observed cell death, selection antibiotics were applied (800μg/ml 
G418 or 0.75-1.5ug/ml puromycin) and cells were selected for 1-2 weeks, depending 
on rate of cell growth.  
 
3T3-NIH transient transfection 
Transient transfection of 3T3-NIH cells was performed with TurboFect in vitro 
transfection reagent (Thermo Scientific). Cells were seeded the day before in 6-well 
plates, so that cells were at 70-80% confluency. Plasmid DNA and TurboFect reagent 
were diluted in 0.5mls of serum free media and incubated at room temperature for 20 
minutes. A total of 4μg DNA and 6l of TurboFect were used per well to transfect 
cells seeded in a 6-well plate. For shRNA mediated KD of over-expressed ITM2A a 
3:1 ratio was used, where 3g of shRNA were co-transfected with 1g of the over-
expression construct. Prior to transfection fresh standard medium was applied to the 
cells and the DNA/TurboFect mix was added drop-wise. Cells were incubated with 
the transfection mix for 6hrs at 37°C in a 5% CO2 incubator, after which fresh standard 
medium was applied. 48hrs post transfection the cells were lysed and ITM2A protein 
analysed by immunoblot.  
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Plasmid Construction  
 
PiggyBac Transposable constructs  
PiggyBac transposable constructs were generated as follows; piggyBac (PB) terminal 
repeats (TR) were amplified from pCyL50 and cloned into the overexpression vectors 
pIRES2-EGFP, and pMSCVpuro, the knockdown vector pRFP-C-RS, and the 
luciferase reporter pGlucBasic, such that they flanked the promoter/MSC, Gaussia 
luciferase gene (pGlucBasic) and mammalian antibiotic resistance markers. The 
5’PBTR and 3’PBTR were amplified using primers listed below in table 5. 
Table 2.5: PCR primers used to amplify piggyBac terminal repeats (PBTR).  
Amplicon Froward primer (5’>3’) Reverse primer (5’>3’) 
5’PBTR GGTACCTCGCGCGACTTGGTTTGC GCTAGCCAACAAGCTCGTCATCGC3 
3’PBTR TTAATTAACGAGAGCATAATATTGATAT GAGCTCGGTATTCACGACAGCAGG 
 
Gibson assembly was used to insert the TR into each construct, and the primers shown 
above in table 5 contained additional ‘overlap’ sequence of approximately 15bp at the 
5’ end, to complement each vector respectively and facilitate the assembly cloning. 
These primers are listed below in table 6. Lower case sequence represents the vector 
‘overlap’ portion of the primer and uppercase sequence is complementary to the insert 
being amplified.  
Table 2.6: Gibson assembly primers used to amplify piggyBac terminal repeats 
(PBTR) in the previously described vectors.  
Primer name  Gibson primer sequence (5’>3’) 
5'PBTR.pIRES2-EGFP5' cgccatgcattagttatGGTACCTCGCGCGACTTG 
5'PBTR.pIRES2-EGFP3' cccgtaattgattactatGCTAGCCAACAAGCTCGTC 
3'PBTR.pIRES2-EGFP5' cgccatgcattagttatTTAATTAACGAGAGCATAATATTGATAT 
3'PBTR.pIRES2-EGFP3' cccgtaattgattactatGAGCTCGGTATTCACGAC 
5'PBTR.pMSCVpuro5' tactgagagtgcaccaGGTACCTCGCGCGACTTG 
5'PBTR.pMSCVpuro3' ggtatttcacaccgcaGCTAGCCAACAAGCTCGTC 
3'PBTR.pMSCVpuro5' gataacgcaggaaagaaTTAATTAACGAGAGCATAATATTGATATC 
3'PBTR.pMSCVpuro3' gctggccttttgctcaGAGCTCGGTATTCACGAC 
5'PBTR.pRFPCRS5' ccggccggatcggtgGGTACCTCGCGCGACTTG 
5'PBTR.pRFPCRS3' gtctttccactggggGCTAGCCAACAAGCTCGTC 
3'PBTR.pRFPCRS5' cactggccaattggttTTAATTAACGAGAGCATAATATTGATAT 
3'PBTR.pRFPCRS3' cgcggctacaattgttGAGCTCGGTATTCACGAC 
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5'PBTR.pGlucbasic5' agtgccacctgacgtGGTACCTCGCGCGACTTG 
5'PBTR.pGlucbasic3' ccgatccgtcgacgtGCTAGCCAACAAGCTCGTC 
3'PBTR.pGlucbasic5' gtatcttatcatgtctgtaTTAATTAACGAGAGCATAATATTGATAT 
3'PBTR.pGlucbasic3' ctagaggtcgacggtaGAGCTCGGTATTCACGAC 
 
The 5’PBTR was inserted into the AseI site of pIRES2-EGFP, the NdeI sites of 
pMSCVpuro, the EcoR1 site of pRFP-C-RS and the Aat II site of pGlucBasic, while 
the 3’PBTR was inserted into the BsaI site of pIRES2-EGFP, the PciI sites of 
pMSCVpuro, the PciI site of pRFP-C-RS and BstZ17I site of pGlucBasic, to generate 
pCMV(PB), pMSCV(PB), pRFP(PB) and pGluc(PB)basic. The transposable pIRES2-
EGFP plasmid with piggyBac terminal repeats will be referred to as pCMV(PB) to 
simplify nomenclature.   
LMNA, ITM2A and IGFBP5 overexpression constructs  
A human LMNA (WT and R482W mutant) cDNA plasmid was kindly provided by 
Howard J Worman (Department of Pathology and Cell Biology, Columbia 
University). LMNA was amplified from this plasmid and inserted into the XhoI and 
EcoRI sites of pCMV(PB) to produce pCMV(PB)-Flag-LMNA-WT and pCMV(PB)-
Flag- LMNA-R482W. LMNA was also amplified and inserted into the XhoI and 
EcoRI sites of pMSCV(PB) to generate pMSCV(PB)-Flag-LMNA-WT and 
pMSCV(PB)-Flag- LMNA-R482W.  
ITM2A mouse cDNA was purchased from Origene, amplified and inserted into the 
XhoI and EcoRI sites of pMSCV(PB), to generate a fusion protein with a 107aa C- 
terminal addition that included a Myc-DDK tag and generated pMSCV(PB)ITM2A. 
The ITM2A cDNA was also amplified and cloned into the EcoR1 and BamHI sites of 
pCMV(PB) with a separate 69aa C-terminal addition also including a Myc-DDK tag 
to generate  pCMV(PB)ITM2A. 
IGFBP5 mouse cDNA was purchased from Origene, amplified and inserted into the 
XhoI and EcoRI sites of pMSCV(PB), to generate a fusion protein with a 59aa C- 
terminal addition that included a Myc-DDK tag and generated pMSCV(PB)IGFBP5. 
Gibson assembly was used to insert LMNA, ITM2A and IGFBP5 into each vector 
backbone and the primers used to generate the above constructs are listed below (Table 
7). 
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Table 2.7: Gibson assembly primers used to amplify LMNA, ITM2A and IGFBP5 
into the previously described vectors.  
Primer name  Gibson primer sequence (5’>3’) 
pIRES2-EGFP.LMNA.F  
 
ctaccggactcagatcATCGAATTAATACGACTCATTATAG  
 pIRES2-EGFP.LMNA.R  
 
taccgtcgactgcagCATGATGCTGCAGTTCTG  
 pMSCVpuro.LMNA.F gccggaattagatctcATCGAATTAATACGACTCATTATAG 
pMSCVpuro.LMNA.R tcccctacccggtagTTACATGATGCTGCAGTTC 
pIRES2-EGFP.ITM2A.F  
 
cgagctcaagcttcgAATTCGTCGACTGGATCC 
pIRES2-EGFP.ITM2A.R  
 
ggagggagaggggcgTAAACCTTATCGTCGTCATC 
pMSCVpuro.ITM2A.F gccggaattagatctcAATTCGTCGACTGGATCC  
 pMSCVpuro.ITM2A.R tcccctacccggtagTAAACCTTATCGTCGTCATC  
 pMSCVpuro.IGFBP5.F gccggaattagatctcAATTCGTCGACTGGATCC 
pMSCVpuro.IGFBP5.R 
 
tcccctacccggtagTAAACCTTATCGTCGTCATC 
 
 
ITM2A, IGFBP5, WNT6 and PTPRQ shRNA constructs 
ITM2A shRNA constructs were purchased from Origene in pRFP-C-RS (Origene 
HuSH-29 shRNA, TF501127). Table 8 shows the 29mer sequence of the ITM2A 
shRNA constructs. PiggyBac transposable arms were then cloned into each construct 
individually, as previously described.  
 
IGFBP5, WNT6 and PTPRQ shRNA sequences were ordered from IDT as ultramer 
oligonucleotides, amplified and inserted downstream of the U6 promoter in the 
BamHI and HindIII sites of pRFP(PB) plasmid, in the final format specified by 
Origene for their HUSH-29 shRNA. The shRNA cassette contains a 29mer target 
specific shRNA sequence, a 7 nucleotide hairpin loop and the reverse 29mer 
complimentary sequence, followed by a 6 nucleotide termination sequence (Origene 
HuSH-29 application guide).  Ultramer sequences and Gibson assembly primers used 
to amplify each ultramer are listed below in table 9. Gibson assembly was originally 
used to insert the shRNA sequences into the pRFP(PB) vector, however due to high 
frequency of recombination, as assessed by sequencing, classical cloning was 
employed instead. Ultramer sequences were amplified with Gibson assembly primers, 
digested with HindIII and Sau3A1 and inserted into the pRFP(PB) construct using 
standard ligation reactions.  
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Table 2.8: ITM2A shRNA sequences. 
shRNA name  shRNA sequence  
TF501127C / FI540152 (shITM2A.1) CGTGCCATTGACAAATGCTGGAAGATTAG 
TF501127A / FI348274 (shITM2A.2) TGTTGGTGGAGCCTGCATTTACAAGTACT 
TF501127D / FI540153 (shITM2A.3) GGCGGCAATTATTCACGACTTTGAGAAGG 
TF501127B / FI540151 (shITM2A.4) GATGTAGAGGCGCTCGTCAGTCGCACTGT 
Origene tube ID reference numbers are listed in shRNA name column. ITM2A 
shRNAs are numbered 1-4 throughout the thesis, and shRNA number i.e. shITM2A.1 
is included in brackets beside the tube ID.  
Table 2.9: Ultramer sequences and Gibson assembly primers for IGFBP5, WNT6 and 
PTPRQ shRNA constructs.  
Oligonucleotide name  shRNA/Gibson primer sequence (5’>3’) 
shIGFBP5.1 GATCGCCAAGCACACTCGCATTTCCGAGCTGAAGTCAAGAGCT
TCAGCTCGGAAATGCGAGTGTGCTTGGTTTTTTGAAGCT 
 
pRFP.shIGFBP5.1.F gtggaaaggacgcggGATCGCCAAGCACACTCG 
pRFP.shIGFBP5.1.R tccacagggtcgacaAGCTTCAAAAAACCAAGCACAC 
sh.WNT6.1 GATCGGGAGGCTGCGGAGACGATGTGGACTTCGGTCAAGAGCC
GAAGTCCACATCGTCTCCGCAGCCTCCTTTTTTGAAGCT 
pRFP.shWNT6.1.F gtggaaaggacgcggGATCGGGAGGCTGCGGAG 
pRFP. shWNT6.1.R tccacagggtcgacaAGCTTCAAAAAAGGAGGCTGCG 
shPTPRQ.1 GATCGTGGAGACATACTGATTACAAAGCTTATGGTCAAGAGCC
ATAAGCTTTGTAATCAGTATGTCTCCATTTTTTGAAGCT 
 
pRFP.shPTPRQ.1.F gtggaaaggacgcggGATCGTGGAGACATACTG 
pRFP.shPTPRQ.1.R tccacagggtcgacaAGCTTCAAAAAATGGAGAC 
shPTPRQ.2 
GATCGCAGAGTGAAGCTGATAGCTGATGTAAGCATCAAGAGTG
CTTACATCAGCTATCAGCTTCACTCTGTTTTTTGAAGCT 
 
pRFP.shPTPRQ.2.F gtggaaaggacgcggGATCGCAGAGTGAAGCTG 
pRFP.shPTPRQ.2.R tccacagggtcgacaAGCTTCAAAAAACAGAGTGAAG 
shPTPRQ.3 GATCGGGCACAGTATATCTTCTTACACCAGTGCATCAAGAGTG
CACTGGTGTAAGAAGATATACTGTGCCTTTTTTGAAGCT 
 
pRFP.shPTPRQ.3.F gtggaaaggacgcggGATCGGGCACAGTATATC 
pRFP.shPTPRQ.3.R tccacagggtcgacaAGCTTCAAAAAAGGCACAG 
Red sequence in the ultramer sequences represents the modified BamHI site (GATCG) 
hairpin loop (TCAAGAG), and termination sequence (TTTTTT).  
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Luciferase reporter constructs  
ITM2A and IGFBP5 promoter regions were amplified from mouse genomic DNA and 
inserted into the EcoRI and HindIII (ITM2A) or BglII and HindIII sites (IGFBP5) of 
pGlucBasic or pGluc(PB)basic, directly upstream of the Gaussia secreted luciferase. 
Gibson assembly was used to insert the ITM2A promoter fragments into 
pGluc(PB)basic, and standard primers with BglII (F) and HindIII (R) restriction sites 
included were used to insert the IGFBP5 promoter fragments into pGlucBasic and 
pGluc(PB)basic.  All primers used to generate the constructs are listed below, in table 
10. 
Four ITM2A promoter fragments were amplified of approximately 2kb, 1.5kb, 1kb 
and 0.5kb upstream of the translational start site. Exact positioning is shown in the 
schematic in Figure 3.3, chapter 3. Two IGFBP5 promoter fragments were amplified 
of approximately 2.4kb and 1.2kb upstream of the translational start site. Exact 
positioning is shown in the schematic in Figure 5, chapter 4. 
Two further ITM2A promoter constructs were generated with a 0.35kb promoter 
fragment and a 0.5kb promoter fragment including a mutated GATA site as shown in 
the schematic in figure 3.4, chapter 3. The 0.35kb and GATA mutant 0.5kb fragments 
were purchased as gBlock gene fragments from IDT, amplified and inserted into the 
EcoRI and HindIII sites of pGluc(PB)basic using Gibson assembly.  
 
Table 2.10: Gibson assembly and standard primers used to amplify ITM2A and 
IGFBP5 promoter fragments for insertion into pGlucBasic/pGluc(PB)basic.  
Primer name  Gibson primer sequence (5’>3’) 
pGlucITM2A.2kb.F gatcgggagatcttggTACTTTTCTGAATAATACAATGTGGACTT
C pGlucITM2A.1.5kb.F 
 
gatcgggagatcttggACATCCTGCTTCTAAGGTCC 
pGlucITM2A.1kb.F gatcgggagatcttggACACCAGCATCTGGTTATATTG 
pGlucITM2A.0.5kb.F gatcgggagatcttggGTTGCAGAACTCAGAAACC 
pGlucITM2A.0.35kb.F gatcgggagatcttggGTAGGAGCATGCCTGGGG 
 
pGlucITM2A.0.5kb.GATA.mt gatcgggagatcttggGCCAGGCCCAAGTTTGGG 
 
pGlucITM2A.R ccgagctcggtaccaGGTGAATCTTCGGGCTGC 
pGlucIGFBP5.2.4kb.F CTATAGATCTgcacacagctcttcttccctct  
pGlucIGFBP5.1.2kb.F CTATAGATCTgaaaggacttcttgggcagggta  
pGlucIGFBP5.R GCATTAAGCTTtttctcggagtctggctttacct  
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Gibson vector overlap sequences are shown in lower case in ITM2A primers. 
Additional bases and restriction sites (underlined) are shown in capitals in IGFBP5 
primers, with promoter complementary sequence in bold lowercase.  
 
Dual constructs  
Dual piggyBac transposable LMNA over-expression and ITM2A/WNT6 shRNA 
constructs were generated by amplifying the shRNA cassette for either shITM2A.1 or 
shWNT6.1 (including U6 promoter) and inserting it into the AflII site of pCMV(PB)- 
FLAG-LMNA WT, pCMV(PB)- FLAG-LMNA R482W and pCMV(PB) empty 
vector. Gibson assembly primers used to amplify the shRNA cassettes are listed below 
(Table 11).  
 
Table 2.11: Gibson assembly primers used to amplify shRNA cassettes. 
Primer name Gibson primer sequence (5’>3’) 
pCMV(PB).shRNA.F caaactcatcaatgtatcAATTCCCCAGTGGAAAGAC 
pCMV(PB).shRNA.R cgcttacaatttacgccCTGACACACATTCCACAG 
 
 
Agarose gel electrophoresis  
Agarose powder was dissolved in Tris-acetate-EDTA (TAE) containing 40mM Tris-
acetate and 1mM EDTA, by microwave heating. SafeView Nucleic Acid Stain was 
added (1l/10ml agarose gel solution) and mixed well before gel was cast. Samples 
were mixed with 6X loading dye, loaded on the agarose gel and ran in 1X TAE buffer 
at 100 volts at room temperature. Running duration was modified depending on the 
size on the DNA product being visualised.  
 
Lithium Borate agarose gel electrophoresis 
A lithium borate system was used for high resolution agarose electrophoresis of the 
small amplified shRNA DNA molecules. Agarose powder was dissolved in 1X lithium 
borate (LB) buffer and SafeView Nucleic Acid Stain was added (1l/10ml agarose gel 
solution) and mixed well before gel was cast. Samples were mixed at a 1:1 ratio with 
a LB loading dye, loaded on the agarose gel and ran in 0.1X LB buffer at 120 Volts at 
room temperature. LB buffer composition is listed below in Table 12.  
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Table 2.12: Lithium borate buffer and loading dye composition.  
Component  Final Concentration  
1X Lithium borate Buffer (pH 8.2-8.5)  
Lithium hydroxide monohydrate 
10mM 
Boric acid  
0.6M 
 
 
Loading Dye 
 
 
 LB buffer 0.5X 
Glycerol  50% 
Bromophenol blue  0.2% 
 
 
Polymerase chain reaction (PCR) amplification  
LMNA, ITM2A, IGFBP5 cDNA, piggyBac terminal repeats, ITM2A and IGFBP5 
promoter fragments, and ITM2A, IGFBP5, PTPRQ and WNT6 shRNA sequences 
were amplified using Q5 or Phusion high fidelity polymerases. PCR reactions were 
set up as recommended by the manufacturer for each polymerase. Briefly, all DNA 
and reagents were thawed and kept on ice while 50l reactions were set up as 
described in Table 13. 
 
Table 2.13: PCR reaction setup. 
Component  50l reaction  Final 
concentration 5X reaction buffer 10l 1X 
10 mM dNTPs 
 
1l 200 µM 
 
10 µM Forward Primer 
 
2.5l 0.5 µM 
 
10 µM Reverse Primer 
 
2.5l 0.5 µM 
 
Template DNA 
 
Variable  
 
<200ng 
GC enhancer/DMSO 10l/2.5l 1X/5% 
Polymerase 0.5l 1 Unit  
ddH2O To 50l  
 
GC enhancer (Q5), GC 5X reaction buffer (Phusion) or DMSO (Phusion) were used 
when appropriate. Template DNA concentrations varied depending on product being 
amplified, promoter fragments were amplified from approximately 100ng of mouse 
genomic DNA while piggyBac terminal repeats, gene cDNA and shRNA sequences 
were amplified from approximately 1-2ng of plasmid/ultramer template. All primers 
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are listed in the plasmid construction section above, and all annealing temperature 
used were as recommended by the NEBuilder assembly tool (www.neb.com) when 
generating Gibson assembly primers. Standard thermocycling conditions were used as 
shown below (Table 14). A hot start was used for all reactions; samples were heated 
to 95C for 1 minute prior to the addition of polymerase. Duration of elongation was 
varied depending on the length of the product with approximately 30 seconds per kb. 
 
Table 2.14: Thermocycling conditions for PCR reactions.  
Step   Cycles Temperature  Duration 
concentratio
n 
Hot start  1 95C 1 minute 
Initial denaturation  1 98C 30 seconds 
Denaturation 35 98C 10 seconds 
Annealing  Variable 30 seconds 
Elongation   72C 
 
variable 
Final Extension  1 72C 
 
2 minutes  
Cooling/Hold  4C unlimited 
 
Promoter fragments, gene cDNA and piggyBac terminal repeat PCR products were 
separated on 1% agarose gels with a 1kb ladder. All shRNA PCR products were 
separated on 2% lithium borate gels with a 100bp ladder. Visualisation of all products 
was carried out using SafeView Nucleic Acid Stain, and the Bio-Rad Gel DocTM EZ 
Gel documentation system. PCR products were purified using the QIAquick PCR 
purification kit for downstream applications.  
 
 Restriction endonuclease digestion  
All restriction endonuclease enzymes were purchased from NEB and digestion 
reactions were carried out as recommended for each individual enzyme. Typically, 
1g of DNA (vector/insert) was digested with 10 units (1l) of restriction enzyme, in 
a 50l reaction containing 1X buffer, for 1 h at 37C. The NEB double digest finder 
was used to select appropriate buffer for double-digests, and these reactions were 
incubated for 2 h at 37C. In all cases, enzymes were added last and samples were 
mixed gently by pipetting. Digested products were separated on 1% agarose gels with 
a 1kb ladder and visualised using SafeView Nucleic Acid Stain, and the Bio-Rad Gel 
DocTM EZ Gel documentation system. Digested products were purified using the 
QIAquick PCR purification kit for downstream applications. 
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Gibson assembly  
All Gibson assembly primers were designed using the NEBuilder assembly tool, with 
15 nucleotide overlaps. The Gibson assembly reaction is summarised in figure 2.1, 
where the key steps of the reaction are illustrated.  
Gibson assembly reactions were carried out as described by Gibson et al., 2009. A 
stock of 5X isothermal reaction (ISO) buffer was prepared and stored at -20C (500 
mM Tris-HCl pH 7.5, 50 mM MgCl2, 1 mM of each dNTP, 50 mM DTT, 25% PEG-
8000, 5 mM NAD). The assembly master mixture was prepared as outlined below 
(Table 15), and 15l aliquots were stored at -20C. For each Gibson assembly 
reaction, an assembly master mix aliquot was thawed on ice, to which 5l of DNA 
was added, mixed well by pipetting and incubated at 50C for 1 h. A total volume of 
5l of DNA was added to each reaction, with varying concentrations of insert and 
backbone. A 5:1 ratio of insert to vector backbone was used in all reactions, with total 
amounts varying depending on the concentrations of purified inserts and digested 
backbones. In all cases, empty vector control reactions were carried out; reactions 
were set up with ddH2O instead of the insert and transformed alongside each reaction. 
5l of each reaction was transformed into 50l of DH5α E. coli bacterial cells.  
 
Table 2.15: Gibson assembly master mixture.  
Component  Volume  
ISO Buffer 100l 
T5 exonuclease  0.2l 
Phusion polymerase 6.25l 
  
Taq DNA ligase 50l 
 ddH2O Up to 375l 
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Figure 2.1: Schematic representation of Gibson assembly reaction. Taken from 
Gibson et al., 2009.  
 
Standard ligation 
Standard ligations were used instead of Gibson assembly for shRNA cloning. 
Amplified shRNA sequences were purified and ligated individually with digested 
pRFP(PB) using Sticky-end Ligase Master Mix or T4 DNA ligase with a 5:1 molar 
ratio of insert to vector. Standard protocols for both the Sticky-end Ligase Master Mix 
and T4 DNA ligase are described by the manufacturer (www.neb.com). Empty vector 
control ligations were set up with ddH2O instead of insert and transformed alongside 
each reaction. 5l of each ligation reaction were transformed into 50l of DH5α E. 
coli bacterial cells. IGFBP5 promoter fragments were inserted into pGluc basic and 
pGluc(PB) basic using standard ligations. Amplified promoter sequences were 
digested and purified, and ligated individually with digested and purified pGluc Basic 
and pGluc(PB)basic using T4 DNA ligase with a 5:1 ratio of insert to vector.  
 
Bacterial transformation 
Competent DH5α E. coli bacterial cells were thawed on ice, 5l (20-100ng DNA) of 
Gibson assembly reactions or standard ligations was added to 50l of competent cells, 
mixed gently by flicking and incubated on ice for 20 minutes. Cells were heat shocked 
at 42C for 90 seconds using a water bath, and placed back on ice. 500l of LB broth 
was added and cells were incubated at 37C for 40-60 minutes. 100l of cells were 
plated on LB agar plates containing a selection antibiotic, and incubated overnight at 
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37C. pCMV(PB) vector reactions were plated with 50g/ml Kanamycin, 
pMSCV(PB) and pGluc(PB) vector reactions were plated with 50g/ml Ampicillin, 
and pRFP(PB) vector reactions were plated with 20g/ml Chloramphenicol.  
 
Identification of positive clones and plasmid purification 
Positive clones were identified either by restriction digest or colony PCR. Bacterial 
colonies were used to inoculate 5 ml of LB broth containing an appropriate selection 
antibiotic (depending on vector backbone), and incubated overnight in a 37C shaking 
incubator. Plasmids were extracted from the bacterial cultures using the QIAprep Spin 
Miniprep Kit and digested with the appropriate restriction enzymes to confirm the 
presence of the insert. Alternatively, colony PCR was performed prior to plasmid 
purification, to identify positive clones. PCR reactions were carried out using Taq 
polymerase as recommended by the manufacturer, individual bacterial colonies were 
added directly to each 25l reaction and lysed during the initial denaturing step. PCR 
products were separated on 1% agarose gels with a 1kb ladder and visualised using 
SafeView Nucleic Acid Stain, and the Bio-Rad Gel DocTM EZ Gel documentation 
system. Positive colonies were used to inoculate 5mls of LB broth containing selection 
antibiotic, incubated overnight in a 37C shaking incubator, and plasmids extracted as 
previously described. Prior to plasmid extraction 25% glycerol stocks of positive 
colonies were made and stored at -20C. Once the insert sequence was confirmed by 
sequencing, plasmids were purified on a larger scale for mammalian cell transfections, 
using the PureYieldTM Plasmid Midiprep System. Briefly, 200-300 ml of LB broth 
with selection antibiotic was inoculated with a glycerol stock (50-100l) and 
incubated overnight in a 37C shaking incubator. The bacterial cells were then pelleted 
by centrifugation, re-suspended and lysed at room temperature. Lysates were 
neutralized and centrifuged again. The cleared lysate was then applied to a 
PureYieldTM clearing and binding column, each column was washed with an endotoxin 
and column wash and the plasmid DNA eluted in 400l of ddH2O.  
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Sequencing  
All promoter fragment, gene cDNA and piggyBac terminal repeat sequences were 
verified by standard sanger sequencing by a service provider (www.gatc-biotech.com) 
and shRNA sequences were verified with an adapted sanger sequencing protocol 
(GATC Supreme run).  
 
Ribonucleic acid (RNA) extraction and complementary (cDNA) synthesis 
Total RNA was extracted from 3T3-L1/3T3-NIH/MEF cell biological triplicates using 
homemade Trizol. Cells were trypsinised and pelleted by centrifugation at 1500 rpm 
for 5 minutes, supernatant was removed gently and cell pellets were stored at -80C 
until RNA extraction. Solid crystalline phenol was melted in a 50C water bath and 
water saturated by adding ddH2O in excess and mixing well. The solution was allowed 
to settle overnight so that excess water separated and settled on top of the saturated 
phenol solution. The lower phenol phase was then used to make homemade Trizol 
with the reagents listed below in Table 16, and stored at 4C. 
 
Table 2.16: Homemade Trizol reagent (50 ml). 
Reagent Volume Final 
concentration ddH2O saturated phenol  19 ml 38% 
Guanidine thiocyanate 
 
4.73g 0.8M 
Ammonium thiocyanate 
 
3.8g 0.4M 
 
Sodium acetate, pH 5.0 (3M) 
 
1.67 ml 0.1M 
Glycerol  
 
2.5 ml 
 
5% 
ddH2O Up to 50 ml  
 
Trizol was added to the frozen cell pellets (approximately 500l per 10cm2 growth 
area) and complete cell lysis was aided by pipetting. Samples were centrifuged at 
12,000 x g, for 10 minutes, at 4C, to remove debris. Supernatant was transferred to a 
new sterile 1.5 ml Eppendorf tube. Chloroform was added to each tube (1/5th of Trizol 
volume) and samples were mixed well by vigorous shaking for 15 seconds. Samples 
were centrifuged at 12,000 x g, for 15 minutes, at 4C. The upper aqueous phase was 
carefully transferred to a new sterile 1.5 ml Eppendorf tube and isopropanol was added 
(1/2 of Trizol volume). Samples were mixed well by vortexing and centrifuged at 
12,000 x g, for 10 minutes, at 4C, to pellet RNA. The RNA pellet was washed once 
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with 80% ethanol, vortexed briefly, and centrifuged at 7,500 x g for 5 minutes, at 4C. 
The ethanol supernatant was removed gently and the RNA pellets were dried briefly 
at room temperature. RNA was re-suspended in ddH2O by pipetting and the 
concentration was determined using a NanoDrop ND-1000 Spectrophotometer. All 
RNA samples were stored at -80C. RNA quality was assessed by checking for intact 
28S and 18S rRNA bands after agarose gel electrophoresis. 
 
cDNA was synthesized using the Tetro cDNA Synthesis Kit, as recommended by the 
manufacturer. Master mix was prepared on ice and 9l aliquoted into individual PCR 
tubes (Table 17). 11l of sample containing between 500ng to 2g of RNA was added 
to each tube. RNA concentrations added were kept constant between biological 
triplicates and controls within an experiment. Both random hexamer and oligo (dT)18 
priming were used concurrently. Samples were mixed gently by pipetting and 
incubated at 25C for 10 minutes, 45C for 30 minutes and the reaction was terminated 
by incubation at 85C for 5 minutes. Samples were chilled on ice and diluted 1 in 2 
with ddH2O. Samples were either kept at 4C for short term or -20C for long term 
storage.  
 
Table 2.17: Tetro cDNA synthesis reaction.  
Component Volume 
RNA 500ng to 2g 
10mM dNTP mix  
 
1l 
Random Hexamer mix 1l 
Oligo (dT)18 mix 1l 
5X RT Buffer 4l 
RiboSafe RNase Inhibitor  
 
 
1l 
 
Tetro Reverse Transcriptase (200u/μl)  
 
1l 
DEPC-treated water  
 
To 20l 
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Quantitative RT-PCR 
Quantitative RT-PCR analysis was performed using IDT PrimeTime qPCR probe- 
based assays, with all predesigned assay IDs listed in the materials sections (Table 3). 
10l reactions were set up containing 1l of 10X probe-primer mix, 2l of HOT 
FIREPol Probe qPCR Mix Plus (ROX) polymerase, 2-3l of cDNA and made up to 
10l with ddH2O. Each biological triplicate was measured in duplicate reactions, in a 
96 well plate on the AB7300 Real- Time PCR cycler. All IDT Probe/primer assays 
were validated with a custom IDT gBlock titration. Expression of each gene was 
normalized to NoNo expression which is a validated reference gene for qPCR analysis 
for 3T3-L1 cells 167 and relative mRNA expression was calculated using the 2(-delta 
delta C(T)) method.  
Western Blotting 
Cell lysates were prepared as follows: 3T3-L1, 3T3 NIH or MEF cells were washed 
with PBS and scraped into lysis buffer (2% SDS, 62.5mM Tris-HCL; pH 6.8, 10% 
glycerol, 0.01% bromophenol blue, 41.6mM DTT). Lysates were sonicated for 
approximately 10 seconds and centrifuged at 16,000 x g for 20 mins at 4°C, and stored 
at -80°C. Tris-glycine SDS-Polyacrylamide gels were cast in 1.5mm BIO-RAD 
casting plates (Table 18, Table 19). For SDS-polyacrylamide gel electrophoresis 
(PAGE), lysates were boiled for 5 minutes and cooled on ice before being separated 
on 8-12% polyacrylamide gels, with the EZ-RunTMprestained protein ladder. 
Electrophoresis was run at 100 volts through the stacking gel, and at 120 volts through 
the resolving gels in Tris-Glycine buffer, until the tracking dye had diffused into the 
buffer. Samples were transferred to nitrocellulose membranes (Amersham Protran 
0.2μm NC), in transfer buffer at 100 volts for 45-60 minutes, and protein transfer was 
confirmed by Ponceau staining. Membranes were blocked for 1hr at room temperature 
and immunoblotted with primary antibodies at 4°C overnight, as recommended by 
antibody manufacturers (Table 19). Membranes were then washed three times for 5 
minutes at room temperature, in wash buffer recommended for each primary antibody 
(Table 19).  Membranes were incubated with HRP-conjugated secondary antibody 
(1:2000 dilution, 5% milk – Amersham ECL IgG, HRP-linked whole ab, GE 
Healthcare Life Sciences), for 1hr at room temperature and washed three times again, 
for 5 minutes, with recommended wash buffer. Signals were detected with 
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SuperSignalTM West Pico/Femto Chemiluminescent Substrate, and developed on CL-
XPosureTM radiography film.   
 
Table 2.18: 5% stacking gel for SDS-PAGE. 
Component Volume (5ml) 
30% Polyacrylamide 
 
0.85 ml 
1M Tris(pH6.8) 
 
0.625 ml 
10% Ammonium persulfate  
 
0.05 ml 
10% SDS  
 
0.05 ml 
TEMED  
 
5 l 
H2O  
 
3.4 ml 
 
Table 2.19: Resolving gels for SDS-PAGE.  
Component Volume (10ml)  
12% 8% 
30% Polyacrylamide 
 
4 ml 2.7 ml 
1.5M Tris(pH8.8) 
 
2.5 ml 2.5 ml 
10% Ammonium persulfate  
 
0.1 ml 0.1 ml 
10% SDS  
 
0.1 ml 0.1 ml 
TEMED  
 
4 l 6 l 
H2O  
 
3.3 ml 4.6 ml 
 
Table 2.20: Primary antibody recommended buffers. 
Antibody Blocking buffer Primary AB incubation  Washing buffer 
Anti-Flag 5% Milk in TBS 5% Milk in TBS TBS 
THETM DYKDDDDK Tag 
antibody 
5% Milk in PBS 1%BSA in PBST PBST 
Anti-PPARγ 5% Milk in TBST 5%BSA in TBST TBST 
Anti-Lamin A/C (2032) 5% Milk in TBST 5%BSA in TBST TBST 
Anti-ITM2A (14407) 5% Milk in TBST 5%Milk in TBST 
 
TBST 
Anti-Β-actin 5% Milk in TBST 5%Milk in TBST 
 
TBST 
Anti-α-tubulin  5% Milk in TBST 5%Milk in TBST 
 
TBST 
 
Table 2.21: Antibody dilutions.  
Antibody Dilution  Dilution for secondary antibody  
Anti-Flag 1:1000 Anti-Mouse 1:2000 
THETM DYKDDDDK Tag 
antibody 
1:1000 Anti-Mouse 1:2000 
Anti-PPARγ 1:1000 Anti-Rabbit 1:2000 
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Anti-Lamin A/C (2032) 1:1000 Anti-Rabbit 1:2000 
Anti-ITM2A (14407) 1:1500 
 
Anti-Rabbit 1:2000 
Anti-Β-actin 1:2000 Anti-Mouse 1:2000 
Anti-α-tubulin  1:2000 Anti-Mouse 1:2000 
 
Table 2.22: Western Blotting buffer compositions. 
Component  Final Concentration  
Tris-Glycine buffer for SDS-PAGE  
Tris Base 25mM 
Glycine 192mM 
 SDS 
 
0.1% (wt/vol) 
 
Transfer Buffer  
Tris Base 25mM 
Glycine 192mM 
Methanol  20% (vol/vol) 
 
Protein precipitation 
Trichloroacetic acid (TCA) and acetone protein precipitation were carried out to 
concentrate secreted proteins in 3T3-L1 and 3T3-NIH medium. Briefly, 1 volume of 
TCA was added to 4 volumes of media sample and incubated at 4°C for 10 minutes. 
Samples were centrifuged at 12,000 rpm for 5 minutes, and the supernatant removed. 
Protein pellets were washed with 200l cold acetone and centrifuged at 12,000 rpm 
for 5 minutes, twice. Protein pellets were then dried for 2-3 minutes on a 95°C heat 
block to remove acetone. For SDS-PAGE 1X lysis buffer (described in western 
blotting section) was added to the protein pellets, and the samples boiled for 10 
minutes before separating on a 12% polyacrylamide gel.  
 
Luciferase reporter assay  
3T3-L1 cells were stably transfected (as described above) and seeded in triplicate for 
each differentiation treatment (MDI/DI/D, LiCL, and testosterone) in 12 well plates. 
Cells were grown to confluence, and induced to differentiate as described above. Small 
aliquots of media (30 l) were taken at 24 h intervals post media changes and stored 
at - 20°C until assayed for luciferase activity. Samples (10μl) were assayed for 
Gaussia secreted luciferase activity with 1.43μM coelenterazine (NanoLight 
Technology) substrate in PBS on the Veritas Microplate Luminometer (Turner 
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Biosystems) as previously described (58). The luciferase activity directed by each 
stably transfected ITM2A/IGFBP5 promoter fragment was normalized to that of the 
pGluc(PB)basic empty vector construct to account for the weak promoter activity of 
the piggyBac transposable arms in the vector backbone (57).  
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CHAPTER 3: ITM2A SILENCING RESCUES LMNA MEDIATED 
INHIBITION OF 3T3-L1 ADIPOCYTE DIFFERENTIATION 
 
INTRODUCTION 
ITM2A was first identified as a novel marker for chondro-osteogenesis in a cDNA 
library screen generated from mouse mandibular condyle explant cultures 168. This 
type II membrane protein belongs to a family of integral membrane proteins that 
includes ITM2B and ITM2C, all of which are part of a BRICHOS superfamily. ITM2 
proteins are composed of four defined regions; a hydrophobic, linker, extracellular 
BRICHOS and the intracellular C-terminal domains. There is a high degree of 
conservation between the ITM2 proteins as well as between mammalian homologues 
169. 
Although the exact function of ITM2A is unclear, a number of studies have described 
a regulatory role in chondrogenic and myogenic differentiation, as well as thymocyte 
development 170–172. ITM2A expression is low during the early stages of 
chondrogenesis and then strongly up-regulated as cells progress through the 
chondrogenic differentiation programme. Bi-potential C3H10T1/2 cells 
overexpressing ITM2A show similar levels of adipogenesis and osteogenesis as 
control cells, when induced to differentiate towards these respective lineages. ITM2A 
over-expression does however appear to inhibit the chondrogenic differentiation of 
this cell line. In addition, ITM2A was identified as differentially expressed between 
ASC and MSC with distinct chondrogenic potentials; ASC have a reduced capacity to 
differentiate into chondrocytes when compared to MSC, and display higher 
endogenous levels of ITM2A 170,173. This may account for the reduced potential of 
ASC to undergo chondrogenesis. 
ITM2A has been identified as a PAX3, GATA3 and PKA CREB target in diverse 
systems 171,172,174. In the C2C12 myoblast cell line, endogenous ITM2A expression is 
increased during cell differentiation and over-expression leads to enhanced myotube 
formation. ITM2A expression is detected at sites of myogenesis in mice and PAX3 
mutant embryos display reduced ITM2A 171,175. ITM2A was described as a GATA3 
target in mouse thymocytes and reported to be down-regulated in GATA3 knockout 
thymocytes when compared to control 172. Recently a novel role for ITM2A has been 
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reported in autophagy. It is described as a PKA-CREB signalling target, and when 
over-expressed appears to interfere with autophagic flux, leading to the accumulation 
of autophagosomes and a block in the formation of autolysosomes. ITM2A silencing 
was also seen to obstruct autophagy, with the formation of large agglomerations within 
the cell 174. These reports highlight the importance of ITM2A in the differentiation of 
a number of cell types, however the exact molecular function of the protein remains 
to be described. ITM2A knock-out mice have been produced independently by two 
different groups 171,172 neither of which have reported a specific altered phenotype.  
This study aims to investigate the relationship between ITM2A, adipogenesis and 
inhibition of adipogenesis by LMNA. 
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RESULTS 
 
Method development and vector construction 
Extensive work was carried out in this thesis aimed at developing a system that 
facilitated the generation of a diverse number of gene constructs and robust analysis 
of transfected gene activity in the adipocyte differentiation 3T3-L1 cell model. In the 
early stages of this work, significant difficulties were encountered with standard 
methods. In particular, transient transfection of LMNA proved problematic as a) the 
3T3-L1 cell line is difficult to transfect with common methods yielding low 
transfection efficiencies, b) following transfection, differentiation of the cells into 
adipocytes takes approximately ten days during which time significant loss of 
transiently transfected constructs occur, c) selection for stable transfectants proved to 
have very variable success rates and influenced the downstream differentiation 
potential of these cells, and d) stable transfection with dual constructs was not feasible. 
To overcome these and other limitations, the piggyBac transposon system was utilised. 
This flexible system was adapted and proved sufficiently robust for use as a central 
method in this thesis. Full details of the development of the piggyBac system and the 
extensive vector construction carried out in this thesis are described in detail in the 
methods section.      
 
LMNA over-expression inhibits 3T3-L1 adipogenesis and increases ITM2A 
expression  
Exogenous expression of human LMNA (WT and R482W mutant) has previously 
been shown to inhibit in vitro differentiation of mouse 3T3-L1 preadipocytes 20. In 
order to investigate the effects of LMNA on the transcriptional profile of these cells 
during the early stages of terminal differentiation 3T3-L1 preadipocytes were 
successfully stably transfected with human LMNA over-expression constructs 
(pCDNA3-LMNA-WT and pCDNA3-LMNA-R482W) and differentiation was 
induced. At 36 h post application of the induction cocktail RNA was extracted from 
the stably transfected cells and RNA-Seq analysis was performed. Altered expression 
of over 200 genes was detected in comparison to control, including ITM2A, with a 16 
and 8 fold increase in expression observed in response to LMNA-WT and LMNA-
R482W mutant respectively.  
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To confirm the effects of LMNA on ITM2A expression 3T3-L1 preadipocytes were 
stably transfected with human pCMV(PB)-Flag-LMNA-WT and pCMV(PB)-Flag-
LMNA-R482W using a piggyBac transposable system. These preadipocytes were 
then induced to differentiate, adipogenesis was assessed at day 8 through Oil Red O 
staining of intracellular lipid droplets (Figure 3.1A) and LMNA over-expression was 
assessed at the mRNA level using quantitative real-time PCR (qPCR) and at the 
protein level by western blotting (Figure 3.1B, C). Cells transfected with EV control 
differentiated well, while cells expressing both WT and R482W mutant LMNA 
accumulated significantly less lipid droplets, confirmed by Oil Red O quantification 
(Figure 3.1A).  
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Figure 3.1: LMNA inhibits differentiation of 3T3-L1 cells and increases ITM2A 
mRNA expression. 3T3-L1 preadipocytes were stably transfected with pCMV(PB)-
Flag-LMNA-WT, pCMV(PB)-Flag-LMNA-R482W or empty vector (EV) control 
pCMV(PB) and induced to differentiate into adipocytes. (A) Adipogenesis was 
assessed at day 8 post induction; cells were stained for lipid droplet accumulation with 
Oil Red O. Oil Red O quantification was carried out using ImageJ and expressed as 
Oil red O absorbance units (ORO a.u.). (B) Total RNA was isolated at day -2 of 
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differentiation from the stably transfected 3T3-L1 preadipocytes and LMNA 
expression measured by qPCR using primers specific for human LMNA. (C) 
Immunoblot analysis of flag-LMNA WT and R482W mutant at day -2. (D, F) Total 
RNA was isolated at day 4 post induction and the expression of PPARγ and CEBPα 
was analysed by qPCR. (E) Immunoblot analysis of PPARγ at day 4 post induction. 
(G) ITM2A expression was analysed at day -2 by qPCR. Student’s t-test (two-tailed, 
assuming equal variance) was used to calculate statistical significance compared to 
empty vector control cells, indicated as follows: *=P<0.05;**=P<0.01; ***=P<0.001. 
 
Previously, several reports have shown that LMNA over-expression reduces PPAR2 
expression in adipogenesis; over-expression of WT and mutant LMNA in 3T3-L1 
cells 20 and in MSCs 176 produced this effect while reduction of PPAR2 expression 
was also observed when LMNA over-expression was driven from an adipose specific 
promoter in transgenic mice (55). To determine the effects of LMNA on specific 
adipogenic markers, PPAR2 and CEBP expression was measured at day 4 in 
differentiating 3T3-L1 cells expressing WT or R482W mutant LMNA and the 
expression of both markers was reduced in these cells in comparison with the control 
(Figure 3.1D, F). Immunoblot analysis of PPAR at day 4 of differentiation revealed 
the presence of 3 PPAR isoforms of ~60, ~55 and ~45 kDa respectively (Figure 3.1E). 
The two larger isoforms PPAR2 and PPAR1, are produced through the use of 
alternative promoters and have differential abilities to promote adipogenesis. PPAR2 
has an additional 28 N terminal amino acids and is exclusively expressed in adipose 
tissue, where it functions as a master regulator of adipogenesis 123–125. A number of 
studies have identified a smaller PPAR isoform, known as ORF4, which does not 
contain the ligand-binding domain of PPAR1 and 2 and displays dominant negative 
activity towards PPAR 125,153. It is likely, although not confirmed, that the 45kDA 
protein detected here is the previously described ORF4. Interestingly, ectopic 
expression of WT and R482W mutant LMNA appears not only to reduce PPAR2 as 
expected, but also ORF4, while having little to no effect on PPAR1 (Figure 3.1E). 
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Having confirmed LMNA over expression and the resulting inhibition of adipogenic 
differentiation, ITM2A expression levels were assessed in the stably transfected 3T3-
L1 preadipocytes. Both WT and R482W mutant LMNA increased endogenous 
ITM2A expression levels (Figure 3.1G).  
 
Endogenous ITM2A expression and promoter activity in 3T3-L1 differentiation 
ITM2A expression has previously been characterised in chondrogenic and myogenic 
differentiation where it is up-regulated at distinct stages of each of the respective 
differentiation programmes 170,171. Microarray analysis of gene expression in 3T3-L1 
differentiation has reported relatively low levels of ITM2A expression throughout 
differentiation with little variation observed across the adipogenic programme 178. 
ITM2A expression was profiled during 3T3-L1 differentiation and similar to the 
microarray data previously described relatively low expression of ITM2A was 
observed, however a significant down-regulation of gene expression at day 2 was 
detected (Figure 3.2), approximately 48 h post application of the induction cocktail. 
This reduction in ITM2A expression was consistently observed at this specific stage 
of cell differentiation. Expression levels consistently reverted back to pre-induction 
levels by 96 h.  
 
The in-vitro differentiation of 3T3-L1 preadipocytes involves the growth of these cells 
to confluence (day-2) where they undergo growth arrest. Induction of differentiation 
(day 0) is triggered by the application of an induction cocktail that activates insulin 
growth factor (Insulin), cAMP (IBMX) and glucocorticoid (dexamethasone) 
signalling pathways. Approximately 16 to 20 h post induction, the cells re-enter the 
cell cycle and undergo MCE, after which point they exit the cell cycle and terminally 
differentiate. The adipogenic transcription factors; CEBP and PPAR, are up-
regulated post MCE and proceed to drive the adipogenic programme (101,88).  
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Figure 3.2: Endogenous ITM2A expression in 3T3-L1 differentiation. 3T3-L1 
preadipocytes were grown to confluence (day-2) and two days later induction media 
was applied (day 0). A further two days later cells were supplemented with fresh media 
containing insulin (day 2). Following this, fresh media was applied every two days 
until day 8. Adipogenesis was assessed at day 8 when cells were stained for lipid 
droplet accumulation with Oil Red O. Total RNA was isolated at the indicated time 
points during 3T3-L1 differentiation. ITM2A and PPARγ expression was analysed by 
qPCR. Transcript expression at the various time points is shown relative to expression 
at day 0. A Student’s t-test (two-tailed, assuming equal variance) was used to calculate 
statistical significance at day 2 is in comparison to transcript levels at day 0, indicated 
as follows: *=P<0.05;**=P<0.01; ***=P<0.001. 
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In order to explore the relationship between these induction components and the 
observed reduction in ITM2A expression we constructed a piggyBac transposable 
luciferase reporter plasmids containing a 2kb fragments of the mouse ITM2A 
proximal promoter (Figure 3.3A) and analysed its activity in response to full (MDI) 
and sub-maximal (DI or D) induction media. 3T3-L1 preadipocytes were stably 
transfected with the luciferase construct, grown to confluence, and induced to 
differentiate. Oil-Red-O staining of lipid droplets at day 8 showed reduced adiposity 
of cells treated with the sub-maximal induction cocktail (DI or D). Luciferase activity 
was measured throughout cell differentiation and the ITM2A reporter construct 
displayed similar activity to that of the endogenous promoter, with reduced luciferase 
activity observed at day 2 of differentiation, in response to the full induction mix 
(MDI) when compared to limited induction with DI or D (Figure 3.3B). These results 
are in agreement with previously detected endogenous down-regulation of ITM2A 
mRNA at day 2 of differentiation, and indicate that full induction of adipogenesis is 
associated with a reduction of ITM2A promoter activity in the early stages of 
differentiation. To identify elements within the 2kb promoter responsible for this 
down-regulation, deletion analysis was carried out in which a series of smaller 
piggyBac transposable luciferase reporter plasmids were constructed containing 
1.5kb, 1kb and 0.5kb fragments of the ITM2A promoter (Figure 3.3A). Luciferase 
activity was assessed during 3T3-L1 differentiation in response to full (MDI) and 
submaximal induction (DI or D), and similar results were observed with these smaller 
promoter constructs (Figure 3.3B). Although the 1kb promoter was found to behave 
slightly differently in that pre-induction expression levels of luciferase were observed 
at day 4 – somewhat earlier than the other constructs. 
 
This luciferase data indicates that the M (IBMX) component of the MDI leads to a 
reduction in ITM2A promoter activity and the region of the promoter governing the 
reduction is in the 500bp immediately upstream of the ITM2A gene. This is most 
likely to be mediated by CREB interaction with the CRE binding site on the ITM2A 
promoter as forskolin like IBMX is known to raise cellular cAMP levels and activate 
the cAMP-PKA-CREB signalling pathway in adipogenesis.  These two agents lead to 
similar levels of 3T3-L1 and MEF cell differentiation when used in an adipogenic 
induction cocktail 180,181. In this scenario, CREB could function as a repressor of 
ITM2a expression, activated through forskolin or IBMX stimulation of the cAMP-
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PKA-CREB signalling pathway. In contrast to the observed situation in adipogenesis 
it has been reported that forskolin mediated PKA-CREB activation leads to increased 
human ITM2A promoter activity through a conserved CRE site in transfected 
HEK293 cells 174. This indicates that regulation of the ITM2A promoter is likely to 
differ in different cell contexts with CREB signalling resulting in ITM2A down-
regulation during 3T3-L1 cell differentiation and up-regulation in HEK293 cells. As 
the focus of this thesis was on aspects of adipogenesis influenced by LMNA, the role 
of CREB in ITM2A regulation was not pursued here, as there have been no reports of 
LMNA interaction with CREB to date.  
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Figure 3.3: ITM2A promoter activity during 3T3-L1 differentiation (A) 
Schematic depiction of ITM2A promoter luciferase constructs generated. 2kb, 1.5kb, 
1kb and 0.5kb promoter fragment were cloned upstream of Gaussia luciferase in 
pGluc(PB) basic vector. The distance (-1915, -1390, -790 and -340) from the 
transcriptional start site (TSS) and previously predicted GATA and CRE binding sites 
are shown. (B) Luciferase activity (secreted) in 3T3-L1 cells stably transfected with 
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pGluc(PB)ITM2A/2kb, pGluc(PB)ITM2A/1.5kb, pGluc(PB)ITM2A/1kb or 
pGluc(PB)ITM2A/0.5kb  throughout differentiation. Cells were induced to 
differentiate using full differentiation media (MDI– methylisobutylxanthine, 
dexamethasone and insulin), sub-maximal media (DI– dexamethasone and insulin) or 
D (dexamethasone) as indicated. Adipogenesis was assessed at day 8 when cells were 
stained for lipid droplet accumulation with Oil Red O. Luciferase activity is 
normalised to the pGluc(PB)basic empty vector control. Student’s t-test (two-tailed, 
assuming equal variance) was used to calculate statistical significance compared to 
MDI induced cells, indicated as follows: *=P<0.05;**=P<0.01; ***=P<0.001. 
 
As previously mentioned ITM2A has been described as a GATA3 target in mouse 
thymocytes where it was identified as one of the most down-regulated genes in a gene 
chip analysis comparison of GATA3 knockout versus WT cells. Subsequently a 
GATA binding site was identified in the proximal ITM2A promoter and GATA3 
overexpression was shown to activate a 2kb ITM2A promoter reporter construct in the 
GATA3 deficient M12 mouse cell line 172.  
The role of specific GATA transcription factors in adipogenesis has previously been 
described in a number of studies. GATA2 and GATA3 are expressed in preadipocytes 
and are down-regulated as the cells progress through the adipogenic programme 182. 
GATA3 over-expression has been shown to inhibit 3T3-L1 differentiation by binding 
directly to the PPAR promoter and down-regulating PPAR expression 182,183, as well 
as by modulating CEBP activity through protein-protein interactions 182.  
Recently, GATA3 has been identified as a Wnt/-catenin signalling target in 
adipogenesis. Canonical Wnt/-catenin signalling is a well characterised modulator of 
adipogenesis. Much like the GATA transcription factors, specific Wnt glycoproteins 
(WNT10a, WNT10b, WNT6) are down-regulated during adipogenesis as they are 
potent inhibitors of adipocyte terminal differentiation (88,183). Wang and Di (2015) 
183 showed that -catenin up-regulates GATA3 expression which leads to the 
inhibition of 3T3-L1 cell differentiation. LiCl treatment is known to activate Wnt/-
catenin signalling and increase cellular -catenin 185. Wang and Di (2015) 
demonstrated that LiCl activation of Wnt/-catenin signalling leads to a marked 
increase in GATA3 expression, increased GATA3 binding to the PPAR promoter 
and a resulting decrease in PPAR expression.  
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Considering that a) the RNA-Seq analysis indicates that overexpressed WT or R482W 
mutant LMNA increases expression of Wnt6, b) Wnt/-catenin signalling can up-
regulate GATA3 expression leading to the inhibition of 3T3-L1 cell differentiation 183, 
and c) previous reports that describe both increased and decreased -catenin activity 
in response to LMNA over-expression and  mutation, respectively 176,186, it was of 
interest to explore the role of the GATA binding site in the ITM2A promoter. 
Two additional luciferase reporter constructs were generated for this purpose. As the 
GATA transcription factors are important modulators of adipogenesis, the previously 
described GATA3 binding site (-222 to -227) was mutated in the 0.5kb ITM2A 
promoter construct, and a smaller 0.35kb reporter construct was generated to 
completely exclude the GATA site (Figure 3.4A). 3T3-L1 preadipocytes were stably 
transfected with these luciferase constructs, grown to confluence, and induced to 
differentiate. Luciferase activity was measured throughout cell differentiation. Both 
the GATA mutant and 0.35kb reporter constructs displayed similar activity to the 
0.5kb ITM2A construct, with a significant down-regulation of promoter activity at day 
2 of differentiation (Figure 3.4B). Therefore, the GATA element in the ITM2A 
promoter does not play a role in ITM2A down-regulation during early 3T3-L1 
differentiation.  
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Figure 3.4: GATA mutation of the ITM2A promoter in 3T3-L1 differentiation. 
(A) Schematic depiction of ITM2A promoter luciferase constructs generated. 0.5kb 
GATA mutant and 0.35kb promoter fragments were cloned upstream of Gaussia 
luciferase in pGluc(PB) basic vector. WT and mutant GATA sequences are shown. 
(B) Luciferase activity (secreted) in 3T3-L1 cells stably transfected with 
pGluc(PB)ITM2A/0.5kb, pGluc(PB)ITM2A/GATA.mt, and 
pGluc(PB)ITM2A/0.35kb during differentiation. Cells were induced to differentiate 
using full differentiation media (MDI). Adipogenesis was assessed at day 8 when cells 
were stained for lipid droplet accumulation with Oil Red O. Luciferase activity is 
normalised to the pGluc(PB)basic empty vector control. Student’s t-test (two-tailed, 
assuming equal variance) was used to calculate statistical significance at day 2  in 
comparison to luciferase activity at day 0, indicated as follows: *=P<0.05;**=P<0.01; 
***=P<0.001.  
 
To investigate the possibility of ITM2A as a downstream target of Wnt/-catenin 
signalling in the context of adipogenesis, 3T3-L1 preadipocytes were grown to 
confluence and induced to differentiate with a 20mM LiCl treatment or vehicle 
control. Oil-Red-O staining of lipid droplets at day 8 of differentiation showed 
complete inhibition of adipogenesis in cells treated with LiCl (Figure 3.5A). To verify 
that the reduced lipid droplet accumulation observed in response to LiCl was not due 
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to cell death or reduced cell viability, an MTT assay was carried out with varying 
concentrations of LiCl applied to 3T3-L1 cells, and a 20mM treatment was seen to 
have no effect on cell viability (Figure 3.5D). PPAR and CEBP expression was 
assessed by qPCR in treated and control cells, and as expected the expression of both 
adipogenic factors was significantly reduced by LiCl mediated inhibition of cell 
differentiation (Figure 3.5B). Analysis of ITM2A expression in these cells, showed 
that LiCl had no effect on ITM2A expression at days 2, 4 or 6 of differentiation (Figure 
3.5A). This suggests that ITM2A expression is unaffected by a -catenin mediated 
increase in GATA3 during 3T3-L1 differentiation, and does not contribute to the LiCl 
mediated inhibition of adipogenesis. Interestingly, analysis of luciferase activity 
during 3T3-L1 differentiation in cells transfected with the 0.5kb, 0.35kb and GATA 
mutant reporter constructs during 3T3-L1 differentiation in response to LiCl treatment 
showed an increase in the luciferase activity in all transfected cells (Figure 3.5C). LiCl 
appeared to increase ITM2A promoter driven luciferase activity at days 4 and 6 of cell 
differentiation despite having no effect on endogenous mRNA expression at these 
same time points. It is unclear why LiCl led to increased ITM2A promoter driven 
luciferase activity in this system, one possible mechanisms could be that the LiCl 
treatment somehow increased the stability of the secreted Gaussia protein, thus 
leading to an increase in luciferase signal.  
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Figure 3.5: LiCl treatment does not affect ITM2A mRNA expression in 3T3-L1 
differentiation. 3T3-L1 preadipocytes were grown to confluence and induced to 
differentiate with a 20mM LiCl treatment or a vehicle control. (A) qPCR analysis of 
ITM2A expression in LiCl and vehicle control treated cells during cell differentiation. 
Oil Red O staining was carried out at day 8 (B) qPCR analysis of PPARγ and CEBPα 
in LiCl and vehicle control treated cells. (C) Luciferase activity (secreted) in 3T3-L1 
cells stably transfected with pGluc(PB)ITM2A/0.5kb, pGluc(PB)ITM2A/GATA.mt, 
and pGluc(PB)ITM2A/0.35kb during differentiation. Cells were induced to 
differentiate using full differentiation media (MDI) and treated with 20mM LiCl 
treatment or a vehicle control. (D) 3T3-L1 preadipocytes were treated with increasing 
concentrations (20mM, 40mM, 60mM) of LiCl for 48hrs and an MTT assay was 
performed to assess cell viability. A Student’s t-test (two-tailed, assuming equal 
D 
 81 
variance) was used to calculate statistical significance between LiCl and vehicle 
control treated cells, indicated as follows: *=P<0.05;**=P<0.01; ***=P<0.001. 
 
The effect of LMNA on ITM2A promoter 
In an attempt to investigate the effects of LMNA expression on the ITM2A promoter 
we carried out a series of transient co-transfections in both 3T3-L1 and 3T3-NIH cells. 
3T3-NIH cells were used as they exhibit a much higher transfection efficiency when 
compared to that observed for 3T3-L1 cells, which would allow for more sensitive 
detection of LMNA mediated effects on ITM2A promoter activity. In all instances 
LMNA overexpression affected the expression of luciferase from the internal 
transfection control preventing data normalisation. This phenomenon was observed 
with all three constitutive promoters commonly used in standard control luciferase 
constructs (CMV, SV40 and HSV-TK promoters). Figure 3.6 shows LMNA mediates 
reduction in SV40 driven firefly luciferase. 
 
 
Figure 3.6: LMNA effect on SV40 driven firefly luciferase. 3T3-NIH cells were 
transiently transfected with a constitutively expressed SV40-Firefly luciferase and 
LMNA over-expression constructs (WT and R482W mutant) or EV control. A 
Student’s t-test (two-tailed, assuming equal variance) was used to calculate statistical 
significance compared to empty vector control transfected cells, indicated as follows: 
*=P<0.05;**=P<0.01; ***=P<0.001. 
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In order to circumvent this issue we made LMNA/ITM2A reporter stable 3T3-L1 lines 
using a two-step transfection and selection approach; 3T3-L1 preadipocytes were 
stably transfected with the 2kb, 1.5kb, 1kb and 0.5kb ITM2A promoter reporter 
constructs (G418 selection) and subsequently stably transfected with LMNA WT or 
R482W over-expression constructs (puromycin selection). This method eliminates 
variation caused by differences in transfection efficiencies and allows for the 
exclusion of an internal control luciferase. These LMNA/ITM2A reporter stable lines 
cells were grown to confluence and induced to differentiate. Luciferase activity was 
measured at various time points throughout differentiation and Oil-Red-O staining of 
lipid droplets at day 8 showed LMNA mediated inhibition of adipogenesis (Figure 
3.7A, B).  
  
Figure 3.7 (A) shows the effect of LMNA on the 2kb, 1.5kb, 1kb and 0.5kb ITM2A 
promoter fragments. Both WT and R482W mutant LMNA significantly increased 
luciferase activity driven by all four promoters at day 4 of differentiation while WT 
LMNA over-expression also led to increased activity from the 2kb promoter fragment 
at day -2. Analysis of ITM2A mRNA expression at day 4 of differentiation in LMNA 
transfected cells identified an increase in ITM2A expression in response to both WT 
and R482W mutant LMNA (Figure 3.7B). 
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Figure 3.7: LMNA effect on ITM2A promoter activity in 3T3-L1 differentiation. 
(A) Luciferase activity (secreted) in 3T3-L1 cells stably transfected with 
pGluc(PB)ITM2A/2kb, pGluc(PB)ITM2A/1.5kb, pGluc(PB)ITM2A/1kb or 
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LMNA 
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pGluc(PB)ITM2A/0.5kb and LMNA over-expression constructs (WT and R482W 
mutant) or EV control. (B) 3T3-L1 cells were stably transfected with pCDNA3-
LMNA-WT, pCDNA3-LMNA-R482W or pCDNA3.EV and induced to differentiate. 
ITM2A expression was assessed at day 4 of differentiation by qPCR. (C) Luciferase 
activity in 3T3-L1 cells stably transfected with pGluc(PB)ITM2A/0.5kb and LMNA 
over-expression constructs (WT and R482W mutant) or EV control. Adipogenesis was 
assessed at day 8 when cells were stained for lipid droplet accumulation with Oil Red 
O. Luciferase activity is normalised to the pGluc(PB)basic empty vector control. 
Student’s t-test (two-tailed, assuming equal variance) was used to calculate statistical 
significance compared to EV control, indicated as follows: *=P<0.05;**=P<0.01; 
***=P<0.001. 
 
Figure 3.7 (A) demonstrates a significant LMNA effect on the ITM2A promoter in the 
four independently established stably transfected cell lines. Figure 3.7 (B) shows that 
WT and R482W mutant LMNA in an independent experiment increases expression of 
endogenous ITM2A at day 4 and is consistent with the result shown in Figure 3.7 (A). 
However, it should be noted that consistency was an issue with respect to 
reproducibility in these experiments. For example, when this experiment was repeated 
with the 0.5kb reporter construct (Figure 3.7C), the opposite effect was observed at 
day 4, with LMNA reducing promoter activity in comparison to the empty vector 
control. However, in this case, LMNA increased 0.5kb promoter activity at day-2, an 
effect which was not observed in the previous experiment. These results indicate that 
significant variation occurs between cell differentiations and the underlying reason for 
this is unclear. In our experience transfection and selection of 3T3-L1 cells can 
sporadically affect the adipogenic potential of these cells. We observed a large degree 
of variation in the ability of dual transfected/selected cells to differentiate as well as 
disparity in the ability of LMNA to inhibit differentiation in this context. The data 
shown here represents differentiations in which LMNA was seen to reduce 
adipogenesis, as assessed by Oil-Red-O staining at day 8 of differentiation. Although 
it is well established here and in prior literature that LMNA over expression inhibits 
adipogenesis in 3T3-L1 cells, a significant number of 3T3-L1 differentiations were 
observed where over expressed LMNA did not effectively inhibit differentiation. The 
reason for this is also unclear. One possibility is that LMNA inhibitory effects may be 
restricted to a limited time period in differentiation with effective inhibitory 
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concentrations being reached at different times in different differentiations. In such a 
scenario, achievement of an effective inhibitory concentration early in differentiation 
or in the period preceding differentiation may affect gene expression at an earlier time 
point than achieving an effective inhibitory concentration later in differentiation. This 
could account for the differences observed between Figure 3.7 (A) vs. 3.7 (C). The 
lack of inhibition of differentiation by LMNA that is observed in some cases may 
indicate that LMNA did not achieve an effective inhibitory concentration during the 
active time period. High resolution measurement of LMNA with respect to time and 
abundance will be required to test such an idea.   
In addition, it is important to note that although LMNA was seen to inhibit 
differentiation in all five of the Oil Red O cell images included in figure 3.7, variation 
is observed in the quantities of lipid droplet accumulation between empty vector 
controls as well as variation in the degree of inhibition mediated by LMNA 
overexpression. It is possible that this variation could contribute to the inconsistencies 
observed in the luciferase data obtained from these cells. 
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ITM2A over-expression inhibits 3T3-L1 differentiation 
To investigate the role of ITM2A in adipogenesis we stably transfected 3T3-L1 
preadipocytes with a piggyBac transposable ITM2A over-expression construct 
(pMSCV(PB)ITM2A) or empty vector control (pMSCV(PB)) and induced the cells to 
differentiate. Oil Red O staining at day 8 showed that 3T3-L1 differentiation was 
inhibited to a moderate but significant degree in the ITM2A expressing cells in 
comparison to EV control (Figure 3.8A). QPCR analysis of ITM2A expression at 
various time points in these differentiating cells confirmed maintenance of ITM2A 
over-expression throughout adipogenesis (Figure 3.8B).  
 
PPAR expression appeared to be unaltered by increased ITM2A expression; qPCR 
analysis showed no significant difference in PPAR expression throughout 
differentiation in comparison to EV control (Figure 3.8C) and PPAR protein isoforms 
were equally unaffected (Figure 3.8D, E). CEBP expression was also assessed 
through qPCR analysis, and although small variations were observed, overall no 
significant differences between ITM2A over expressing cells and EV control were 
observed (Figure 3.8F).  
Detection of ectopic ITM2A protein in 3T3-L1 cells was attempted using both a Flag 
antibody and a commercially available ITM2A antibody, but was unsuccessful 
presumably due to limited over expression. Similar results were reported in a previous 
study 170 where detection of ITM2A protein in the bipotential C3H10T1/2 cell line 
proved difficult. The mechanism underlying the difficulty in overexpressing ITM2A 
to high levels in 3T3-L1 cells is unclear. In the experiment described, the overall levels 
of ITM2A mRNA over-expression in 3T3-L1 cells were approximately 8 fold higher 
than control. Attempts were made to over-express ITM2A at a higher level by placing 
the gene under the control of a strong CMV promoter to see if adipogenesis could be 
inhibited further by higher ITM2A expression levels and to facilitate ITM2A protein 
detection. However, expression levels of ITM2A gene under the CMV promoter 
(pCMV(PB)ITM2A), were similar to the levels observed with the MSCV promoter.  
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Figure 3.8: ITM2A over-expression in 3T3-L1 differentiation. 3T3-L1 
preadipocytes were stably transfected with pMSCV(PB)-ITM2A or empty vector 
control pMSCV(PB) plasmid and induced to differentiate into adipocytes. (A) 
Adipogenesis was assessed at day 8 post induction by staining with Oil Red O and 
quantification was performed using ImageJ and expressed as Oil red O absorbance 
units (ORO a.u.). (B,C,F) qPCR analysis of ITM2A,PPARγ and CEBP expression 
during differentiation of stably transfected 3T3-L1 cells. (D) Immunoblot analysis of 
PPARγ at day 4 post induction. (E) Quantification of PPARγ protein relative to β-
actin, with mean and standard deviations determined by densitometry from two 
biological replicates. A Student’s t-test (two-tailed, assuming equal variance) was 
used to calculate statistical significance compared to empty vector control cells, 
indicated as follows: *=P<0.05;**=P<0.01; ***=P<0.001. 
 
F 
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Knockdown of ITM2A enhances 3T3-L1 adipogenesis 
The role of endogenous ITM2A in 3T3-L1 cell differentiation was explored by 
silencing ITM2A expression. Initially 3T3-L1 preadipocytes were stably transfected 
with pRFP.shITM2A(1,2,3 and 4) or scramble control pRFP.shControl and induced to 
differentiate. A stimulatory effect on adipogenesis was observed with 3 (shITM2A-1, 
-2 and -3) out of 4 different shITM2A constructs assayed when compared to the 
scramble control (Figure 3.9A). QPCR analysis of ITM2A expression confirmed the 
knockdown of endogenous ITM2A by shITM2A-1, -2 and -3 at various time points 
across differentiation (Figure 3.9B) and shITM2A-1 was selected as the most potent 
knockdown agent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.9: shRNA mediated knockdown of ITM2A in 3T3-L1 differentiation. 
(A) 3T3-L1 preadipocytes were stably transfected with pRFP(PB).shITM2A(1,2,3 and 
4) or scramble control pRFP(PB).shControl and induced to differentiate. Adipogenesis 
A 
B 
C 
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was assessed at day 8 post induction by staining with Oil Red O; quantification was 
carried out using ImageJ and expressed as Oil Red O absorbance units (ORO a.u.). (B) 
qPCR analysis of ITM2A expression at day 2 during 3T3-L1 differentiation. (C) 20X 
microscope image depicting Oil red O staining of shControl and shITM2A.1 
transfected cells (Leica DM IL). Statistical significance compared to scramble control 
cells indicated as follows: *=P<0.05;**=P<0.01; ***=P<0.001. 
 
 
3T3-L1 preadipocytes were stably transfected with a piggyBac transposable ITM2A 
shRNA knockdown construct, pRFP(PB).shITM2A.1 or scramble control 
pRFP(PB).shControl and induced to differentiate. Knockdown of endogenous ITM2A 
appeared to enhance adipogenesis in comparison to control cells (Figure 3.10A). The 
stably transfected cells were induced to differentiate using full induction media MDI, 
sub-maximal media DI or D alone. Enhanced adipogenesis was observed in response 
to the full MDI induction media while a significant difference was not observed with 
DI or D alone (Figure 3.10A). QPCR analysis of ITM2A expression confirmed the 
knockdown of endogenous ITM2A at various time points across differentiation 
(Figure 3.10B). Similarly to the difficulty encountered with detection of ectopically 
expressed ITM2A, detection of the endogenous ITM2A protein in 3T3-L1 cells using 
the commercial ITM2A antibody was unsuccessful. In contrast, ITM2A over-
expression was detectible in transfected 3T3-NIH mouse fibroblasts. Thus, validation 
of shRNA mediated ITM2A knockdown at the protein level was performed in these 
cells. 3T3-NIH cells were transfected with pCMV.ITM2A and either 
pRFP(PB).shITM2A or scramble control pRFP(PB).shControl. ITM2A protein 
knockdown was analysed by immunoblot with ITM2A and Flag antibodies (Figure 
3.10C) and a number of ITM2A protein species were detected.  
 
To date, there is a limited amount of data published on the murine ITM2A protein. 
The predicted molecular weight of the 263 amino acid protein is 30kDa 168, however 
immunoblot detection has previously reported a 45kDa protein in mouse brain tissue 
and two protein species of 45kDa and 43kDa in the EL4 T lymphocyte cell line  187,188. 
An N-linked glycosylation site is predicted at amino acid 166 168, and protein de-
glycosylation in the EL4 T lymphocytes was seen to convert the 45kDa and 43kDa 
proteins to a smaller 39kDa protein 188. Proteolytic processing of the ITM2A related 
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protein ITM2B (human) has been characterized in HEK293TR cells, and a number of 
cleavage events identified. Firstly, a propeptide is released from the C-terminal of the 
protein through furin-mediated cleavage, followed by shedding of the extracellular 
BRICHOS domain via ADAM10 processing. Finally, the residual N-terminal 
fragment undergoes intramembrane proteolysis by a signal peptide peptidase-like 2 
(SPPL2) protease, to produce an intracellular domain 189,190. As protein structure is 
highly conserved within the ITM2 family 169, it is likely that ITM2A is also processed 
in a similar fashion.  
 
A number of protein species were detected when ITM2A was over-expressed in 3T3-
NIH cells. A 90kDa protein was detected using both ITM2A and FLAG antibodies 
(Figure 3.10C) and its expression was inhibited by shITM2A. Although much larger 
than the predicted ITM2A size, it could represent a heavily glycosylated form of the 
protein. We consistently detected a 20kDa protein, which was eliminated by shITM2A 
expression. This protein could potentially represent an ITM2A N-terminal fraction 
produced by cleavage similar to that described for ITM2B. ITM2A is Flag-tagged at 
the C terminal and in support of our cleavage theory, the Flag antibody was unable to 
detect the 20kDa protein. A 40 kDa protein was also detected using the FLAG 
antibody which was partially knocked down by the shITM2A. Finally, the ITM2A 
antibody was seen to bind a 20kDa protein in the cell culture media, which could 
potentially represent the cleaved and secreted BRICHOS domain (Figure 3.10H).  
PPAR and CEBP expression in transfected cells was analysed by qPCR during 
differentiation. No differences were observed in the expression of either transcription 
factor in response to ITM2A knockdown (Figure 3.10D). Surprisingly, when PPAR 
protein levels were measured in these cells, an increase in all three PPAR isoforms 
was observed at day 2 and 4 of differentiation in comparison with control cells (Figure 
3.10E, F). Increased PPAR1 protein was also observed at day 0 (Figure 3.10E, F) 
before induction of the adipose specific PPAR2 isoform.  Densitometry performed 
across biological replicates (Figure 3.10G) confirmed a significant increase in 
PPAR1 and PPAR2 protein isoforms, while elevated ORF4 was less consistent. 
The observation that there was no difference in PPAR mRNA expression between 
shITM2A and shControl transfected cells indicates that ITM2A knockdown is likely 
to influence PPAR protein stability. An increase in PPAR2 protein stability during 
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adipogenic differentiation would be expected to promote adipogenesis and could 
account for the observed increase of lipid droplet accumulation in cells transfected 
with shITM2A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 3.10: shRNA mediated knockdown of ITM2A enhances 3T3-L1 
differentiation and increases PPARγ protein. 3T3-L1 preadipocytes were stably 
transfected with pRFP(PB).shITM2A or scramble control pRFP(PB).shControl and 
induced to differentiate using full induction media MDI (methylisobutylxanthine, 
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dexamethasone and insulin), sub-maximal media DI (dexamethasone and insulin) or 
D (dexamethasone) as indicated. (A) Adipogenesis was assessed at day 8 post 
induction by staining with Oil Red O; quantification was carried out using ImageJ and 
expressed as Oil Red O absorbance units (ORO a.u.). (B, D) qPCR analysis of ITM2A, 
PPARγ and CEBPα and immunoblot analysis of PPARγ (E, F) expression during 
differentiation of 3T3-L1 cells stably transfected with pRFP(PB).shITM2A or 
scramble control pRFP(PB). (C) Immunoblot analysis of ITM2A knockdown in 3T3-
NIH cells dual transfected with pCMV.ITM2A and pRFP(PB).shITM2A or 
pRFP(PB).sh.Control. (G) Quantification of PPARγ protein isoforms relative to β-
actin, with mean and standard deviations determined by densitometry from two 
biological replicates. (H) Immunoblot analysis of ITM2A in 3T3-L1 culture media.  
Statistical significance compared to scramble control cells indicated as follows: 
*=P<0.05;**=P<0.01; ***=P<0.001. 
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ITM2A knockdown rescues LMNA inhibition of adipogenesis in 3T3-L1 
differentiation 
The observation that LMNA increases ITM2A expression and knockdown of ITM2A 
enhances adipogenesis led us to consider whether ITM2A knockdown could 
ameliorate LMNA inhibition of adipogenesis. To investigate this idea we generated a 
series of six dual constructs that contained either LMNA WT, LMNA R482W or 
empty vector (EV) with shITM2A or shControl. The constructs created were 
pCMV(PB)-Flag-LMNA-WT.shITM2A, pCMV(PB)-Flag-LMNA-WT.shControl, 
pCMV(PB)-Flag-LMNA-R482W.shITM2A, pCMV(PB)-Flag-LMNA-
R482W.shControl, pCMV(PB).shITM2A and pCMV(PB).shControl. 3T3-L1 
preadipocytes were stably transfected with these constructs and induced to 
differentiate. Figure 3.11(A) shows that ITM2A knockdown rescued inhibition of 
adipogenesis mediated by both LMNA-WT and LMNA-R482W. Moreover, ITM2A 
knockdown in the LMNA expressing 3T3-L1 cells enhanced adipogenesis to the same 
extent as ITM2A knockdown enhanced adipogenesis in the EV control cells. LMNA 
over-expression was assessed at the mRNA and protein levels (Figure 3.11B, C). 
Interestingly, increased amounts of LMNA protein were observed when ITM2A 
expression was reduced (Figure 3.11C), lending support to the notion that ITM2A 
knockdown somehow influences protein stability in 3T3-L1 cells.  
As previously mentioned ITM2A knockdown does not appear to alter PPAR 
expression in comparison to shControl (Figure 3.10D). Figure (3.11D) reiterates this, 
with ITM2A knockdown having no effect on PPAR mRNA levels at day 4 of 
differentiation when cells were stably transfected with pCMV(PB).shITM2A or 
pCMV(PB).shControl. ITM2A knockdown was however able to rescue the LMNA 
mediated reduction of PPAR mRNA, and restore it to EV control expression levels. 
PPAR was assessed at the protein level and as previously observed LMNA (WT and 
R482W) over-expression was seen to reduce PPAR2 while ITM2A knockdown 
increased the protein levels of all three PPAR isoforms (Figure 3.11E) This 
significant increase in PPAR2 protein, presumably mediated by increased stability, 
is most likely the driving force behind the enhanced adipogenesis observed in 
shITM2A transfected cells. The increase in PPAR2 protein arising from ITM2A 
knockdown is able to enhance adipogenesis despite the LMNA mediated reduction in 
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PPAR transcription and expression. Thus, ITM2A knockdown not only rescues but 
also overrides LMNA inhibition of adipogenesis. 
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Fig 3.11: shRNA mediated knockdown of ITM2A rescues LMNA inhibition of 
3T3-L1 differentiation. 3T3-L1 preadipocytes were stably transfected with 
pCMV(PB)-Flag-LMNA-WT.shITM2A, pCMV(PB)-Flag-LMNA-WT.shControl, 
pCMV(PB)-Flag-LMNA-R482W.shITM2A, pCMV(PB)-Flag-LMNA-
R482W.shControl or empty vector control pCMV(PB).shITM2A and 
pCMV(PB).shControl dual constructs. The cells were induced to differentiate. (A) 
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Adipogenesis was assessed at day 8 post induction by staining with Oil Red O; 
quantification was carried out using ImageJ and expressed as Oil red O absorbance 
units (ORO a.u.). (B) Total RNA was isolated at day -2 of differentiation from the 
stably transfected 3T3-L1 preadipocytes and LMNA expression measured by qPCR 
using primers specific for human LMNA. (C) Immunoblot analysis of flag-LMNA 
WT and R482W mutant at day -2. (D) Total RNA was isolated at day 4 post induction 
and the expression of PPARγ was analysed by qPCR. (E) Immunoblot analysis of 
PPARγ at day 4 post induction. Student’s t-tests (two-tailed, assuming equal variance) 
were used to calculate statistical significance compared to empty vector control cells, 
indicated as follows: *=P<0.05;**=P<0.01; ***=P<0.001. 
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ITM2A expression in LMNA wild type and KO MEFs 
To further elucidate the relationship between LMNA and ITM2A we investigated the 
endogenous levels of ITM2A expression in wild type and LMNA knockout mouse 
embryonic fibroblasts (MEFs). Previously generated LMNA -/- MEFS were grown as 
described and LMNA knockout was confirmed at the protein level in these cells 
(Figure 3.12A). Measurement of ITM2A expression in the LMNA KO MEFs showed 
that ITM2A was significantly reduced in these cells in comparison with wild type 
MEFs (Figure 3.12B), supporting the theory that LMNA increases or modulates 
ITM2A expression in some way.  
 
 
Figure 3.12: ITM2A expression is down-regulated in LMNA KO MEFs. (A) Total 
RNA was isolated from LMNA wild type (+/+) and knockout (-/-) MEFs and the 
expression of ITM2A was analysed by qPCR. (B) Immunoblot analysis of mouse 
LMNA in WT and KO MEFs. Student’s t-test (two-tailed, assuming equal variance) 
was used to calculate statistical significance compared to LMNA WT control cells, 
indicated as follows: *=P<0.05;**=P<0.01; ***=P<0.001. 
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DISCUSSION 
 
While significant advances have been made in understanding the pathophysiology of 
FPLD2, the molecular aetiology of the disease remains to be confirmed. Previous 
reports have described pleiotropic effects of LMNA on gene regulation and interaction 
of LMNA with multiple proteins. Both of these aspects are altered by mutations in the 
LMNA gene (151,152,154,155). In the case of FPLD2, there is a clear impact of 
LMNA mutations on adipogenesis and a number of studies have proposed altered 
LMNA-SREBP1 interactions as the driving force of the disease phenotype 
145,151,152,191. Here, we investigated the effect of LMNA in the early stages of 
adipogenesis though the exploring genes identified using RNA-Seq which indicated 
that ITM2A regulation is altered by LMNA over-expression. This led us to explore 
the relationship between ITM2A expression and adipogenesis as well as the 
modulatory relationship between LMNA and ITM2A within this context. 
 
ITM2A in adipogenesis 
Characterisation of ITM2A activity during 3T3-L1 differentiation identified a distinct 
expression profile for this gene in adipogenesis and showed that endogenous ITM2A 
is transiently down-regulated in early cell differentiation. This transient down-
regulation has not been reported previously even though global gene expression has 
been profiled during 3T3-L1 adipogenesis 178. Our work here indicates that ITM2A is 
a lowly expressed gene/protein in 3T3-L1 cells and that it’s expression is only altered 
for a specific period, around day 2 of adipogenesis (Figure 3.2). Investigation of cells 
stably transfected with a 2kb, 1.5kb, 1kb or 0.5kb ITM2A promoter reporter constructs 
confirmed that ITM2A promoter activity is reduced in 3T3-L1 cells when 
adipogenesis is fully induced using MDI, while a reduction in promoter activity is not 
observed under limiting induction conditions with  DI or D alone (Figure 3.3B). Thus, 
full induction of adipogenesis is associated with reduced ITM2A promoter activity in 
the early stages of differentiation. 
 
Investigation of the role of ITM2A in adipogenesis showed that ectopic expression of 
ITM2A moderately but significantly inhibited the differentiation of 3T3-L1 cells 
(Figure 3.8). However, the mechanism of this inhibition is unclear as there were no 
obvious effects on the mRNA or protein levels of the key adipogenic transcription 
 100 
factors PPAR and CEBP in ITM2A over-expressing cells. Knockdown of 
endogenous ITM2A had the opposite effect to over-expression and enhanced 
adipogenesis in comparison to control cells. Similar to ITM2A over-expression, 
knockdown of ITM2A did not effect PPAR and CEBP mRNA levels. In contrast, a 
significant increase in PPAR1 and PPAR2 protein isoforms was observed and 
although not significant, a similar trend was observed for the ORF4 isoform (Figure 
3.10 D, E). These observations suggest that ITM2A knockdown enhances PPAR 
protein stability. Such an enhancement could explain the effect of ITM2A knockdown 
on adipogenesis as an increase in PPAR2 protein stability would be expected to 
promote adipogenesis.  
 
In the rescue experiment (Figure 3.11) ITM2A knockdown was seen to increase or 
rescue PPARγ expression in LMNA transfected cells as well as increase PPAR2 
protein levels. This is the only context in which we observed an effect of ITM2A 
silencing on PPARγ expression, as ITM2A knockdown or over-expression alone were 
not seen to alter its expression in comparison to controls. The mechanism of action 
underlying the effect of ITM2A on PPARγ expression in LMNA transfected cells is 
unclear. However, as PPARγ and CEBPα are known to cross-activate each other 88,104, 
it is possible that increased PPARγ protein activity may influence its own expression 
by up-regulating CEBPα, which can in turn up-regulate PPARγ expression through a 
C/EBP regulatory element in the PPARγ promoter 106. However, similar to PPARγ 
expression, we did not observe any differences in CEBPα expression in response to 
3T3-L1 cells transfected with shITM2A.1 vs. scrambled shControl (Figure 3.10D). 
This suggest that ITM2A knockdown only influences the expression of these 
transcription factors (possibly through PPARγ protein stabilization) under the 
inhibitory conditions of LMNA overexpression.  
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Adipogenesis and autophagy  
While the mechanisms underlying enhanced PPAR protein stability in ITM2A knock 
down cells are unclear, altered regulation of autophagy during cell differentiation may 
be involved.  
Autophagy is an evolutionarily conserved catabolic pathway in which cytoplasmic 
components are degraded through the formation of double membrane vesicles 
(autophagosomes) that fuse with lysosomes (autolysosomes) to facilitate the 
breakdown of the vesicle contents 193. Recent studies have described the regulatory 
role of autophagy in adipogenesis in a number of different contexts. Silencing of 
autophagy genes Atg5 and Atg7 in 3T3-L1 and MEF cells have been shown to inhibit 
cell differentiation while the adipose specific knockout of Atg7 in mice generates a 
lean phenotype with impaired white adipose tissue development 194,195. In addition 
increased autophagy activity has been reported in the adipose tissue of obese patients 
196.  During 3T3-L1 differentiation autophagy is up-regulated upon the addition of the 
induction cocktail, during the early phase of adipogenic differentiation (day 0 to 4) 
197–199. Guo et al., (2013) 198 have demonstrated that CEBPβ activation of autophagy 
genes and autophagic degradation of adipogenic inhibitors are necessary for cell 
differentiation. Finally, Zhang et al., (2013) 199 recently proposed a model in which 
autophagy activation functions to stabilize PPARγ2 in 3T3-L1 differentiation through 
the repression of proteasome-dependent PPARγ2 degradation. 
As previously described, ITM2A is reported to regulate autophagic flux by interacting 
with specific v-ATPases, the proton pumps that mediate lysosome acidification 174,200. 
In HEK293 human embryonic kidney cells ITM2A overexpression is seen to interfere 
with autophagic flux in a similar way to BafA1, an autophagy inhibitor that blocks the 
formation of mature autolysosomes. Silencing of ITM2A in Hela cells appears to 
block starvation induced autophagy as well as reduce BafA1 driven autophagosome 
accumulation 174. Although it is clear that ITM2A is involved in the regulation of 
autophagic flux, the exact consequences of ITM2A silencing are unclear. 
We observed that endogenous ITM2A expression is transiently down-regulated during 
3T3-L1 differentiation. This reduction in ITM2A expression coincides with activation 
of autophagy in adipogenesis 197,198. It is therefore possible that ITM2A down-
regulation is involved in autophagic activation or flux, and that ITM2A silencing 
somehow enhances this process, leading to enhanced adipogenesis. When we 
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investigated the effects of ITM2A knockdown on markers of adipogenesis we 
observed a significant increase in PPARγ protein at the beginning of cell 
differentiation (day 0 to Day 4), around the same time as autophagy activation. We 
propose a model in which ITM2A knockdown functions to modulate autophagy and 
promote 3T3-L1 differentiation. We suggest that the reduced ITM2A expression 
observed at day 2 in normal 3T3-L1 differentiation may play a role in the endogenous 
up-regulation of autophagy observed at this stage of cell differentiation 198,199 and that 
ITM2A knockdown in the context of differentiation functions to stabilize PPARγ2 
through altered regulation of autophagy. Further investigation is required to elucidate 
the role of ITM2A in adipogenesis and confirm the involvement of autophagy in this 
process.   
 
LMNA and ITM2A 
Consistent with previous reports 20,177, we observed that over-expression of WT and 
R482W mutant LMNA have an inhibitory effect on 3T3-L1 differentiation. Here we 
show that endogenous ITM2A expression is up-regulated during adipogenesis in 
LMNA WT and R482W mutant cells (Figure 3.1G), suggesting that LMNA mediated 
altered regulation of ITM2A may play a role in LMNA inhibition of adipogenesis. In 
agreement with this, we detected significantly lower levels of endogenous ITM2A 
expression in LMNA knockout vs. normal MEFs (Figure 3.12B). Taken together, 
these data indicate that LMNA has a regulatory role in the control of ITM2A 
expression.  
We attempted to determine if LMNA WT or mutant directly affected the expression 
of ITM2A using the ITM2A promoter reporter constructs. However, data 
normalisation proved problematic as transient LMNA over-expression had significant 
effects on the expression of firefly luciferase from all three constitutive promoters 
commonly used for normalisation purposes in promoter reporter assays. 
This is not surprising given that LMNA is implicated in many different aspects of 
genome biology through extensive interactions with chromatin 8 and with proteins of 
the nuclear lamina 3.  
Data normalisation issues were overcome by generating LMNA/ITM2A reporter 
stable 3T3-L1 lines using a two-step transfection and selection approach.  Both WT 
and R482W mutant LMNA significantly increased luciferase activity driven by all 
four promoters at day 4 of differentiation and this was in agreement with qPCR data 
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(Figure 3.7). The data indicates that the key element though which LMNA mediates it 
effects is in the 500bp ITM2A promoter region immediately upstream from the 
structural gene. Further investigation will be necessary to identify the precise factor(s) 
in the ITM2A promoter mediating the LMNA effect.  
While there were some consistency issues, taken together the data supports a model 
whereby overexpression of WT or R482W LMNA up-regulate ITM2A expression 
during adipogenesis and this up-regulation is likely to contribute to LMNA mediated 
inhibition of adipogenesis. The data presented here combined with previously 
published data suggests that LMNA over-expression is likely to inhibit adipogenesis 
through a combination of mechanisms. In addition to previous work showing that 
LMNA alters SREBP1 and FXR1P function in adipogenesis 191,192 and reduces PPAR 
expression 20, our work demonstrates a LMNA effect on ITM2A expression that is 
likely to have a functional effect on adipogenesis in 3T3-L1 preadipocytes. 
It is not clear how LMNA alters ITM2A expression in this context. One plausible 
mechanism stems from the report by Lund et al., (2013) where they identified 4000 
genes that disengage from LMNA during human ASC differentiation. They compared 
genes present in lamin rich domains or LDRs before (pre-induction: day 0) and after 
(day 21) differentiation into mature adipocytes and observed that approx. 80% of the 
genes that lost or gained LMNA association did not exhibit changes in expression. 
Therefore the effect of ITM2A disassociation on ITM2A expression is unknown. 
Although this phenomenon has not been confirmed in mouse adipogenesis, it is 
possible that disengagement of ITM2A from LMNA during adipogenesis may 
facilitate its transient down-regulation in cell differentiation. LMNA disassociation 
may allow for the binding of a repressor to the ITM2A promoter, to produce the 
distinct ITM2A expression profile observed. If follows that LMNA overexpression 
may prevent this disengagement and thus prevent ITM2A down-regulation in 
adipogenesis. The impact of this newly described relationship on ITM2A expression 
and function in an endogenous FPLD2 patient setting is unknown. 
 
 
 
 
 
 104 
LMNA and Autophagy  
The observation that knockdown of ITM2A enhances adipogenesis prompted us to 
explore whether LMNA inhibition of adipogenesis could be rescued by knocking 
down ITM2A expression. Interestingly the LMNA inhibition was completely rescued 
by this approach (Figure 3.8A). Moreover, the rescue was effective despite the 
observation that the ITM2A knockdown enhanced the stability of LMNA. A likely 
explanation for this is that the increased stability of PPARγ in the ITM2A knockdown 
cells drives adipogenesis forward and its effects are dominant over the inhibitory 
effects of the increased LMNA. 
The relationship between ITM2A and autophagy and the demonstration that ITM2A 
knockdown can suppress LMNA inhibition of adipogenesis suggests a potential role 
for autophagy modulation in the treatment of lamin associated lipodystrophies. A 
recent study has described autophagy dysregulation in the LMNA H222P driven 
cardiomyopathy, where increased AKT-mTORC1 signalling is observed in human 
patients 201. Treatment of LMNA H222P/H222P mice with the mTOR inhibitor 
temsirolimus was seen to reactivate autophagy and lead to improved cardiac function 
in these mice 201. In addition, the treatment of HGPS patient primary fibroblasts with 
the mTOR inhibitor rapamycin, was seen to improve the disease phenotype and slow 
senescence of these cells by stimulating autophagy 202. Thus, taken together our 
findings suggest that exploration of therapies that reactivate autophagy are warranted 
for treatment of FPLD2 and related lipodystrophies such as HAART- associated 
lipodystrophy.  
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CHAPTER 4: IGFBP5 IN 3T3-L1 ADIPOGENESIS 
 
INTRODUCTION 
The Insulin-like Growth Factor System and Adipogenesis 
Insulin, insulin-like growth factors (IGF-I/II) and their receptors play an important 
role in the regulation of key mammalian processes such as growth, survival and 
metabolism 203,204. Insulin is known to promote adipogenesis through IGF-I receptor 
signalling and is an essential ingredient in the 3T3-L1 cell induction cocktail 92. IGF-
1 present in culture media serum also contributes to the progression of these cells 
through the differentiation programme 124. The importance of insulin and IGF-1 
signalling in adipogenesis is emphasised in a number of mouse studies in which 
various components of the system are lost or mutated. Mice deficient in insulin or 
IGF-1 receptors experience severe growth defects, are underweight and usually die 
shortly after birth 205,206, while transgenic mice with adipose tissue specific silencing 
of both insulin and IGF-1 receptors display significant loss of adipose tissue 207. Loss 
of the insulin receptor substrate proteins (IRS) is seen to perturb adipogenesis 92,205,206 
and other downstream factors involved in the insulin/IGF signalling cascade, such as 
PI3K, AKT and mTOR, have also been shown to modulate adipogenesis in various 
contexts 92,206.  
 
Insulin Growth Factor Binding Proteins 
Insulin growth factor binding proteins (IGFBPs) function to modulate IGF availability 
both positively and negatively, as well as having IGF-independent properties 208 . 
There are six highly conserved binding proteins that are secreted by various cell types 
in a cell-, tissue- and development stage specific manner. Each of these proteins has 
unique context-specific functions and characteristics. Of the six binding proteins, 
IGFBP5 is the most highly conserved in mammals 208,209. Most IGFs in circulation are 
IGFBP bound and these binding proteins have a higher affinity for IGF than that of 
the IGF receptors 210. There are a number of ways in which IGF and IGFBP 
interactions are altered or reduced, which leads to important changes in IGF and 
IGFBP activity. These include IGFBP5 proteolysis, phosphorylation and IGFBP 
interaction with extracellular matrix (ECM) components 209.  
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IGFBP5: Structure, interactions and proteolysis 
The IGFBP5 protein has a tripartite structure consisting of a C-terminal domain, a 
mid-region and an N-terminal domain that contains a 20-amino acid signal peptide, 
which is cleaved to produce the mature secreted IGFBP5 protein (Figure 4.1) 208. Each 
of these regions play important roles in IGFBP5 function. The N-terminal contains the 
primary IGF-binding site 211, the mid-region is where most post-translational 
modifications occur 208, and the C-terminal domain contains a basic region involved 
in ECM, ALS and cell membrane interactions 212–214. The C-terminus also contains a 
nuclear localisation signal which is involved in the importin- mediated nuclear 
import of IGFBP5 208. 
 
 
Figure 4.1: Schematic representation of IGFBP5 protein structure. Adapted from 
Schneider et al., (2002)208. 
 
IGFBP5 has been shown to directly bind numerous components of the ECM in various 
cell models, including collagens, fibronectin, laminin, heparin sulphate, vitronectin, 
thrombosondin-1, and osteopontin 215–217. These interactions are of biological 
significance, as they appear to modulate IGF-1-binding, which in turn influences IGF-
1 activity 209. The IGFBP5 mid-region contains specific residues that can be 
glycosylated 218 or phosphorylated 219, as well as multiple proteolytic cleavage sites. 
IGFBP5 proteolysis has been reported in many different cell types and is mediated by 
diverse proteases. This processing plays an integral role in regulating IGFBP5 activity, 
as it alters the proteins ability to bind IGF-1 208. IGFBP5 can be protected from 
cleavage through interactions with IGF-I 220 or ECM components 221 and it has been 
suggested that IGFBP5 cleavage products may have associated biological activity 209. 
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IGFBP5 promoter  
Previous studies have identified multiple elements that positively and negatively 
regulate IGFBP5 transcriptional activity in a cell-type specific manner. These include 
cell signalling molecules, metabolites, hormones, glucocorticoids, transcription 
factors and growth factors.  
Interestingly, two of the 3T3-L1 induction components, elevated cAMP (IBMX) and 
dexamethasone, have been shown to modulate IGFBP5 in different cell systems. As 
previously mentioned forskolin, like IBMX, can be used to increase intracellular 
cAMP and induce the adipogenic differentiation of 3T3-L1 preadipocytes 180. 
Induction of IGFBP5 promoter activity by cAMP has been reported in GM10 
fibroblasts, where it was shown that forskolin treatment lead to increased activity 
through conserved AP-2 elements within the IGFBP5 proximal promoter 222. In these 
cells AP-2 was shown to increase IGFBP5 promoter driven luciferase in a biphasic 
manner; low levels of AP-2 overexpression lead to transactivation of the promoter 
constructs (-503 to +775) while higher levels of AP-2 did not. This was not observed 
in other cell lines (HepG2 and A673) where AP-2 was seen to increase IGFBP5 
promoter activity in a dose dependent fashion 222. Similarly, PTH has been shown to 
increase IGFBP5 mRNA in rat osteosarcoma cells through a cAMP-mediated 
mechanism 223. Dexamethasone is reported to decrease IGFBP5 mRNA and secreted 
protein, which is thought to contribute to dexamethasone mediated inhibition of 
human osteoblast-like cell differentiation 224.  
IGFBP5 promoter analysis in various bone cell lines has reported increased promoter 
activity in response to progesterone, parathyroid hormone (PTH) and prostaglandin 
E2, while reduced promoter activity has been described in response to cortisol and 
bone morphogenetic protein 7 225–228. In addition to AP-2, several other transcription 
factors or co-activators have been shown to regulate IGFBP5 promoter activity 
through conserved sequences, including NF1, C/EBP, MN1 and Myb 101,229–232. 
Retinoic acid (RA) is reported to up-regulate IGFBP5 promoter activity by reducing 
C/EBP/ mediated repression of IGFBP5 in neuroblastoma differentiation 230. In 
undifferentiated cells the C/EBP factors mediate a repressive effect through 
interaction with a C/EBP element in the IGFBP5 promoter. In the same study RA 
stimulation is also shown to promote C/EBP induction of IGFBP5 promoter activity 
through interaction with a conserved TATA box. Therefore, depending on the 
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differentiation status of these cells and to which promoter element it binds, C/EBP 
appears to either inhibit or induce IGFBP5 promoter activity 230. Testosterone has been 
shown to activate an IGFBP5 promoter (1278bp) reporter in human androgen 
responsive fibroblasts and increase IGFBP5 mRNA 233. Finally, numerous studies 
have reported increased IGFBP5 mRNA and protein in response to IGF-1 in various 
cell systems 220,223,233,234. 
 
IGFBP5 in cancer  
The IGF axis is known to play an important role in normal and malignant cell growth, 
proliferation and differentiation 210. IGFBP5 is expressed in many different tissues, 
where its expression and distinct functions are modulated by tissue-specific ECM 
interactions, proteolysis and hormonal regulation 209. Dysregulation of IGFBP5 
expression is a feature of many human cancers, and has been most extensively studied 
in breast cancers models. Mammary epithelial cells are known to secrete IGFBP5 and 
a role for this binding protein has been outlined in mammary gland involution, where 
it functions to inhibit IGF survival signalling in this setting and promote post-lactation 
involution 235. IGFBP5 expression and activity have been assessed in a many different 
breast cancer cell lines where it appears to have conflicting actions; either to promote 
cell survival or induce apoptosis 236. In addition to breast cancers, altered IGFBP5 
expression has been linked to many other cancer types; overexpression has been 
reported in prostate 237 ovarian 238, lung 239, pancreatic 240 and thyroid cancers 241, while 
reduced IGFBP5 expression is associated with squamous cell carcinomas of the head 
and neck 242,243, as well as cervical carcinomas 244. The various roles of IGFBP5 in 
these diverse systems are unclear, however a recurrent theme appears to be that 
IGFBP5 expression, regulation and function are highly dependent on cellular context.  
 
IGFBP5 and differentiation 
IGFBP5 expression and activity have been described in diverse systems. Of relevance 
to our study, is the characterisation of this secreted protein in the differentiation of 
various cell types, including myogenesis, osteogenesis, chondrogenesis and neuronal 
cell differentiation.  
Analysis of IGFBP5 expression in C2 myoblasts identified up-regulation of IGFBP5 
expression and secretion during the differentiation of these cells 212. Surprisingly no 
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other IGFBPs were detected during C2 myoblast differentiation in this study. 
Subsequently James et al., (1996) 245 investigated the role of IGFBP5 in C2 
myogenesis and reported reduced myogenic differentiation in response to IGFBP5 
over-expression and enhanced cell differentiation in C2 myoblasts expressing an 
IGFBP5 antisense transcript. The inhibitory effect of exogenous IGFBP5 expression 
on myogenesis was rescued by the addition of IGF-1 to the culture media during cell 
differentiation, suggesting that the action of IGFBP5 in this system is IGF-dependent 
245. In agreement with these findings Cobb et al., (2003) 246 demonstrated that the an 
IGFBP5 non-IGF binding mutant was unable to inhibit C2 myogenic differentiation. 
Cobb et al., (2003) also described an IGF-independent anti-apoptotic function of 
IGFBP5 in these cells.  
 
IGFBP5 has been studied in bone cell proliferation, differentiation and in vivo 
formation, where it appears to have different effects depending on the experimental 
method and model system 247. IGFBP5 treatment or overexpression in various bone 
cell lines has been shown to either increase 208,248 or decrease 249 osteoblast 
differentiation. Liu et al., (2015) have recently reported enhanced osteogenic 
differentiation of MSC in response to IGFBP5 over-expression and reduced 
osteogenic differentiation in response to IGFBP5 silencing. In vivo IGFBP5 treatment 
studies have been shown to increase bone formation 248,250 in mice, however 
differences in effect are observed depending on delivery method which may influence 
IGFBP5 proteolytic cleavage 247. IGFBP5 overexpression from an osteoblast specific 
251 or -actin 252 promoter in transgenic mice have also been reported to reduce bone 
formation. Finally, IGF-independent functions of IGFBP5 have also been proposed in 
the context of osteogenesis 208,247.  
 
To date, there is little published data on the role of IGFBP5 in chondrogenesis. Sekiya 
et al., (2001)253 have reported increased IGFBP5 expression in the differentiation of 
human adult stem cells isolated from bone marrow stroma, however the function of 
IGFBP5 during this process is unknown. IGF-1 and IGFBP5 appear to play a role in 
chondrocyte proliferation, where IGFBP5 enhances the proliferative effect of IGF-1 
in these cells and IGF-1 in turn increases IGFBP5 expression through the PI3-kinase 
signalling 254. Finally, Samuel et al., (2010) 255 reported substantial IGFBP5 down-
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regulation in human retinal pigment epithelial cells during neuronal differentiation. 
C/EBP is thought to mediate this reduction as a downstream regulator of MAPK 
signalling, through a C/EBP response element in the IGFBP5 promoter 255,256. In 
contrast to these results, Tanno et al., (2005) 257 observed impaired neuronal 
differentiation in response to IGFBP5 silencing in a number on neuronal cell lines 
(LAN-5, SY5Y), which was rescued by treatment with recombinant IGFBP5. In 
addition, a role for IGF-1 and IGFBP5 has been described in Schwann cell 
differentiation in which IGF-1 was observed to stimulate differentiation and increase 
IGFBP5 expression. IGFBP5 overexpression was also seen to promote the 
differentiation of these cells 258.  
 
IGFBPs and WNT  
Recent studies have reported interactions between various IGFBPs and the Wnt/-
catenin signalling pathway in both cancer and cell differentiation settings. The anti-
tumoral actions of IGFBP3 has been described in metastatic melanoma cells, where it 
interacts with GSK-3 to activate cytoplasmic -catenin degradation 259. IGFBP5 is 
reported to be involved in the down-regulation of Wnt/-catenin signalling in colon 
cancer cells 260, and the regulation of IGFBP5 itself is modulated by a canonical -
catenin signalling dependent mechanism, in WNT1 driven mammary tumours 261. 
IGFBP4 has been shown to induce cardiomyocyte differentiation through inhibition 
of canonical Wnt/-catenin signalling in the murine P19CL6 cell model. This IGF-
independent action is mediated through direct interactions with the frizzled and 
LRP5/6 wnt receptors. Endogenous IGFBP4, 3 and 5 expression is up-regulated in 
P19CL6 cardiomyocyte differentiation and silencing of IGFBP4 is seen to inhibit the 
differentiation of these cells. IGFBP3 and IGFBP5 knockdown did not affect 
cardiomyogenesis 262. In addition, IGFBP4 has been shown to protect the ischemic 
heart by inhibiting Wnt/-catenin signalling 263.  
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IGFBP5 in adipogenesis  
The above studies suggest diverse roles for IGFBP5 in the differentiation of numerous 
cell types. Both IGF-dependent and IGF-independent functions have been described 
in the various systems, and the experimental model used appears to influence IGFBP5 
activity, emphasising the effect of context on IGFBP5 gene function. 
IGFBP5 activity and function have yet to be characterised in adipogenesis, however 
numerous studies have commented on the IGFBP expression of adipose cells in vivo 
and in vitro. Boney et al., (1994) 264 described IGFBP expression and secretion in 3T3-
L1 cells before and after differentiation; up-regulation of IGFBP2, 3, and 4 was 
observed while IGFBP5 was undetected in this study. IGFBP1 is reported to inhibit 
adipocyte differentiation 265, and transgenic over-expression of both IGFBP1 and 2 
are seen to protect against obesity in mice 266,267. While the IGFBP1 and 2 effects on 
adipogenesis are thought to be mediated by IGF-1 sequestration, IGFBP3 has been 
shown to inhibit adipogenic differentiation in an IGF-independent manner 268. Studies 
on 3T3-L1 preadipocytes have demonstrated that IGFBP3 can inhibit insulin 
stimulated glucose uptake in these cells 269, as well as interfere with PPAR-RXR 
interactions to inhibit their transcriptional activity 270. Interestingly, Wabitsch et al., 
(2000) 271 measured an increase in IGF-I and IGFBP3 expression in human adipocytes 
when compared to preadipocytes isolated from human subcutaneous adipose tissue. It 
is possible that increased IGFBP3 expression during adipocyte differentiation may be 
part of a negative feedback mechanism 268.  
Conflicting reports of IGFBP5 expression have been reported in porcine adipocytes. 
High levels of IGF-II and IGFBP5 expression where observed in porcine 
preadipocytes, both of which were seen to decrease during the in vitro differentiation 
of these cells, alongside increased expression of adipogenic markers and Insulin, IGF-
I and IGF-I receptor genes 272. In contrast, Hausman et al., (2002) 273 measured high 
levels of IGFBP5 in mature porcine adipocytes isolated form subcutaneous pig 
adipose tissue. Recently, characterisation of human adipose depot specific gene 
expression profiles identified increased IGFBP5 expression in abdominal adipose 
depots when compared to gluteal fat. In this study, differential endogenous IGFBP5 
expression was associated with differences in fat depot methylation patterns 274.  
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Several transgenic and knockout mouse models have been employed to investigate 
IGFBP5 function in various settings. Transgenic over-expression of IGFBP5 from the 
bone specific osteocalcin promoter generated mice with decreased bone volume and 
impaired osteoblast function 251, while CMV/ß-actin promoter driven expression of 
IGFBP5 lead to decreased bone density that was dependent on both age and gender 
252. Neither of these studies reported any changes in weight or fat accumulation 
between transgenic mice and their respective wild type littermates. IGFBP5 over-
expression has also been studied in mouse mammary glands, where the mammary 
specific B-lactoglobulin promoter was used to express the transgene in this 
environment. These mice experienced impaired mammary gland development 275. The 
most severe phenotype was reported in mice that over-expressed IGFBP5 ubiquitously 
from early development. Reduced female fertility, growth inhibition, decreased body 
weight and impaired muscle development were observed, suggesting an important role 
for IGFBP5 in mouse development 252.  
 
IGFBP knockout mouse models are reported to display modest phenotypes, 
presumably due to compensation by other IGFBPs 252,276. IGFBP5 null mice develop 
normally, with no differences observed in general growth, fat pad and organ weight, 
skeletal muscle, circulating IGF-1 levels and mammary gland development in 
comparison to wild type littermates. These mice do however show increased levels of 
IGFBP3 as well as impaired mammary gland involution post weaning 277. In contrast, 
triple IGFBP3/4/5 KO mice have significantly reduced growth with smaller fat pads 
containing smaller adipocytes, reduced circulating IGF-1, increased insulin secretion 
and enhanced glucose disposal, in comparison to their wild type littermates 276. These 
studies suggest congruent roles for IGFBP5 and IGFBP3 in mouse development and 
growth 276.  
 
RNA-Seq analysis identified a differential decrease in IGFBP5 expression in response 
to mutant and wild type LMNA. The aim of this study was to characterise IGFBP5 
activity and function in 3T3-L1 differentiation, and investigate whether the LMNA 
mediated changes in IGFBP5 gene expression contribute to the altered adipogenesis 
observed in the FPLD2 phenotype. 
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RESULTS 
 
Endogenous IGFBP5 expression in 3T3-L1 differentiation 
Microarray analysis of gene expression in 3T3-L1 and hASC differentiation by 
Mikkelsen et al., (2010) 178 measured relatively constant levels of IGFBP5 expression 
across 3T3-L1 differentiation, while a dramatic increase was observed in the early 
differentiation of hASC (day 1-3), with expression levels remaining high in mature 
human adipocytes (day 14) (Figure 4.2A). IGFBP5 expression was assessed during 
3T3-L1 differentiation and in contrast to this microarray data, variable IGFBP5 
expression was detected during cell differentiation. A highly specific expression 
pattern was observed in which IGFBP5 is lowly expressed in preadipocytes (day-2) 
and then highly up-regulated at day 2, post induction of differentiation. IGFBP5 
expression levels were reduced at day 4/6 and then up-regulated again at day 8 of 
differentiation. Figure 4.2 (B) shows the characteristic induction of PPAR expression 
in adipogenesis alongside the distinct IGFBP5 expression profile, which was 
consistently observed in 3T3-L1 differentiation. 
 
 
Figure 4.2: Endogenous IGFBP5 expression during 3T3-L1 differentiation. (A) 
IGFBP5 gene expression in 3T3-L1 and hASC differentiation, as measured by 
microarray analysis carried out by Mikkelsen et al., (2010). (B) 3T3-L1 preadipocytes 
were grown to confluence and induced to differentiate. Adipogenesis was assessed at 
day 8 when cells were stained for lipid droplet accumulation with Oil Red O. Total 
RNA was isolated at the indicated time points during 3T3-L1 differentiation. IGFBP5 
and PPARγ expression was analysed by qPCR. Transcript expression at the various 
time points is shown relative to expression at day 0. 
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Originally, qPCR analysis of IGFBP5 expression in 3T3-L1 differentiation was 
carried out with cDNA in which oligo dT primers were used to prime the cDNA 
synthesis reaction. In these samples, the dramatic increase in IGFBP5 expression at 
day 2 of differentiation was not detected. Examination of the mouse (and human) 
IGFBP5 transcripts shows that it has an extraordinarily long 3’ untranslated region 
(UTR) of approximately 5 kilobases. Figure 4.3 illustrates the distribution of 3’UTR 
sizes within the human, mouse and rat genomes, highlighting the unusually length of 
the IGFBP5 3’UTR 278. As oligo dT priming involves the use of the poly-A tail at the 
3’ end of mRNA transcripts, the 5’ ends of very long mRNAs can be under represented 
in the resulting cDNA pool. This offers an explanation for the reduced detection of 
IGFBP5 using qPCR approaches that employ oligo dT priming for cDNA synthesis. 
When random hexamers were used for priming in cDNA synthesis, detection of 
IGFBP5 by qPCR was enhanced and a considerable increase in IGFBP5 expression at 
day 2 of differentiation was observed (Figure 4.2). The expression profile detected in 
these cells is unusual, in that IGFBP5 expression is low prior to induction of 
differentiation, increases significantly at day 2, is down-regulated at day 4 and 6 of 
differentiation and then increased again at day 8. The mechanisms regulating this 
complex expression profile are unclear and were not pursued here. The large size of 
the 3’ untranslated region of the IGFBP5 is intriguing and one possibility is that this 
3’ region might affect RNA degradation and stabilization rates that could account for 
the expression pattern observed. Further investigation is required to elucidate the 
mechanism governing the complex control of IGFBP5 expression in 3T3-L1 
differentiation.  
 
 
Figure 4.3: Distribution of 3′-UTR sizes in human, mouse and rat genomes. 
Taken from Andres-Leon et al., 2015 278. 
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IGFBP5 overexpression in 3T3-L1 differentiation 
To investigate the role of IGFBP5 in adipogenesis 3T3-L1 preadipocytes were stably 
transfected with a piggyBac transposable IGFBP5 over-expression construct 
pMSCV(PB)IGFBP5, or empty vector control pMSCV(PB), and induced to 
differentiate. IGFBP5 over-expression was confirmed by qPCR and did not appear to 
affect lipid droplet accumulation in comparison to empty vector control (Rep 1) 
(Figure 4.4A). To assess whether IGFBP5 overexpression influenced adipogenesis 
during submaximal induction of differentiation, cells were induced to differentiate 
using full induction media MDI, sub-maximal media DI or D alone. The reduced 
induction cocktail DI appeared to reveal a slight inhibition of differentiation in 
response to IGFBP5 overexpression, however when Oil Red O quantification was 
carried out the observed reduction in lipid droplet accumulation was not found to be 
statistically significant (Figure 4.4B). Immunoblot detection of over-expressed 
IGFBP5 using both a Flag and Myc antibody was unsuccessful in these cells.  
Interestingly, when this experiment was repeated as part of a larger rescue experiment, 
over-expression of IGFBP5 was seen to significantly inhibit lipid droplet 
accumulation in comparison to the empty vector control (Rep. 2) (Figure 4.4C). These 
cells were dual transfected with either pMSCV(PB) and pCMV(PB) (EV Control) or 
pMSCV(PB)IGFBP5 and pCMV(PB) (IGFBP5) and selected with both G418 and 
puromycin as part of a larger experiment designed to investigate the effects of both 
LMNA and IGFBP5 overexpression on 3T3-L1 differentiation. Although the larger 
rescue experiment was unsuccessful (LMNA did not inhibit differentiation in this 
particular experiment) the IGFBP5 overexpression alone appeared to influence cell 
differentiation. It is unclear why IGFBP5 over-expression produced inconsistent 
effects on cell differentiation. A possible explanation could be the varying degrees of 
IGFBP5 over-expression achieved in the respective replicates. QPCR analysis of 
IGFBP5 expression in the two independent experiments (Figure 4.4A, C) revealed a 
significant disparity in the levels of exogenous expression, which could potentially 
account for the distinct impacts on 3T3-L1 differentiation observed. IGFBP5 was 
over-expressed approximately 200-fold in the first replicate and approximately 5000-
fold in the second replicate. Oil Red O staining at day 8 showed that 3T3-L1 
differentiation was unaffected by moderate overexpression (Figure 4.4A) while higher 
levels of overexpression lead to inhibition of adipogenesis (Figure 4.4C) in 
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comparison to EV control. Oil Red O quantification confirmed a significant reduction 
in lipid droplet accumulation in response to greater IGFBP5 overexpression (Figure 
4.4C).  
Again, immunoblot detection of over-expressed IGFBP5 was unsuccessful in these 
cells. The IGFBP5 protein over-expressed in these experiments contains a C-terminal 
dual Myc-Flag tag which was undetected by both antibodies. Considering the 
extensive levels of over-expression achieved in these experiments, this is unusual. 
Unspecific binding of the Flag antibody was observed at the predicted size of IGFBP5 
in both over-expressed and empty vector samples, which may have obstructed 
IGFBP5 detection, however this was not observed with the Myc antibody. The 
difficulties experienced in detecting this highly expressed gene at the protein level, 
could suggest an unusual translational aspect for this protein. Further investigation is 
required to optimize protein detection in this system.  
As IGFBP5 is a secreted factor, the effect of IGFBP5 in 3T3-L1 culture media on cell 
differentiation was investigated. Conditioned media was harvested from IGFBP5 
overexpressing 3T3-L1 preadipocytes or EV control transfected cells and used along 
with the standard induction cocktail (MDI) to induce differentiation of un-transfected 
3T3-L1 preadipocytes. No difference in lipid droplet accumulation was observed in 
comparison to EV control, as assessed by Oil Red O staining and quantification 
(Figure 4.4D). 
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Figure 4.4: IGFBP5 overexpression has varied effects on 3T3-L1 differentiation. 
(A) 3T3-L1 preadipocytes were stably transfected with pMSCV(PB)-IGFBP5 or 
empty vector control pMSCV(PB) plasmid and induced to differentiate into 
 118 
adipocytes. qPCR analysis of ectopic IGFBP5 expression was performed at day -2 of 
differentiation in stably transfected 3T3-L1 cells. (B) Cells stably transfected with 
pMSCV(PB)-IGFBP5 or empty vector control pMSCV(PB) plasmid were induced to 
differentiate using full induction media MDI (methylisobutylxanthine, dexamethasone 
and insulin), sub-maximal media DI (dexamethasone and insulin) or D 
(dexamethasone) as indicated. (C) 3T3-L1 preadipocytes were stably transfected with 
pMSCV(PB)-IGFBP5 and pCMV(PB) (IGFBP5) or empty vector controls 
pMSCV(PB) and pCMV(PB) (EV Control) and induced to differentiate into 
adipocytes. qPCR analysis of ectopic IGFBP5 expression was performed at day -2 of 
differentiation in stably transfected 3T3-L1 cells. (D) Media was harvested from 
growing 3T3-L1 preadipocytes stably transfected with pMSCV(PB)-IGFBP5 or 
empty vector control pMSCV(PB). Un-transfected 3T3-L1 preadipocytes were 
induced to differentiate using the standard MDI induction cocktail in the previously 
harvested IGFBP5 conditioned medium. The condition medium was used throughout 
differentiation. Adipogenesis was assessed at day 8 post induction by staining with 
Oil Red O. Quantification was performed using ImageJ and expressed as Oil Red O 
absorbance units (ORO a.u.). A Student’s t-test (two-tailed, assuming equal variance) 
was used to calculate statistical significance compared to empty vector control cells, 
indicated as follows: *=P<0.05; **=P<0.01; ***=P<0.001. 
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IGFBP5 knockdown in 3T3-L1 differentiation 
To investigate the role of endogenous IGFBP5 in 3T3-L1 cell differentiation shRNA 
constructs were designed to silence IGFBP5 expression. 3T3-L1 preadipocytes were 
stably transfected with a piggyBac transposable IGFBP5 shRNA knockdown 
construct, pRFP(PB).shIGFBP5 or scramble control pRFP(PB).shControl and induced 
to differentiate. Knockdown of endogenous IGFBP5 appeared to enhance 
adipogenesis in comparison to control cells, as assessed by Oil Red O staining and 
quantification (Figure 4.5A). QPCR analysis of IGFBP5 expression at day -2, 4 and 8 
(Figure 4.5A) showed variable silencing of IGFBP5 expression during differentiation. 
No knockdown was detected at day -2, a slight reduction in expression levels was 
observed at day 4, and IGFBP5 was significantly reduced at day 8. It is not clear why 
the stably transfected shIGFBP5 only appeared to significantly reduce IGFBP5 
expression at day 8. It would be of interest to assess the effects of shITM2A at other 
time points during differentiation. Although there are no reports of alternative splicing 
for IGFBP5 in the literature, the presence of different IGFBP5 isoforms at different 
time-points during cell differentiation could account for the time-point specific 
knockdown of IGFBP5 expression by the shRNA construct. It would be of interest to 
assess IGFBP5 expression at day 2 of differentiation, as this is the only other time-
point during differentiation in which IGFBP5 is highly expressed. This experiment 
warrants repetition and further analysis to fully elucidate the pattern of IGFBP5 
expression in response to shIGFBP5 transfection during cell differentiation. 
Immunoblot analysis of PPAR at day 4 of differentiation revealed an increase in 
PPAR2 protein in shIGFBP5 transfected cells (Figure 4.5B). This is consistent with 
the observed increase in lipid droplet accumulation in these cells. The RNA–Seq data 
indicate that LMNA over expression decreases IGFBP5 expression, raising the 
possibility that IGFBP5 down regulation plays a role in LMNA mediated adipogenesis 
inhibition. By contrast, the knockdown of IGFBP5 reported here shows the opposite 
effect namely that IGFBP5 down regulation enhances adipogenesis. The reason for 
these incongruous findings is unclear, however, given the complex nature of IGFBP5 
and its activity it is possible that knockdown of IGFBP5 in the early stage of 
adipogenesis has the opposite effect to knockdown of IGFBP5 in the later stages of 
adipogenesis. Given the findings reported in the previous chapter where ITM2A 
knockdown can rescue adipogenesis inhibition by LMNA over expression, it would 
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be interesting to determine whether such inhibition could also be rescued by IGFBP5 
knockdown. 
 
 
 
 
 
 
 
 
Figure 4.5: shRNA mediated knockdown of IGFBP5 expression in 3T3-L1 
differentiation. 3T3-L1 preadipocytes were stably transfected with 
pRFP(PB).shIGFBP5.1 or scramble control pRFP(PB).shControl and induced to 
differentiate. (A) qPCR analysis of IGFBP5 expression at the indicated time points 
during 3T3-L1 cell differentiation. Adipogenesis was assessed at day 8 by staining 
with Oil Red O; quantification was carried out using ImageJ and expressed as Oil Red 
O absorbance units (ORO a.u.). (B) Immunoblot analysis of PPAR at day 4 post 
induction. Student’s t-test (two-tailed, assuming equal variance) was used to calculate 
statistical significance compared to shControl, indicated as follows: *=P<0.05; 
**=P<0.01; ***=P<0.001. 
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IGFBP5 promoter analysis in 3T3-L1 differentiation 
As previously described the IGFBP5 promoter has been studied in diverse systems. 
To characterise IGFBP5 promoter activity in 3T3-L1 differentiation a series of 
luciferase reporter plasmids were constructed containing fragments of the mouse 
IGFBP5 promoter (1.2kb and 2.4kb) (Figure 4.6A) and their activity was analysed 
during differentiation. 3T3-L1 pre-adipocytes were transfected with the luciferase 
constructs, grown to confluence, and induced to differentiate. The 1.2kb IGFBP5 
promoter fragment directed luciferase activity throughout differentiation, while the 
larger 2.4kb was not active as a promoter and directed less luciferase activity than the 
empty pGluc control construct (Figure 4.6B). Similar results have been reported in 
some of the previously described promoter studies, in which larger IGFBP5 promoter 
constructs failed to direct luciferase activity in comparison to smaller segments 226. 
This suggests the presence of an inhibitory element between 1.2 to 2.4 kb upstream of 
the IGFBP5 gene.  
Surprisingly, the 1.2kb promoter activity observed during differentiation did not 
follow the pattern of endogenous IGFBP5 gene expression described in Figure 4.2B. 
IGFBP5 promoter activity appeared to be significantly reduced at day 2 of 3T3-L1 
differentiation, in stark contrast to the increase observed in the endogenous IGFBP5 
mRNA at this same time point when measured by qPCR.  
Despite this inconsistency, the effect of LMNA over expression on the 1.2 kb IGFBP5 
promoter was examined to determine if LMNA had any effect on the cloned IGFBP5 
promoter. As previously mentioned LMNA overexpression appears to affect 
luciferase activity driven from internal transfection control promoters in standard 
dual-luciferase transient transfections, preventing data normalisation. Thus, the effects 
of LMNA on the IGFBP5 promoter were not assessed in this format. Rather, 
LMNA/IGFBP5 1.2kb reporter stable 3T3-L1 lines were generated using a two-step 
transfection and selection approach (as previously described in chapter 3). Briefly, 
3T3-L1 preadipocytes were transfected with piggyBac transposable reporter 
constructs and selected with one antibiotic. Once selected, these cells were transfected 
again with piggyBac LMNA over-expression constructs and selected with a second 
antibiotic. The 1.2kb IGFBP5 promoter fragment was cloned into a piggyback 
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transposable pGluc(PB) construct to allow for stable integration and selection in these 
experiments.  
Both WT and R482W mutant LMNA over-expression appeared to increase IGFBP5 
promoter activity prior to induction (day 0) and decrease promoter activity after the 
cells were induced and throughout differentiation (day 4, 6 and 8) (Figure 4.6C). Oil-
Red-O staining showed reduced lipid droplet accumulation in R482W mutant LMNA 
transfected cells, however the WT LMNA did not appear to affect adipogenesis.  
 
Finally, the effects of LiCl and testosterone on IGFBP5 promoter activity were 
assessed during differentiation. As previously described IGFBPs have been shown to 
interact with various components of the canonical Wnt/-catenin signalling pathway 
in diverse settings. Wnt signalling plays an important inhibitory role in adipogenesis, 
and its down-regulation is necessary for cells to progress through the differentiation 
programme (92). LiCl treatment inhibits 3T3-L1 differentiation through activation of 
Wnt/-catenin signalling and increased cellular -catenin. Testosterone has previously 
been shown to activate the IGFBP5 promoter in androgen responsive fibroblasts and 
numerous publications have reported testosterone mediated inhibition of adipocyte 
differentiation 280–282. To assess the effects of these components on IGFBP5 promoter 
activity in adipogenesis 3T3-L1 preadipocytes were stably transfected with 
pGluc(PB)/IGFBP5/1.2kb, grown to confluency and induced to differentiate with full 
induction media (MDI) including LiCl or testosterone. Oil Red O staining confirmed 
LiCl inhibition of cell differentiation as these cells did not accumulate any lipid 
droplets (Figure 4.6D). Testosterone, in contrast to published reports, however did not 
have any effect on 3T3-L1 differentiation (Figure 4.6D). This was consistently 
observed across many differentiations and for increased concentrations of 
testosterone, and will be discussed further in chapter 5. LiCl treatment appeared to 
reduce IGFBP5 promoter activity significantly at day 2, 6 and 8 of differentiation, 
while testosterone treatment had very little effect on promoter activity, with a small 
reduction observed on day 2 of differentiation.  
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Figure 4.6: IGFBP5 promoter activity in 3T3-L1 differentiation. (A) Schematic 
depiction of IGFBP5 promoter luciferase constructs bearing a 2.4kb or 1.2kb promoter 
fragment cloned upstream of Gaussia luciferase in the pGluc(PB) basic vector. The 
distance (-1654, -442) from the transcriptional start site (TSS) is shown. (B) Luciferase 
activity (secreted) in pGluc/IGFBP5/1.2kb and pGluc/IGFBP5/2.4kb transfected 3T3-
L1 cells at various time points throughout differentiation. (C) Luciferase activity in 
3T3-L1 cells stably transfected with pGluc(PB)/IGFBP5/1.2kb and LMNA 
overexpression constructs (WT and R482W mutant) or EV control. Luciferase activity 
in 3T3-L1 cells stably transfected with pGluc(PB)/IGFBP5/1.2kb and treated with 
LiCL (20mM) and testosterone (100nM). Adipogenesis was assessed at day 8 by 
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staining with Oil Red O. Student’s t-test (two-tailed, assuming equal variance) was 
used to calculate statistical significance compared to MDI (B, C), EV Control (D) or 
vehicle control (D), indicated as follows: *=P<0.05; **=P<0.01; ***=P<0.001. 
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LMNA overexpression has variable effects on IGFBP5 expression in 3T3-L1 
differentiation  
The previously described RNA-Seq data identified reduced expression of IGFBP5 36 
h post differentiation induction of cells overexpressing WT and R482W mutant 
LMNA. Interestingly IGFBP5 expression was reduced 50-fold in response to WT 
LMNA and only 5-fold in response to the R482W mutant.  
 
To confirm these distinct effects of WT and R482W mutant LMNA on IGFBP5 
expression, 3T3-L1 preadipocytes were stably transfected with human LMNA 
overexpression constructs and induced to differentiate. Figure 4.6 shows two separate 
transfection experiments in which LMNA over-expression inhibited lipid droplet 
accumulation when compared to empty vector controls, as determined by Oil Red O 
staining (Figure 4.7A, C). IGFBP5 expression analysis identified conflicting effects 
of LMNA on IGFBP5 expression between the two replicates. Increased IGFBP5 
expression was observed in replicate 1(Figure 4.7B), while reduced IGFBP5 
expression was observed in the second replicate (Figure 4.7D).  It is important to note 
that WT and R482W mutant LMNA had distinct effects on IGFBP5 expression in both 
replicates. In the first replicate, an overall trend of increased IGFBP5 expression was 
observed in response to both LMNA WT and R482W mutant, although not always 
significant at each time point. In the second replicate, WT LMNA appeared to 
significantly reduce IGFBP5 expression at day 2 and 4 of 3T3-L1 differentiation, 
while the R482W mutant LMNA did not alter IGFBP5 expression at any point. This 
is a similar trend to the distinct fold reductions measured in the RNA-Seq experiment, 
where LMNA WT over-expression lead to a much greater decrease in IGFBP5 
transcription (50 fold), in comparison to R482W mutant LMNA (5 fold).  
 
The reason for this disparity is unclear and some possible explanations are provided 
in the discussion.  
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Figure 4.7: LMNA over-expression both increases and decreases IGFBP5 
expression in 3T3-L1 differentiation. (A, C) 3T3-L1 preadipocytes were stably 
transfected with pCMV(PB)-Flag-LMNA-WT, pCMV(PB)-Flag-LMNA-R482W or 
pCMV(PB) in replicate 1 (A) and pcDNA3-Flag-LMNA-WT pcDNA3-Flag-LMNA-
R482W or pcDNA3.EV in replicate 2 (C). Adipogenesis was assessed by Oil Red O 
staining at day 8 of differentiation and ORO quantification was carried out using 
ImageJ and expressed as Oil Red O absorbance units (ORO a.u.). QPCR analysis of 
LMNA over-expression was performed at day -2 for each replicate. (B, D) QPCR 
analysis of IGFBP5 expression in replicate 1 (B) and 2 (D) at day -2, 2 and 4 of 
differentiation. A Student’s t-test (two-tailed, assuming equal variance) was used to 
calculate statistical significance compared to empty vector control cells, indicated as 
follows: *=P<0.05; **=P<0.01; ***=P<0.001. 
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DISCUSSION 
 
IGFBP5 in 3T3-L1 differentiation  
The IGF axis plays a critical role in preadipocyte survival, proliferation and 
differentiation. The adipose organ is known to secrete many bio-active factors that are 
important in the regulation of metabolism, and has been described as a major source 
of secreted IGF-1 283. IGFBPs have been studied extensively in a variety of systems 
and display diverse IGF-dependent and independent functions, depending on their 
environment. As targets of transcriptional and hormonal regulation, the IGFBPs 
appear to have highly specific expression profiles, and their activities are further 
regulated by protein interactions and proteolytic degradation.  
 
A previous study in 3T3-L1 preadipocytes failed to detect secreted IGFBP5 in this 
system 264 and conflicting reports of IGFBP5 expression have been reported in porcine 
adipocytes 272,273. In this study, a distinct expression profile for IGFBP5 has been 
described in 3T3-L1 differentiation. Endogenous IGFBP5 expression is highly up-
regulated at day 2 of 3T3-L1 differentiation, 48 h post application of the induction 
cocktail, and again at day 8 of differentiation, when the cells have accumulated lipid 
droplets and are considered mature adipocytes (Figure 4.2B). This specific expression 
pattern has not been observed previously when global gene expression was assessed 
in 3T3-L1 differentiation (Figure 4.2A), however it does resemble the human IGFBP5 
expression profile of differentiating hASC, in which a sharp increase in gene 
expression is observed following induction of differentiation 178.  
 
Investigation of IGFBP5 promoter activity in this system using a 1.2kb IGFBP5 
promoter reporter constructs produced unexpected results. Promoter activity 
decreased in response to the induction cocktail rather than increase, which was 
predicted due to the dramatic increase in IGFBP5 mRNA at this stage of 
differentiation. Previous studies have reported increased IGFBP5 promoter activity in 
response to cAMP (forskolin) and reduced activity in response to dexamethasone, both 
ingredients of the 3T3-L1 induction cocktail. It is unclear if either of these induction 
components are responsible for the decrease observed in this system.  A number of the 
aforementioned studies characterised IGFBP5 promoter activity in various systems 
using much smaller, yet still highly active promoter fragments in their respective 
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reporter assays. A much larger or smaller promoter segments might behave differently 
in the context of 3T3-L1 differentiation. Further analysis of additional promoter 
regions would be required to elucidate the complicated transcriptional events involved 
in the control of IGFBP5 expression in 3T3-L1 differentiation. McCarthy et al., (1996) 
226 reported that PGE2 both stimulated IGFBP5 promoter activity and enhanced 
IGFBP5 mRNA stability in rat osteoblasts. Tardif et al., (2009) 284 identified 
microRNA regulation of IGFBP5 expression in human osteoarthritic chondrocytes. 
Over-expression of mir140 in these cells appeared to decrease IGFBP5 expression, 
with a corresponding decrease in protein production. The large 3’ untranslated region 
in the IGFBP5 transcript contains approximately 13 predicted microRNA binding sites 
(TargetScan) and it would be of interest to investigate the activity of these microRNA 
in adipogenesis, with respect to IGFBP5 gene regulation. These studies highlight the 
complexity of IGFBP5 regulation and suggests that a number of mechanisms may be 
involved. 
 
Investigation of the role of IGFBP5 in adipogenesis showed that exogenous expression 
of IGFBP5 could inhibit 3T3-L1 differentiation (Figure 4.3B). Moderate IGFBP5 
over-expression (approx. 200-fold) did not appear to affect differentiation (Figure 
4.3A), while higher levels of over-expression (approx. 5000-fold) reduced lipid 
droplet accumulation significantly (Figure 4.3B). Differential effects of IGFBP 
overexpression have previously been reported to produce distinct phenotypes in 
IGFBP3 transgenic mice. A study carried out by Silha et al., (2002), 285  reported 
glucose intolerance and insulin resistance in transgenic mice over-expressing human 
IGFBP3 from PGK and CMV promoters. Interestingly, the mice expressing IGFBP3 
from the CMV promoter showed increased expression of the transgene in their skeletal 
muscle tissue when compared to PGK driven IGFBP3 and displayed increased 
adiposity. This difference in phenotype was attributed to variation in tissue levels and 
timing of IGFBP3 expression between the transgenic mice 285. It is possible that the 
varied effects of IGFBP5 on adipogenesis observed here are due to the variation in 
levels of over-expression.  
Addition of IGFBP5 to culture media, using conditioned media harvested from 
IGFBP5 transfected preadipocytes, did not appear to affect differentiation (Figure 
4.3D). Attempts to detect the secreted protein in this conditioned media using a Flag 
antibody were unsuccessful. Therefore, the quantity or stability of secreted IGFBP5 
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was not assessed. To accurately examine the modulation of 3T3-L1differentiation by 
IGFBP5, recombinant IGFBP5 protein could be added to differentiating cells in 
culture at varying concentrations and at different time points during differentiation. 
The observation that large amounts of exogenous IGFBP5 reduces cell differentiation 
suggests that increased IGFBP5 might bind to and sequester IGF-1, thus inhibiting its 
stimulatory effect on the in vitro differentiation of these cells. Cobb et al., (2003) 246 
demonstrated that over-expression of WT IGFBP5 inhibited myogenesis by binding 
IGF-1 to modulate IGF-1 signalling in this system. It is possible that IGFBP5 over-
expression plays a similar role in adipogenesis.  An exact function for IGFBP5 in 3T3-
L1 differentiation remains to be confirmed and additional experiments would need to 
be performed to elucidate whether these effects are IGF-dependent or independent.  
 
Knockdown of endogenous IGFBP5 enhanced lipid droplet accumulation in 
comparison to the scramble control (Figure 4.3A) and increased PPAR2 protein was 
observed at day 4 of differentiation in these cells. This effect is consistent with the 
model that IGFBP5 inhibits IGF-1 stimulation of 3T3-L1 differentiation, as reduced 
IGFBP5 protein would result in an increase of IGF-1 available to bind IGF-1 receptors.  
A few technical issues were encountered when attempting to generate IGFBP5 shRNA 
constructs. Originally a synthetic Gibson assembly approach was employed, where 
shRNA sequences were purchased as ultramer oligonucleotides (long oligonucleotides 
of up to 200 bases) from IDT, PCR amplified with Gibson overlap primers and cloned 
into the pRFP(PB) backbone. High levels of recombination were observed using this 
technique with frequent deletion of nucleotides within the shRNA 29 mer sequence. 
A traditional cloning approach was then employed to reduce recombination and one 
of the three attempted shIGFBP5 constructs was cloned successfully. To confirm the 
effect of IGFBP5 silencing on 3T3-L1 differentiation additional shRNA constructs 
would need to be assayed to eliminate the possibility of off target effects. 
Alternatively, considering the distinct IGFBP5 expression pattern during 3T3-L1 
differentiation, it would of interest to investigate the effects of siRNA mediated 
IGFBP5 knockdown at specific time points during differentiation i.e. from day 0 to 
day 2. As IGFBP5 expression appears to be up-regulated in response to 3T3-L1 
induction it would be interesting to see if blocking this up-regulation had an impact 
on cell differentiation. 
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The sharp up-regulation of IGFBP5 during early adipogenic differentiation is 
reminiscent of the dramatic increase in IGFBP5 observed in mammary gland 
involution. This hormonally induced stimulation of IGFBP5 expression functions to 
block IGF-1 survival signalling and induce epithelial cell apoptosis in the involuting 
mammary gland 275. The mechanism behind IGFBP5 up-regulation as well as the 
subsequent function of IGFBP5 protein in early 3T3-L1 differentiation are unclear. 
Some studies have described enhanced IGF-1 signalling through ECM-associated 
IGFBP5 215, where extracellular bound IGFBP5 potentiates the stimulatory growth 
effects of IGF-1 potentially by acting as some sort of IGF-1 transport and delivery 
system 275. If IGFBP5 were to behave in such a manner during 3T3-L1 adipogenesis 
it could play a role in augmenting specific IGF-1 action in these differentiation cells. 
To define IGFBP5 action in adipogenesis, multiple factors need to be addressed, 
including IGF-1 binding, ECM component interactions, IGFBP5 protein stability and 
proteolytic degradation. As well as modulating IGF-1 activity in this system, IGFBP5 
could be affecting differentiation through IGF-1 independent actions. Assessing the 
effects of an IGFBP5 mutant, unable to bind IGF-1, on 3T3-L1 differentiation could 
help elucidate the IGFBP5 mechanism of action. 
 
 
IGFBP5 and LMNA 
To investigate the relationship between LMNA and IGFBP5 indicated by the RNA-
Seq analysis, 3T3-L1 preadipocytes were stably transfected with human WT and 
R482W mutant LMNA overexpression constructs and IGFBP5 expression was 
assessed during cell differentiation (Figure 4.6). Conflicting results were obtained as 
LMNA over-expression appeared to both increase (Replicate 1) and decrease 
(replicate 2) IGFBP5 expression during differentiation. In the second experimental 
replicate, a decrease in IGFBP5 expression was observed in response to WT LMNA 
in comparison to the null effect of the R482W mutant. This mirrors the variation 
observed in our RNA-Seq data. Finally, the effect of LMNA on IGFBP5 expression 
was investigated using a 1.2kb IGFBP5 promoter reporter construct (Figure 4.5C). 
LMNA appeared to enhance IGFBP5 promoter activity prior to induction and reduce 
promoter activity during differentiation. However, this method proved problematic 
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and it was not possible to demonstrate a direct effect of LMNA on the IGFBP5 
promoter activity during differentiation. 
 
The effects of LMNA on IGFBP5 in this system are unclear as considerable variation 
was observed in all lines of enquiry. A number of experimental factors may be 
responsible for the issues observed in reproducibility. While cell culture conditions 
were kept as consistent as possible, the complex nature of IGFBP5 regulation might 
call for tighter controls in this system. During 3T3-L1 cell differentiation, cell 
confluency is judged by eye prior to induction. It is possible that small variations in 
cell confluency, passage number and time points during differentiation may have 
contributed to the inconsistencies observed. In addition, different LMNA over-
expression constructs were used in the replicates described in figure 4.6. Although 
both constructs contained a CMV promoter, G418 selection cassette and the same 
LMNA cDNA sequence, variable effects of LMNA on IGFBP5 were observed. This 
could be due to the handling of the cells, and relate to the complex control of IGFBP5 
expression in this system.  
Another consideration is that IGFBP5 null mice develop normally whereas triple 
knockouts for IGFBP3, 4 and 5 have smaller fat pads. This suggest that the relationship 
between LMNA inhibition of adipogenesis and the IGFBPs should consider the 
combined response of these three IGFBPs in relation to LMNA WT and R482W over 
expression. Interestingly, the RNA-Seq data suggest that minimally IGFBP3 should 
be analysed in combination with IGFBP5 as the expression of IGFBP3 is altered 
(albeit at a lower magnitude than IGFBP5) in the opposite direction to IGFBP5 (Table 
1, Chapter 1). 
A substantial limitation in this study is the level of intrinsic variation observed in 3T3-
L1 transfection and differentiation. The lack of precision in degrees of overexpression 
of IGFBP5 leads to difficulties in data reproduction and interpretation. Accurate 
manipulate of IGFBP5 in this system calls for a better understanding on its regulation 
in adipogenesis.  
The initial incentive in studying IGFBP5 was to identify factors that might promote 
adipogenesis and could potentially be used in novel FPLD2 therapy. Due to the 
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complicated nature of IGFBP5 regulation in this system, it is not a good therapeutic 
lead. As LMNA overexpression lead to a reduction in IGFBP5 expression in the RNA-
Seq analysis, it was postulated that IGFBP5 overexpression might have a stimulatory 
effect during adipogenesis. However this was not the case, and the opposite was 
observed where IGFBP5 over-expression either had no effect or reduced adipogenesis 
while shRNA mediate IGFBP5 knockdown enhanced adipogenesis. In addition, 
proximal promoter activity was not in keeping with the mRNA expression profile 
during adipogenesis. Previously, the study of ITM2A in this system produced robust 
and reproducible data, and while the reasons behind the observed variability in the 
study of IGFBP5 are unclear, they are most likely related to the highly regulated and 
differential expression of IGFBP5 during the process of adipogenesis. An alternative 
approach might be to assess endogenous IGFBP5 expression and secretion profiles in 
FPLD2 patient samples or laminopathy/lipodystrophy mouse models.  
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CHAPTER 5: PRELIMINARY INVESTIGATIONS OF PTPRQ, WNT6 AND 
TESTOSTERONE IN 3T3-L1 DIFFERENTIATION 
 
 
SECTION 1: PTPRQ 
 
INTRODUCTION 
 
The phosphorylation and de-phosphorylation of protein tyrosine residues, by protein 
tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs) respectively, plays 
an important role in cellular signalling transduction systems involved in numerous 
processes such as cell growth, metabolism and differentiation 286. The PTP enzyme 
superfamily are a large group of hydrolytic enzymes that can be divided into three 
main sub-groups including classical PTPs, low molecular weight PTPs and dual-
specificity PTPs 287. PTPRQ was first identified in rat mesangial cells where it is 
dramatically up-regulated following renal injury (Wright et al., 1998), and is classified 
as a type–III receptor PTPase with a single catalytic domain and 18 fibronectin type 
III domains (FN3) 288.  
 
Relatively little research has been carried out on PTPRQ with only 25 article published 
on PTPRQ gene function to date. The majority of published work centres on the role 
of PTPRQ in cochlear hair bundle integrity in the inner ear. A number of PTPRQ 
mutations have been reported in cases of autosomal recessive non-syndromic hearing 
impairment (arNSHI), where either nonsense or missense mutations lead to hearing 
loss and vestibular dysfunction 289,290. PTPRQ is essential for the formation of shaft 
connectors in mouse hair bundles, and for the normal development of cochlear hair 
bundles 291,292. It has been suggested that there may be multiple PTPRQ isoforms  
expressed in these hair bundles 293, and a number of alternatively spliced mRNAs have 
been identified in human tissues, leading to protein isoforms differing in FN3 domain 
number 289.   
 
Previous studies have identified distinct PTPRQ isoforms that are expressed in a tissue 
specific manner. PTPRQ is detected in a large receptor-like form or as a smaller 
cytoplasmic protein in different cell types. Seifert et al., (2002), 288 reported expression 
of the larger PTPRQ transcript in human kidney and lung tissues, while smaller 
transcripts were detected in the brain and testis. Both alternative splicing 289,294 and 
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the use of alternative promoters have been described as mechanisms responsible for 
the distinct PTPRQ isoforms 294. In addition, alternative promoters are reported to 
generate receptor-like and cytoplasmic isoforms of various other PTPases 295,296. 
Figure 5.1.1 illustrates the different transcripts detected by Seifert et al., (2002)294 in 
various human tissues.  
 
 
Figure 5.1.1: Alternative PTPRQ transcripts and protein forms. Three PTPRQ 
transcripts are detected in human tissues; 7.5kb, 7.4kb and 1.8kb. (A) The 7.5kb 
transcript predicts a 250kDa receptor like protein that has an extracellular domain 
composed of 18 FN3 repeats, a transmembrane domain (TM) and a catalytic domain 
that are separated by a small juxtamembrane (JM) segment. The catalytic domain 
contains the PTP active site. (B) Alternative splicing can lead to the generation of 
protein lacking a catalytic domain. (C) Alternative promoter usage leads to the 
generation of a 1.8kb transcript that encodes a truncated catalytic domain, predicted 
at 22 kDa. Taken from Seifert et al., (2002) 294.  
 
Numerous studies have reported that PTPRQ exhibits low levels of PTPase activity in 
comparison to other PTP enzymes, and that its predominant activity is as a 
phosphatidylinositol phosphatase (PIPase) against a broad range of 
phosphatidylinositol phosphates (PIPs)297–299. The PTPRQ catalytic domain contains 
a Glu residue in place of an Asp that is essential for PTPase activity, and highly 
conserved in other PTPases, suggesting that PTPRQ may not favour phosphotyrosine 
as a substrate 297.  PIPase enzymes function to inhibit signalling through PI(3,4,5)P3 
activated pathways, preventing downstream AKT/PKB phosphorylation 294. 
Oganesian et al., (2003) 297 demonstrated that overexpression of the rat PTPRQ 
cytoplasmic region (from the first amino acid inside the TM domain) in human 
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glioblastoma cell lines (U87MG, U373MG) that do not express PTEN (a well 
characterised PIPase), leads to a decrease in phosphorylated AKT/PKB and 
significantly reduced rates of proliferation, mediated by PIPase activity. In addition, 
Yu et al., (2013) 299 have demonstrated that the PTPRQ catalytic loop adopts a flat 
active-site pocket conformation, making it suitable for de-phosphorylation of larger 
PI substrates.  
 
In chapter 4 the role of insulin and IGF-1 signalling in adipogenesis was discussed and 
the phenotypes of multiple mouse models lacking insulin/IGF-1 signalling 
components were described. As downstream elements of the insulin/IGF-1 signalling 
cascade phosphatidylinositol-3 kinase (PI3K) and AKT1/protein kinase B (PKB) or 
AKT2/PKB are essential for adipogenesis. AKT1/AKT2 double knockout mice 
display severe growth defects with impaired development of bone and skin tissues, 
skeletal muscle atrophy and a block in adipocyte differentiation 300.  AKT1/AKT2 
double KO MEFs fail to differentiate in-vitro as PPAR up-regulation is blocked in 
these cells. It has since been shown that insulin stimulates AKT/PKB mediated 
phosphorylation and nuclear exclusion of the PPAR repressor, FOXO1 92,301. In 
addition, PI3K inhibitors and rapamycin mediated inhibition of mTOR have been 
shown to inhibit 3T3-L1 differentiation 302,303. Figure 5.1.2 illustrates the activity of 
various extracellular signalling factors during the process of adipogenesis, where 
insulin and IGF-1 activation of the PI3K/AKT signalling pathway is shown to be 
involved in the downstream up-regulation of pro-adipogenic factors.  
 
Figure 5.1.2: Extracellular factors involved in the regulation of adipogenesis. Taken 
from Rosen and MacDougald (2006) 92.  
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PTPRQ activity and function have previously been described in the context of in-vitro 
adipogenesis. Jung et al., (2009) 298 reported PTPRQ down-regulation during the 
adipogenic differentiation of both MSCs and 3T3-L1 preadipocytes. In their study 
over-expression of the human PTPRQ cytoplasmic region was seen to reduce lipid 
droplet accumulation in both cell types by reducing AKT/PKB phosphorylation. 
PTPRQ mutants inactive against just phosphatidylinositol phosphates or both 
phosphatidylinositol phosphates and phosphotyrosine did not inhibit cell 
differentiation indicating that wild type PTPRQ reduces intracellular PIP3, which in 
turn leads to reduced AKT/PKB phosphorylation and inhibition of adipogenesis 298.   
The previously described RNA-Seq analysis identified a 4-, and 10-fold increase in 
PTPRQ mRNA in response to WT and R482W mutant LMNA, respectively. Since 
previous studies have reported PTPRQ mediated inhibition of 3T3-L1 adipogenesis, 
the relationship between LMNA and PTPRQ was investigated. An additional 
incentive for the investigation of PTPRQ in adipogenesis is the recent development of 
novel PTPRQ phosphatase inhibitors 304. If a LMNA mediated increase in PTPRQ 
expression contributed to the inhibition of adipogenesis, then PTPRQ inhibition could 
potentially rescue adipogenesis in this system.  
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RESULTS  
PTPRQ expression is down-regulated during 3T3-L1 differentiation 
Consistent with previous reports 298, endogenous PTPRQ expression was down-
regulated during 3T3-L1 differentiation. QPCR analysis revealed low levels of 
PTPRQ in pre-adipocytes that were further reduced as the cells progressed through 
the differentiation programme (Figure 5.1.3A). The highest PTPRQ expression was 
detected at day -2, after which expression levels dropped significantly. PTPRQ was 
undetected at day 4 and 6 and minimal detection was observed at day 6 and 8. PTPRQ 
was consistently detectable at day -2 and 0, however it was not detected at day 6 and 
8 in all 3T3-L1 differentiation replicates.  
 
PTPRQ silencing in 3T3-L1 differentiation 
To investigate the role of endogenous PTPRQ in 3T3-L1 cell differentiation, three 
shRNA constructs were designed to silence PTPRQ expression as described in 
materials and methods. 3T3-L1 preadipocytes were stably transfected with piggyBac 
transposable PTPRQ shRNA knockdown constructs, pRFP(PB).shPTPRQ.1,2 and 3, 
or scramble control pRFP(PB).shControl and induced to differentiate. One out of the 
three knockdown constructs, shPRPTQ.3, was seen to moderately inhibit lipid droplet 
accumulation in these cells (Figure 5.1.3C) and when PTPRQ expression was assessed 
only shPRPTQ.3 appeared to have reduced endogenous PTPRQ expression, in 
comparison to the scramble control (Figure 5.1.3B). The two remaining constructs, 
shPTPRQ.1 and 2 did not have a significant effect on either differentiation (Figure 
5.1.3C) or PTPRQ mRNA expression (Figure 5.1.3B) in comparison to the scramble 
control. It is not clear why some of the KD constructs were unsuccessful in reducing 
PTPRQ expression. All three constructs contained 29mer shRNA sequences directed 
at the last 1000bp of the mouse PTPRQ gene, in order to target the catalytic domain.  
 
PTPRQ expression in response to LMNA overexpression 
To investigate the effects of WT and R482W mutant LMNA on PTPRQ expression 
reported in the RNA-Seq analysis, 3T3-L1 preadipocytes were stably transfected with 
human LMNA overexpression constructs and induced to differentiate. PTPRQ 
expression was assessed at day -2 of differentiation and no significant changes in 
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expression were observed in response to LMNA overexpression (Figure 5.1.3D). 
LMNA overexpression data for replicate one and two is shown in chapter 4 figure 4.7.  
 
 
 
Figure 5.1.3: PTPRQ in 3T3-L1 differentiation and in response to LMNA.  (A) 
3T3-L1 preadipocytes were differentiated as previously described and adipogenesis 
was assessed at day 8 by staining with Oil Red O. Total RNA was isolated at the 
indicated time points during 3T3-L1 differentiation. PTPRQ and PPARγ expression 
was analysed by qPCR. Transcript expression at the various time points is shown 
relative to expression at day -2.  (B) 3T3-L1 preadipocytes were stably transfected 
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with pRFP(PB).shPTPRQ.1,2 and 3 or scramble control pRFP(PB).shControl and 
induced to differentiate. PTPRQ expression was assessed by qPCR analysis at day-2. 
(C) Adipogenesis was assessed at day 8 post induction by staining with Oil Red O; 
quantification was carried out using ImageJ and expressed as Oil Red O absorbance 
units (ORO a.u.). (D) 3T3-L1 preadipocytes were stably transfected with pCMV(PB)-
Flag-LMNA-WT, pCMV(PB)-Flag-LMNA-R482W or pCMV(PB) in replicate 1 and 
pcDNA3-Flag-LMNA-WT pcDNA3-Flag-LMNA-R482W or pcDNA3.EV in 
replicate 2 (ORO images and expression data shown in Figure 4.7, chapter 4). PTPRQ 
expression was analysed by qPCR at day -2 of differentiation for each replicate. A 
Student’s t-test (two-tailed, assuming equal variance) was used to calculate statistical 
significance compared to empty vector control cells or LMNA WT (+/+) MEFs (E), 
indicated as follows: *=P<0.05; **=P<0.01; ***=P<0.001. 
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DISCUSSION 
 
The role of insulin/IGF-1 activated PI3K/AKT signalling in adipogenesis has been 
extensively studied in numerous in-vitro and in-vivo settings. The importance of this 
system in whole body metabolism is emphasised by the severe lipodystrophic 
phenotype observed in the previously described AKT1/AKT2 double KO mouse. In 
addition, severe insulin resistance and type 2 diabetes mellitus have been reported in 
a family with an inherited mutation in the catalytic domain of AKT2/PKB 80. In the 
context of adipogenesis, PTPRQ PIPase activity has been shown to reduce Akt/PKB 
phosphorylation, down-regulating this signalling cascade and inhibiting the in-vitro 
differentiation of 3T3-L1 and human MSCs 298. RNA-Seq analysis of the gene 
expression profile in differentiating 3T3-L1 cells transfected with human WT and 
R482W LMNA, identified an increase in PTPRQ mRNA in response to LMNA over-
expression. Since cytoplasmic PTPRQ over-expression is known to inhibit the 
differentiation of these cells, it was postulated that the observed increase in PTPRQ 
could contribute to the LMNA mediated block in adipogenesis.  
 
Investigation of the role of PTPRQ in 3T3-L1 differentiation identified very low levels 
of expression in pre-adipocytes, which were further down-regulated during 
differentiation (Figure 5.1.3A). PTPRQ expression was not detected at day 2 or 4 of 
differentiation in any of the experimental replicates. This is in keeping with previous 
reports, where Jung et al., (2009) 298 observed that PTPRQ expression was low in 3T3-
L1 cells, specifically in comparison to expression levels observed in human MSCs.  
 
To explore the role of endogenous PTPRQ in 3T3-L1 differentiation, cells were stably 
transfected with shPTPRQ constructs and the effects of PTPRQ silencing on 
differentiation were assessed (Figure 5.1.2B,C). Although three different KD 
constructs were designed and constructed, only one of these appeared to reduce 
PTPRQ expression in these cells (sh.PTPRQ.3), and surprisingly this was seen to 
reduce lipid droplet accumulation in comparison to the scramble control (Figure 
5.1.3C). As cytoplasmic PTPRQ over-expression inhibits 3T3-L1 differentiation, it 
was predicted that PTPRQ KD might lead to enhanced adipogenesis through increased 
AKT/PKB phosphorylation and enhanced downstream signalling. It is unclear why 
this in not the case. Further analysis of the effects of PTPRQ silencing is required to 
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elucidate the mechanism by which it leads to reduced cell differentiation. As only one 
of the three shRNA constructs generated produced a significant reduction in PTPRQ 
expression, additional shRNA constructs would need to be assayed to confirm 
inhibition of adipogenesis and eliminate the possibility of off target effects. Next, 
analysis of phosphorylated AKT/PKB and intracellular PIP3 would be essential to 
elucidate the impact of PTPRQ knockdown on the PI3K/AKT signalling pathway in 
these cells.  
 
Finally, PTPRQ expression was assessed in response to LMNA over-expression in 
3T3-L1 differentiation and LMNA KO in MEFs. In contrast to the increased PTPRQ 
mRNA observed in the RNA-Seq analysis, both WT and R482W mutant LMNA failed 
to significantly alter PTPRQ expression in repeated experimental replicates (Figure 
5.1.3D). Previous studies have identified distinct PTPRQ isoforms that are expressed 
in a tissue specific manner. This complex system of regulation suggests that PTPRQ 
function and activity may be controlled by cellular localisation and is highly specific 
to cell type 294. PTPRQ isoform expression as well as factors effecting PTPRQ 
expression in adipogenesis have yet to be established. The shRNA constructs and 
qPCR probes used in this study were directed towards the later exons in the PTPRQ 
gene (qPCR probes – exon 41), however it is possible that isoforms may exist in mouse 
adipocytes that are unaffected by the KD constructs used here or undetected by the 
qPCR probes. A significant limitation in this study was the endogenously low levels 
of PTPRQ expression detected in these cells. The RNA-Seq analysis was carried out 
at 36 h post induction of differentiation in this cell system, however in the LMNA 
over-expression experiments performed to confirm this result, PTPRQ was undetected 
past day 0 of differentiation. Thus, the effect of LMNA on PTPRQ was assessed at 
day -2 when the endogenous expression was detectable. This variation in experimental 
approach may be responsible for the discrepancies observed in LMNA effect on 
PTPRQ.  
 
This preliminary investigation of PTPRQ activity and function in adipogenesis has 
brought to light various limitations in this system. Very low levels of endogenous 
PTPRQ transcripts in these cells make it difficult to measure changes in response to 
LMNA or other factors. These difficulties in PTPRQ detection may have contributed 
to the observed variation in experimental results. In keeping with our results, PTPRQ 
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was undetected in microarray analysis of gene expression in 3T3-L1 and hASC 
differentiation 178. As higher levels of PTPRQ expression have been reported in human 
MSCs 298, a practical solution would be to study the effects of PTPRQ on adipogenesis 
in this alternative cell system. Finally, it is important to consider the complexity of 
PTPRQ regulation that has been reported in various cell types 294, as it suggests distinct 
cell-type specific PTPRQ function and control mechanisms, neither of which have 
previously been addressed in the context of adipogenesis.  
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SECTION 2: WNT6 
 
INTRODUCTION 
The wingless-type MMTV integration site (Wnt) family members are a group of 19, 
highly conserved, secreted glycoproteins that activate diverse intracellular signalling 
pathways to regulate developmental processes, such as cell proliferation and 
differentiation 305. Of the numerous pathways activated by Wnt proteins, including Jun 
N-terminal kinase (JNK) and calcium signalling pathways, the canonical Wnt/-
catenin signalling system is the most well-characterised 306. Figure 5.2.1 depicts this 
signalling cascade in which Wnt ligands bind to the frizzled (FZD) receptor and 
lipoprotein-receptor-related protein-5 or -6 (LRP5/6) co-receptor, and leads to the 
stabilisation of cytoplasmic β-catenin. Once stabilised, this multi-functional protein is 
translocated to the nucleus where it binds the T-cell factor/Lymphoid enhancer factor 
(TCF/LEF) family of transcription factors to regulate Wnt/β-catenin target genes 307. 
 
MSCs have the potential to differentiate into multiple cell types including adipocytes, 
osteoblasts, myocytes and chondrocytes 308. Canonical Wnt signalling has been 
identified as a regulator of MSC fate. MSC adipogenic differentiation is a complex 
process that involves two main stages, lineage commitment and terminal 
differentiation. Wnt/β-catenin signalling has been implicated in both stages of the 
adipose development programme, functioning as an activator of lineage commitment 
96 and an inhibitor of adipocyte terminal differentiation 184. Wnt signalling has been 
shown to repress adipogenesis through the inhibition of C/EBP and PPAR induction 
95.   
 
Numerous studies have characterised the activity of certain Wnt ligands in 
adipogenesis. Endogenous expression of Wnt10a, Wnt10b and Wnt6 is down-
regulated during in vitro adipogenic differentiation of 3T3-L1 and bi-potential ST2 
cells 184. Ectopic over-expression of specific Wnt ligands (Wnt1, Wnt10b, Wnt10a and 
Wnt6) has been shown to block adipogenesis in 3T3-L1 preadipocytes and promote 
osteogenesis in ST2 cells. Conversely, the knockdown of Wnt expression is seen to 
enhance adipogenesis and repress osteogenesis 95,184.  Similarly, transgenic mice 
expressing Wnt10b from an adipose-specific FABP4 promoter display a significant 
decrease in white adipose tissue, total loss of brown adipose tissue and increased bone 
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mass, and are resistant to diet induced obesity 309. Furthermore, it has been established 
that these effects are mediated through the Wnt/β-catenin signalling pathway, as β-
catenin knockdown is seen to abrogate the effects of altered Wnt expression on both 
osteogenesis and adipogenesis 184,309.  
 
 
Figure 5.2.1: Canonical Wnt/-catenin signalling pathway (Cell Signalling 
Technology (2016)).  
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RNA-Seq analysis identified an 8-, and 6-fold increase in Wnt6 expression in response 
to WT and R482W mutant LMNA, respectively. As a well characterised inhibitor of 
adipogenesis, this study aimed to explore the relationship between Wnt6 and LMNA 
in the context of adipogenesis and determine whether increased Wnt6 expression was 
responsible for the LMNA mediated block in 3T3-L1 differentiation. A final aim of 
this study was to investigate if Wnt6 silencing could rescue LMNA mediated 
inhibition of adipogenesis.   
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RESULTS 
Wnt6 expression is down-regulated during 3T3-L1 differentiation 
Endogenous Wnt6 expression was assessed during 3T3-L1 differentiation as in 
agreement with previously published results 184, Wnt6 was significantly down-
regulated during adipogenesis (Figure 5.2.2).   
 
 
Figure 5.2.2: WNT6 expression in 3T3-L1 differentiation. 3T3-l1 cells were 
differentiated as previously described and adipogenesis was assessed at day 8 by 
staining with Oil Red O. Total RNA was isolated at the indicated time points during 
3T3-L1 differentiation. WNT6 and PPARγ expression was analysed by qPCR. 
Transcript expression at the various time points is shown relative to expression at day 
-2. A Student’s t-test (two-tailed, assuming equal variance) was used to calculate 
statistical significance compared to day 0, indicated as follows: *=P<0.05; **=P<0.01; 
***=P<0.001.  
 
 
Wnt6 silencing in 3T3-L1 differentiation 
Cawthorn et al., (2011) 184 have previously demonstrated enhanced 3T3-L1 
differentiation in response to shRNA mediated silencing of Wnt6 expression. 3T3-L1 
preadipocytes were stably transfected with a piggyBac transposable Wnt6 shRNA 
knockdown construct, pRFP(PB).sh.WNT6 or scramble control pRFP(PB).shControl 
and induced to differentiate using full induction media MDI, and sub-maximal media 
DI or D as indicated (Figure 5.2.3A). Knockdown of endogenous Wnt6 significantly 
enhanced adipogenesis in comparison to control cells in all differentiation conditions, 
as assessed by Oil Red O staining and quantification (Figure 5.2.3A). However, qPCR 
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analysis of Wnt6 expression at day 0, 2 and 4 (Figure 5.2.3B) did not detect a reduction 
in Wnt6 expression in pRFP(PB).sh.WNT6 transfected ells. Interestingly, Cawthorn 
et al., (2011)184 have previously described a similar phenomenon in which they had 
difficulty detecting Wnt knockdown in the ST2 cell line. Wnt6 knockdown was only 
detectable in these cells when qPCR primers flanking the shRNA target site were used. 
Thus, Wnt6 custom primers (CP) were designed flanking the shWNT6 target site and 
qPCR analysis of Wnt6 expression at day 0, 2 and 4 was repeated with these primers 
(Figure 5.2.3 – CP). However, Wnt6 expression levels were unaffected by 
pRFP(PB).sh.WNT6 transfection regardless of the qPCR primer location. The 
enhanced adipogenesis of pRFP(PB).sh.WNT6 transfected cells suggests a reduction 
in Wnt/β-catenin signalling, but whether Wnt6 expression is affected by the shRNA 
is unclear.  
 
Cawthorn et al., (2011)184 also reported cross-regulation of Wnt ligands, in that 
Wnt10b expression was also reduced in shWNT6 transfected cells. Therefore, it would 
be of interest to assess the expression of other Wnt ligands such as Wnt10a and 
Wnt10b to identify possible down-regulation that might lead to the observed increase 
in adipogenesis. It would also be of use to measure total β-catenin in the cells, as any 
reduction in Wnt ligand expression would lead to reduced β-catenin. Alternatively, 
additional shRNA constructs could be assayed with flanking qPCR primers for 
successful detection of Wnt6 knockdown.  
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Figure 5.2.3: WNT6 silencing in 3T3-L1 differentiation.  (A) 3T3-L1 preadipocytes 
were stably transfected with pRFP(PB).shWNT6 or scramble control 
pRFP(PB).shControl and induced to differentiate. Adipogenesis was assessed at day 
8 post induction by staining with Oil Red O; quantification was carried out using 
ImageJ and expressed as Oil Red O absorbance units (ORO a.u.) (B) WNT6 
expression was assessed by qPCR analysis at day 0, 2 and 4 with a predesigned WNT6 
primers and custom primers (CP). A Student’s t-test (two-tailed, assuming equal 
variance) was used to calculate statistical significance compared to scramble control, 
indicated as follows: *=P<0.05; **=P<0.01; ***=P<0.001. 
 
As previously mentioned in chapter 4, technical difficulties were encountered when 
cloning the various shRNA constructs employed in this thesis. High levels of 
recombination were observed with frequent deletion of nucleotides within the shRNA 
29 mer sequence. Sequencing of the shWNT6 construct used here identified a 10-
nucleotide deletion in one of the 29mer arms. Hairpin formation of the modified 
sequence was assessed using the IDT OligoAnalyzer tool and formation of a hairpin 
of similar structure to the original sequence was predicted, suggesting the deletion 
might not influence shRNA function. If shWNT6 efficiency is affected by this 
deletion, it could explain the difficulties experienced in detecting Wnt6 knockdown. 
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None the less, the enhanced adipogenic phenotype suggests modulation of gene 
expression to some extent. In order to confirm accurate shWNT6 action and eliminate 
the possibility of off target effects, a Wnt6 specific antibody should be employed to 
detect endogenous Wnt6 in this system.  
 
 
Wnt6 expression in response to LMNA overexpression 
To investigate the LMNA mediated increase in WNT6 expression detected in the 
RNA-Seq analysis, 3T3-L1 preadipocytes were stably transfected with human LMNA 
overexpression constructs and induced to differentiate. Wnt6 expression was assessed 
at day -2 and 2 of differentiation (Figure 5.2.4 A, B) in two independent experimental 
replicates. A significant increase in Wnt6 expression in response to LMNA WT 
overexpression was detected at day -2 in the second replicate (Figure 5.2.4B) but was 
not reproducible. Mutant LMNA did not appear to affect Wnt6 expression at any of 
the time points assessed in either of the replicates. In both experiments LMNA (WT 
and R482W) was seen to significantly reduce lipid droplet accumulation in 
comparison to empty vector control (Chapter 4, Figure 4.7). As difficulties were 
experienced in detecting WNT6 knockdown using qPCR, as described above, it would 
be of interest to confirm the effects of LMNA over-expression on wnt6 at the protein 
level.  
 
To investigate whether the increase in adipogenesis in response to pRFP(PB).shWNT6 
transfection could rescue LMNA mediated inhibition of adipogenesis, dual constructs 
similar to those described in chapter 4 were generated; pCMV(PB)-Flag-LMNA-
WT.shWNT6, pCMV(PB)-Flag-LMNA-WT.shControl, pCMV(PB)-Flag-LMNA-
R482W.shWNT6, pCMV(PB)-Flag-LMNA-R482W.shControl, 
pCMV(PB).shWNT6 and pCMV(PB).shControl. 3T3-L1 preadipocytes were stably 
transfected and induced to differentiate, however LMNA did not appear to inhibit 
differentiation in this experiment and therefore these results have not been included. 
It would be of interest to repeat this rescue experiment with an alternative shRNA 
sequence, without mutation and with which the Wnt6 silencing is detectable.  
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Figure 5.2.4: WNT6 expression in response to LMNA over-expression. (A) 3T3-
L1 preadipocytes were stably transfected with pCMV(PB)-Flag-LMNA-WT, 
pCMV(PB)-Flag-LMNA-R482W or pCMV(PB) and induced to differentiate. WNT6 
expression was analysed by qPCR at day -2 and day 2 of cell differentiation. (B) 3T3-
L1 preadipocytes were stably transfected with pcDNA3-Flag-LMNA-WT, pcDNA3-
Flag-LMNA-R482W or pcDNA3.EV and induced to differentiate. WNT6 expression 
was analysed by qPCR at day -2, 2 and 4 of cell differentiation.  (ORO images and 
expression data shown in Figure 4.7, chapter 4). A Student’s t-test (two-tailed, 
assuming equal variance) was used to calculate statistical significance compared to 
empty vector control cells, indicated as follows: *=P<0.05; **=P<0.01; ***=P<0.001. 
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DISCUSSION 
Wnt proteins are important regulators of adipogenesis. The role of canonical Wnt/β-
catenin signalling has been extensively studied in this context and endogenous Wnt 
ligands that activate this pathway are down-regulated during the process of in vitro 
cell differentiation. Of the 19 secreted glycoproteins, Wnt1 95, Wnt 3a 310, Wnt10a, 
Wnt10b and Wnt6 184 have all been shown to inhibit adipogenesis through β-catenin 
signalling. Interestingly, various other Wnts, including Wnt5a, Wnt4 311 and Wnt5b 
312, have been shown to enhance adipogenesis. These proteins appear to act through 
alternative signalling pathways to inhibit canonical Wnt/β-catenin signalling and 
promote cell differentiation, once again emphasising the importance of the canonical 
pathway in the control of adipogenesis.  
 
The aim of this study was to investigate the relationship between Wnt6 and LMNA 
and to determine whether the stimulatory action of Wnt6 silencing could rescue 
LMNA mediated inhibition of 3T3-L1 differentiation. Previous studies have described 
LMNA mediated effects on Wnt signalling in diverse systems. LMNA over-
expression has been shown to enhance osteoblast differentiation and inhibit the 
adipogenesis in MSCs, through up-regulation of Wnt7b and Wnt10b as well as other 
osteogenic genes in these cells. Increased levels of β-catenin were reported in MSCs 
over-expressing LMNA and reduced β-catenin was seen in response to LMNA KD 
176. Recently, dysregulation of ECM genes and Wnt signalling has been reported in a 
HGPS mouse model. Hernandez et al., (2010) 186 examined the gene expression profile 
of LMNA9 (Exon 9 deletion generating a truncated LMNA variant that leads to 
characteristic HGPS proliferative arrest) MAFs and identified altered expression of 
cell adhesion and ECM genes. Impaired Wnt/β-catenin signalling was reported in 
LMNA9 MAFs, caused by reduced TCF/Lef1 activity and cell proliferation was 
rescued by inhibition of GSK3 (β-catenin degradation) in these cells 186. Tong et al., 
(2011) 313 have also described reduced Wnt10b and β-catenin in LMNA -/- mice, along 
with increased PPAR and C/EBP associated with the fat infiltration on muscle and 
bone tissues in these mice. Similarly, RNA-Seq analysis of 3T3-L1 gene expression 
during differentiation identified increased Wnt6 expression in response to LMNA WT 
and R482W overexpression. To confirm the effects of LMNA on Wnt6 expression, 
3T3-L1 preadipocytes were stably transfected with human LMNA overexpression 
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constructs and induced to differentiate. However, qPCR analysis of Wnt6 expression 
in these cells did not detect a consistent increase in response to LMNA (Figure 5.2.4). 
RNA-Seq analysis was carried out 36 h post induction of differentiation, while qPCR 
analysis was carried out at day -2, day 2 (48 h post induction) and day 4 (not shown). 
The LMNA effect on Wnt6 expression might be specific to early adipogenic induction 
and should be assessed by qPCR sooner than 48 h post induction (day 2). In addition, 
it would be of interest to assess the expression of other Wnt proteins and β-catenin in 
this system as LMNA has previously been reported to affect Wnt10b in various cell 
types 176,186,313.  
 
While the mechanisms controlling Wnt down-regulation during adipogenesis have yet 
to be elucidated, numerous factors have been implicated. Various components of the 
induction cocktail are reported to stimulate the down-regulation of specific Wnt 
ligands, including insulin, via IRS-1 signalling 314 and cyclic AMP 315. PPAR is 
reported to suppress Wnt/β-catenin signalling in adipogenesis 315 and numerous 
additional factors such as TZD treatment or obesity are seen to influence Wnt 
expression in adipose tissue 184,316. This raises the question of whether LMNA 
modulates Wnt directly in 3T3-L1 differentiation or through an indirect mechanism. 
It is possible that LMNA may influence factors involved in adipogenic Wnt regulation 
to modulate Wnt6 expression rather than affecting its expression directly. Previous 
studies have reported increased TCF/Lef1 activity in response to LMNA 
overexpression in MSC 176 and reduced TCF/Lef1 activity in response to LMNA9 in 
MAFs 186. Both studies utilized a Topflash luciferase reporter assay to measure β-
catenin mediated activation of TCF/Lef1 transcriptional activity. This Topflash 
system was employed in this work (data not shown) in an attempt to measure an effect 
of LMNA WT and R482W mutant on TCF/Lef1 transcriptional activity in 3T3-L1 
cells. However a number of technical difficulties were experienced. Previously 
employed dual stable transfection (LMNA and reporter construct) is not appropriate 
here as basal Topflash activity in these cells was very low, this construct was only 
seen to direct luciferase activity in response to LiCl treatment, which inhibits 3T3-L1 
differentiation as previously shown. The Topflash system does not appear to be 
sensitive enough to measure altered Wnt/β-catenin signalling in this system. In 
addition, the activity of various ECM, signalling and transcription factors is highly 
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regulated during the process of 3T3-L1 differentiation. Measuring the influence of 
LMNA on any of these factors in pre-adipocytes or other cell models might not reflect 
the effects observed in the context of cell differentiation.  
 
Technical difficulties were also encountered during attempts to knockdown Wnt6 as 
well as accurately detect the knockdown in these cells, as outlined in the results 
section. In addition, a preliminary attempt at the previously outlined rescue experiment 
was unsuccessful as LMNA failed to inhibit cell differentiation. Due to the large 
amount of data in the literature supporting a potential role for LMNA in Wnt/ β-catenin 
regulation during adipogenesis, expansion and optimization of these experiments are 
warranted.  
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SECTION 3: TESTOSTERONE  
 
INTRODUCTION 
 
Modulation of various signalling pathways during adipocyte differentiation activates 
the characteristic transcriptional cascade that leads to a mature adipocyte phenotype. 
Figure 5.1.2 illustrates numerous pathways that transduce both stimulatory and 
repressive signals from extracellular components during adipogenesis 92. Various 
hormones are known to have important regulatory functions in the process of 
adipogenesis. Here, the role of testosterone will be considered as it has previously 
been shown to influence adipocyte function.  
 
Androgen metabolism and action in adipose tissue is highly complex. Sex steroids are 
thought to contribute to the sexual dimorphism of body fat distribution as they appear 
to have both depot-specific and sex-specific actions in adipose tissue 317. Adipose 
tissue has been identified as a steroid hormone reservoir 318, and androgens are 
reported to influence key functions of adipose tissue including lipid metabolism 
(lipolysis and lipogenesis), insulin signalling, adipokine secretion and preadipocyte 
differentiation 317.  
 
Huang et al., (2013) 319 have described a role for androgen signalling in osteoporosis 
and obesity, where androgen receptor (AR) deficiency is shown to inhibit osteogenesis 
and promote adipogenesis. AR KO mice are obese and show abnormal white adipose 
tissue metabolism 320,321. AR KO is reported to reduce IGFBP3 expression in bone 
derived MSCs, leading to Akt activation and stimulation of adipogenesis. IGFBP3 has 
previously been shown to block IGF-1 driven Akt signalling 269 and Huang et al., 
(2003) 319 report that AR up-regulates IGFBP3 expression to suppress adipogenesis in 
this system. These results suggest AR modulation of the IGF-Akt axis as the 
mechanism by which androgens influences adipogenesis. Androgens have also been 
reported to impair human ASC commitment to the preadipocyte cell lineage in 
subcutaneous abdominal adipocytes 282.  
 
The repressive effects of testosterone on 3T3-L1 differentiation are reported to 
function though AR/-catenin interaction and translocation to the nucleus, leading to 
the up-regulation of various Wnt signalling target genes 282.  Testosterone and DHT 
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treatments were seen to reduce the expression of early adipogenic factors including 
C/EBP,,  and PPAR and induced the translocation of a fraction of cytoplasmic -
catenin into the nucleus. -catenin was subsequently shown to interact with both AR 
and TCF4 in the nucleus. Finally, testosterone inhibition of 3T3-L1 differentiation was 
blocked by over-expression of a dominant negative TCF4, suggesting that testosterone 
mediated inhibition of adipogenesis might function through the TCF4 signalling 
pathway 282.   
 
As the FPLD2 adipose specific symptoms are seen to develop post puberty it has been 
suggested that a hormonal component might be involved in driving this phenotype 33. 
Another indicator of the involvement of hormones is the sex dependent aspect of the 
disease, where symptoms are generally more severe in female patients 48,49. Finally, 
the primary symptom of FPLD2 is adipose tissue re-distribution in distinct fat depots 
in the body, another area in which sex hormones are thought to play a role 317. If sex 
hormones were involved in the pathogenesis of FPLD2, the repurposing of androgen 
deprivation therapy (ADT) could be considered as a potential therapeutic lead.  
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RESULTS 
 
Throughout this study, the effects of testosterone were investigated on various 
elements during adipogenesis. Testosterone treatments were applied to 3T3-L1 cells 
during differentiation at varying concentrations on numerous occasions, however the 
hormone was not observed to reduce cell differentiation under any circumstances. As 
this is conflicting with all the published data described above, testosterone treatments 
were applied to 3T3-L1 cells from alternative sources to investigate the possibility that 
the lack of inhibition was a cell line specific feature. Previous studies have shown 
inhibition of lipid droplet accumulation in response to 100nM testosterone treatments 
282. In this study, treatments of up to 200nM testosterone were applied to 3T3-L1 cells 
from three different sources, repeatedly and with no effect (Figure 5.3.1). In addition, 
treatments of 500nM testosterone did not appear to influence ZenBio 3T3-L1 
differentiation (data not shown). To exclude the possibility that the testosterone used 
in these experiments was inactive, the more potent androgen DHT was assayed as 
well. Previous reports have demonstrated inhibition of differentiation with 10nM 
DHT. DHT treatments up to 250nM were applied to ZenBio 3T3-L1 cells during 
differentiation, and no effect was observed (Figure 5.3.1). In all instances, testosterone 
and DHT were solubilized in ethanol as previously described in numerous published 
studies 282,322.  
 
Previously, the effects of testosterone on IGFBP5 promoter activity during 3T3-L1 
differentiation was assessed (chapter 4), as the sex hormone is reported to activate 
IGFBP5 promoter activity in human androgen responsive fibroblasts 233. No effect was 
observed on cell differentiation or promoter activity (Chapter 4 Figure 4.6C). In 
addition, testosterone was applied to IGFBP5, LMNA WT and LMNA R482W 
overexpressing cells repeatedly to see if the hormone enhanced or repressed the effects 
of either on 3T3-L1 differentiation. In all instances, testosterone treatment has no 
effect.  
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Figure 5.3.1: Testosterone and DHT treatment during 3T3-L1 differentiation. 
3T3-L1 preadipocytes were grown to confluency and differentiated with either 
testosterone or DHT treatments as indicated. Treatments were applied at day -2 and 
continuously with every media change as described in materials and methods. 3T3-L1 
cells from ATCC and ZenBio were assayed, along with cells obtained from Prof. 
Michael Schupp (MS), Charite, Berlin.  
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DISCUSSION 
Studying the effects of androgens on adipocyte differentiation are of interest 
considering the puberty induced onset of FPLD2 pathogenesis. It is unclear why 
neither testosterone nor DHT had an effect on 3T3-L1 differentiation in this study. 
The volume of data published on androgen action in adipogenesis suggests that this 
effect is specific to the cells used in this study and it is possible that these cells are not 
androgen sensitive. In agreement with this, Hartig et al., (2013) 322 found that DHT 
and a synthetic androgen Metribolone (R1881) had no effect on 3T3-L1 differentiation 
due to low levels of the androgen receptor (AR) expression in these cells. AR over-
expression was shown to sensitise these cells to DHT/R1881 inhibition leading to 
reduced PPAR and C/EBP along with the up-regulation of various osteogenic 
genes. This is in keeping with the results observed in this study, where testosterone 
was unable to inhibit 3T3-L1 differentiation, and suggests that the 3T3-L1 cells model 
is not a suitable for the study of androgen effects on adipogenesis.  
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GENERAL DISCUSSION 
 
FPLD2 is a rare autosomal dominant disease for which there is no effective therapy. 
Interest in the development of novel therapeutics for partial lipodystrophies has been 
accelerated by the increasing prevalence of HAART associated partial lipodystrophies 
in HIV/AIDS patients 323,324. While advances have been made in elucidating the 
molecular mechanisms driving this disease phenotype, the exact aetiology of FPLD2 
is unclear.  
To date, several studies have described pleiotropic effects of LMNA on gene 
regulation and interaction of LMNA with multiple proteins in adipogenesis. The 
majority of published work addressing the FPLD2 mechanism of action, propose 
reduced protein interaction of mutant LMNA with SREPB1 as the principle factor 
driving the dysregulation of adipogenesis. Lund et al., (2013)141 have described the 
remodelling of sub-nuclear architecture in human ASC differentiation, in which 
LMNA-promoter interactions are modified thus altering the expression capacity of a 
subset of genes during this process. Considering the well characterised role of LMNA 
in the regulation of chromatin organization and gene transcription, it follows that 
LMNA mutation might lead to the distortion of these processes during the dynamic 
process of adipogenesis 8. 
 
An investigation into the effects of LMNA on the early stages of adipogenesis though 
the use of RNA-Seq analysis identified altered expression ITM2A, IGFBP5, WNT6 
and PTPRQ transcripts in the 3T3-L1 cell model. Analysis of IGFBP5, WNT6 and 
PTPRQ in the context of adipogenesis and with respect to LMNA proved challenging. 
Significant obstacles were encountered in relation to the complex regulation of 
IGFBP5 expression in adipogenesis. This study reports novel effects of IGFBP5 over-
expression and silencing on 3T3-L1 differentiation, however further characterisation 
of IGFBP5 function and activity is required to elucidate its dynamic role in the process 
of adipogenesis.  
 
Preliminary manipulations of PTPRQ in this cell system identified novel effects of 
PTPRQ silencing on adipogenesis. However, difficulties were encountered in the 
detection and manipulation of the lowly expressed PTPRQ, in this cell model. Both 
IGFBP5 and PTPRQ were investigated with the intention of identifying factors that 
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might enhance adipogenesis through simple manipulation, for example the addition of 
IGFBP5 protein to the cells, or the inhibition of PTPRQ with recently developed 
PTPRQ inhibitors 325. Neither of these factors were seen to stimulate adipogenesis in 
this context and thus are not suitable candidates for therapeutic manipulation.  
 
Wnt6 activity was addressed in this system under the hypothesis that Wnt6 silencing, 
which is known to enhance adipogenesis 184, might be sufficient to rescue the LMNA 
mediated block in adipogenesis. However, previously reported difficulties in detecting 
Wnt6 silencing in these cells rendered this gene very problematic to work with. Aside 
from issues in consistent candidate gene detection and manipulation, the major 
limitation of this study in the lengthy and arduous nature of 3T3-L1 transfection and 
differentiation experiments. This dynamic process is highly variable and producing 
consistent result in this system proved challenging.  
 
Finally, characterisation of ITM2A in adipogenesis was successful as this work 
uncovered a role for ITM2A in the regulation of adipogenesis and suggests a 
modulatory relationship between LMNA and ITM2A within this context. This study 
describes a novel stimulatory effect of ITM2A silencing in adipogenesis, which is 
sufficient to rescue the LMNA mediated block in adipogenesis. Throughout this study, 
ITM2A knockdown robustly enhanced 3T3-L1 differentiation by increasing PPAR 
protein levels in these cells, and ITM2A manipulation in this context has suggested a 
possible role for autophagy modulation in the treatment of FPLD2 and for exploration 
for treatment of HAART associated partial lipodystrophies. 
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